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Summary 
 
 Glioblastoma Multiforme is a WHO grade IV brain tumor with glial characteristics 
leading to more years of life lost than any other cancer. A better understanding of GBM 
biology and valid animal models are the two key elements to improved therapeutic 
results. We found Deltex1, which is part of an alternative Notch pathway, to activate both 
the PI3K/PKB and the MAPK/ERK pathway and to induce anti-apoptotic Mcl-1. DTX1 over-
expression resulted in increased clonogenic and growth potential and also induced cell 
migration and invasion. Microarray gene expression analysis identified a DTX1-specific 
transcriptional program related to the changes in phenotype observed. Patients with low 
DTX1 levels have a favorable prognosis. Therefore, we propose the alternative Notch 
pathway via DTX1 as an oncogenic factor in glioblastoma. This could partially explain 
previous findings linking Notch status to prognosis wherein high Notch2 levels correlated 
with reduced patient survival. We found activated Notch2 in neural stem cells to induce 
glioma-inducing-cell features including increased proliferation, reduced apoptosis and 
astrocytic lineage commitment. These observations were found both in vitro and in vivo 
using a conditional mouse model. Together, these findings indicate an important role for 
Notch signaling (both canonical and non-canocical) in high grade glioma, offering a 
potential treatment target. We have also established an in vivo model of GBM which 
allowed us to analyze the efficacy of novel treatment regimens. Short term treatment of 
orthotopic xenograft gliomas in nude mice with histone deacetylase inhibitors and 2-
deoxy-D-glucose resulted in prolonged survival, reduced tumor growth and induction of  
cancer cell apoptosis. Therefore, epigenetic reprogramming in combination with energy 
deprivation was found to have anti-tumor activity in vivo. In an independent project we 
identified GSK3β as a downstream target of Bmi1. GSK3β maintains a more stem cell like 
characteristic in GBM cells, potentially also in the glioma inducing cells. Several inhibitors 
to GSK3β exist and LiCl, which is often used in the clinic, correlates with reduced glioma 
incidence. Altogether, we believe we have added considerable knowledge on the biology 
of gliomas thereby helping to characterize the underlying events of gliomagenesis. 
Furthermore, we have established proof of principle for a novel treatment strategy in 
vivo.   
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Introduction 
 
 
The human body consists of roughly 50 trillion (50*1012) cells. Each one contains the 
full genetic information, but only uses a small fraction thereof to exert its biological function. 
The number of biological processes taking place in these cells is indicative of the likelihood of 
mistakes. While many, if not most processes are quenched by control mechanisms or 
redundant systems, some of them manifest and may cause malignant aberrations. A 
biological organism will be exposed to harmful effects ab initio. Internal effects like DNA 
replication errors, chromosomal dislocations or miss-segregations can occur throughout 
development or later in life. On top of that, an organism is exposed to a wide array of 
chemical, physical and biological influences potentially harmful to the genetic information. 
These errors accumulate over time in a growth selective process [1] eventually leaving the 
cell with a significantly altered genome which can ultimately cause uncontrolled growth and 
neoplastic disorders. Cancer is projected to become – and in the European Union it already is 
– the leading cause of death worldwide (Figure 1). The average age of the world population 
and the overall life expectancy is steadily increasing, giving mutations ever more time to 
accumulate in individual cells. Therefore, this trend appears to become even more sustained 
over the coming decades.  
 
Basically every human tissue can develop neoplastic disorders and usually there are 
several forms of tumors per tissue type, leaving a plethora of different diseases which all 
carry the inherent genetic variability of the individual. Currently we are still unable to 
determine individualized cancer profiles for patients due to technical and financial limits. 
However, with the rise of fast throughput and large scale analysis tools like microarrays or 
on-chip proteomics, there is hope to get closer to this approach. Fortunately there seem to 
be few, generally applicable concepts inherent to specific cancer subclasses offering a 
unifying understanding of the particular disease and indicating possible routes of treatment.  
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Figure 1. Causes of death in the EU in 2006 (adapted from EUROSTAT survey 2006). 
 
In the EU-27 malignant neoplastic disorders were the leading cause of death in 2006. Y-axis shows related 
deaths per 100’000 inhabitants.  
 
  
 Independent of the tumor type or location, several characteristic traits are found in 
all neoplastic disorders and are key features of cancer. Although the resulting feature may 
be the same, the underlying cause can be different. Several genotypes can lead to the same 
clinical phenotype. An overview of such traits and their underlying causes in general and in 
high grade gliomas (HGG) in particular are stated below.  
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A Brief History of Cancer Cell Biology  
 
 Seven features distinguish tumors and cancer cells from normal tissue [2]. They can 
be grouped into features which enable the cell to proliferate and grow even when not 
intended to, the ability to circumvent internal and external control mechanisms (e.g. 
immune evasion and neutralization of intrinsic apoptotic clearance), to ensure sufficient 
supply of nutrients and ultimately to disseminate. These traits can be related to malignant 
changes in seven distinct cellular mechanisms:  
 
Cell Growth. A normal cell cannot grow in the absence of specific, growth promoting signals. 
These signals are usually external – either soluble factors or extracellular matrix components 
– and are detected and usually conveyed by membrane bound receptors. The signal is then 
transmitted via intracellular signaling cascades. A cancer cell can acquire self-sufficiency of 
growth signals at all three levels of such cascades. Mutations can lead to the aberrant 
expression of growth factors which then act in an autocrine fashion back on the cell itself 
providing the necessary growth-stimulus. The productions of PDGF in HGGs or TGFα in 
sarcomas are examples thereof [3]. Over-expression of receptors can render the cell 
independent of ligand through ligand-independent dimerization or make it hyper-responsive 
to ambient levels of growth factors. Alternatively, mutations can yield constitutively active 
versions of receptors making the down stream signal transmission independent of ligands or 
receptor amounts. For example, a truncated version of the EGFR lacking most of the 
cytoplasmic receptor fires constitutively due to the lack of regulatory domains. Complex 
down stream signaling networks conveying these receptor signals offer manifold options for 
alterations. Ectopic expression of proteins, hyper-activating mutations of kinases or loss-of-
function in inhibitors and phosphatases are commonly found in cancer cells.   
 
Insensitivity to Growth Inhibiting Signals. Soluble or localized ligands activate cell surface 
receptors and this signal is then conveyed by signaling cascades blocking cell growth and 
proliferation usually arresting cells in the G1-phase of the cell cycle. The main gatekeeper or 
integrator of this signaling is the Rb protein which blocks proliferation if hypo-
phosphorylated. It is therefore not surprising that mutations in the Rb protein are commonly 
found in various cancer types [3]. Mutations again occur at all levels of this circuitry: loss of 
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integrins and other cell surface receptors, mutations in the signaling mediators or in 
intermediate and final targets like Smad4 or Rb itself are related to insensitivity to anti-
growth signals of cancer cells [4]. A tumor can only proliferate if the anti-growth circuitry is 
circumvented independent of the cell of origin.  
 
Evasion of Apoptosis. The cell intrinsic program of cell death – apoptosis – is present in all 
tissues and cell types. Activation of apoptosis leads to the controlled disintegration of the 
cell within hours. The induction of apoptosis is one of the main causes of tumor attrition and 
therefore has to be overcome by cancer cells. The apoptotic machinery can be divided into 
two major components: sensors and effectors. Sensors probe the cell environment (e.g. 
extra-cellular matrix, plasma, cell-cell contacts, etc.) as well as the cell interior for the lack of 
survival signals or the presence of death signals. TNFα binding to TNFα-R1 is an example of a 
death signal inducing apoptosis [5]. The main effectors are the Bcl-2 protein family members 
which integrate the signals onto the mitochondria inducing the release of cytochrome C into 
the cell plasma. This activates a series of Caspases ultimately leading to the controlled 
disassembling of the cell. However, other members of the Bcl-2 family have anti-apoptotic 
functions balancing the system [2]. Approximately 50% of all human cancers and the 
majority of high grade glioma (HGG) have mutations in the tumor suppressor p53 which is 
part of the apoptotic signaling cascade [6]. The precise control of growth and apoptosis are a 
prerequisite to multi-cellular life. Therefore it is not surprising that redundant pathways and 
control mechanisms exist. It is noteworthy that the mutations most commonly found in 
tumors are affecting signaling nodes integrating several of these pathways leaving no or only 
limited control mechanisms intact.  
 
Abnormal Replicative Potential.  All of the above traits affect signaling pathways which 
integrate signals from the cell environment and the cell intrinsic state. However, cells 
contain an independent program limiting their overall replicative potential irrespective of 
the signaling input. Therefore, cultured primary cells have a finite replicative potential and 
hyper-activation of proliferation signals does not suffice to override this limit [7]. Loss-of-
function of Rb and p53 can disable this block – leaving the cell in a state called senescence – 
leading to a state of genome instability, called crisis. About one out of 10 million cells will 
survive crisis and will have become immortalized [8]. Most cancer cell lines derive exactly 
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from such cells and a similar mechanism is likely to take place in the tumor itself. Normally, 
the gradual loss of telomeric DNA at the ends of the chromosomes will induce cellular 
senescence and crisis, limiting the number of cell divisions to about 60-70. 85-90% of all 
tumors have up-regulated telomerase enzyme activity preventing the gradual loss of 
telomeres and thereby circumventing this limiting effect [9].  
 
Angiogenesis. A human tumor cell – like any other cell – needs O2 and nutrients for survival 
and growth. Therefore, all cells have to reside within approx. 100μm of a capillary vessel 
providing these pivotal elements. Angiogenesis is tightly regulated during morphogenesis 
and organogenesis and regulatory effects are mainly mediated by cell surface proteins [10]. 
Initiation of vascularization is triggered by the soluble factors VEGF or FGF which are 
detected by cell surface receptors on endothelial cells. Tumors induce neo-vasculariziation 
through the ectopic expression of VEGF and FGFs and/or through the loss of inhibitory cell 
surface proteins like Thrombospondin-1. Angiogenesis is related to tumor progression and 
usually occurs in mid to late stage tumors. Angiogenesis offers an appealing therapeutic 
target. Bevacizumab (Roche), a humanized monoclonal antibody against VEGF, has become 
the first-in-line treatment for several cancers worldwide (eg. high grade and metastasizing 
lung, colon and breast cancer). Although highly effective in preventing further angiogenesis 
and therefore further tumor growth, anti-angiogenic therapies will not suffice to kill tumors. 
Pre-existing vasculature will always provide the outer layers of the tumor with sufficient 
nutrients leaving a pool of cancer cells under the selective pressure of blocked angiogenesis. 
Therefore, anti-angiogenic therapies are most appealing in combination with cytotoxic 
agents rather than as a mono-therapy. 
 
Invasion and Metastasis. Metastases account for ~90% of all cancer related deaths. Gliomas 
represent a special case given that they do not form metastases. However, they are highly 
invasive. In order to leave the original location of the tumor, cells have to acquire several 
traits. First, cell adhesion has to be reduced. This usually occurs by changing the expression 
pattern of intergrins and CAMs to variants with lower binding capacity or even repulsive 
character. The change of the cell-cell or cell-ECM binding also leads to alterations in the 
signaling networks of the cells [2]. Next, the cells have to survive in a different micro-
environment. Again the changes in the cell surface proteins enable this step. To leave the 
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original niche and invade into any other tissue, the cells have to be able to loosen the ECM 
with the help of proteases. Therefore, invasive and metastatic cells express high levels of 
proteases digesting the connective tissue by which they are engulfed or at the site of 
invasion. Finally, the cells need to actively migrate over certain distances driven by 
intracellular cytoskeleton rearrangements in coordination with the binding strength to the 
ECM (avoid “slipping or sticking”).  
 
Evasion of Immunosurveilance. The human body is under constant surveillance of the 
immune system not only wading off pathogens, but also attacking and eliminating cells with 
destructive potential to the body. Cytotoxic T-cells and NK-cells specifically kill cells which 
display abnormal or non-self peptides and molecular fragments on their MHC-I proteins or 
MHC-like ligands, respectively. Therefore, cancer cells which display their mutated proteins 
on their cell surface have to evade this clearance mechanism. This can occur through the 
generation of an inflammatory micro-environment which changes the response of 
leucocytes to given cues or through insensitivity to apoptosis promoting signals (see above: 
Evasion of Apoptosis). The down regulation of MHC proteins or other markers is also 
frequently found.  
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The Case of Gliblastoma Multiforme 
 
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. 
It is of glial origin and is graded by the WHO as stage IV tumor (Figure 2). The prognosis is 
particularly poor with cancer related death in almost all cases. Treatment includes surgical 
resection, radio- and chemo-therapy. However, average survival has not improved 
substantially over the past decades and remains between 8-14 months after diagnosis [11]. 
Currently there is no cure available and even the most aggressive treatment regimens only 
expand the survival time by weeks [12]. GBM incidence ranges from 2.9 to 3.5 per 100’000 in 
Europe and North America [13]. No clear risk factors are known except for the exposure to 
high doses of ionizing radiation. Males are 1.7 times more often affected than women and 
the prevalence for GBM is higher in Caucasians than in African Americans. The average age 
at diagnosis is 64 years of age. GBM in children are rare. GBMs are usually spontaneous 
diseases; however, rare families with a history of Li-Fraumeni- or Turcot-Syndrom have an 
increased risk of developing GBM [14].  
 
 
Figure 2. Current World Health Organization (WHO) classifications for diffuse glioma and medulloblastoma 
[15]. 
 
(a) Schematic showing the classification of diffuse gliomas of astrocytic and oligodendroglial lineages. 
Representative micrographs of histological HE stainings for each tumor class are given. The hallmark 
histological features of glioblastoma, microvascular proliferation (black arrowhead) and pseudopalisading 
necrosis (black arrows) are also indicated.  
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Figure 3. The neuro-glial cell lineage tree [15]. 
 
Self-renewing, common progenitors are thought to produce committed neuronal and glial progenitors that 
eventually differentiate into mature neurons, astrocytes and oligodendrocytes. Although the precise cells of 
origin for diffuse glioma variants and medulloblastoma remain largely unknown, a selection of likely candidates 
for each (dashed arrows) is indicated. 
 
 
 Glioblastoma usually arise de novo with no history of previous brain neoplasias. Only 
~5% of all GBM are secondary lesions progressing from lower grade astrocytomas [13]. 
Primary and secondary GBM show distinct patterns of mutations, but the prognosis is not 
significantly different. If the tumors arise from dedifferentiated glial cells or from stem- or 
precursor-cells with accumulated mutations is still under debate. However, recent findings 
point toward precursor cells as cells-of-origin for astro-glial tumors (Figure 3) [16-19]. GBMs 
mostly originate in the white matter of the brain, but then massively infiltrate adjacent 
areas. Most GBMs are located in the frontal and temporal lobe. GBMs are rarely found in the 
cerebellum, brain stem or spinal cord, but can expand through the corpus callosum to the 
contralateral hemisphere. They are highly invasive with no clear demarcation between 
tumor tissue and healthy brain. The clinical presentations of GBM are manifold and depend 
mostly on the tumor location. General symptoms can develop rapidly through the high 
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proliferative rate and can include head ache, epileptic seizures, localized neurological deficits 
based on the tumor location and changes of the patient’s personality. Signs of increased 
intra cranial pressure like nausea or even coma develop later and indicate a poor prognosis. 
Histologically, GBMs can be distinguished from anaplastic astrocytomas (AA) through the 
presence of necrotic areas, micro-vasculature and pseudo-palisading cells around necrotic 
areas (Figure 2) [14]. The cells are mostly GFAP positive and often more than 20% are 
positive for the proliferation marker Ki-67. Tumors with mutated p53 show aberrant 
aggregation of p53 protein in the nucleus [20].  
 
 GBM pose several exceptional problems during treatment: i) It is located in the 
central nervous system. This makes both detection and accessibility particularly difficult. ii) 
GBMs grow rapidly leaving only a small time window for treatment. Even considerable 
tumor resection will be overridden by the rapid proliferation within months. iii) Well-proven 
principles of tumor treatment, e.g. respecting a safe resection margin of 2 cm, can not be 
applied due to the location in the CNS. For example, tumor resection is limited to the 
neoplastic tissue and does not include adjacent areas in order to minimize brain damage. 
This leads to incomplete resection or even tumor cell dissemination.  
 
Molecular Genetics of GBM. GBM – a heterogenic group of primary brain neoplasias – can 
be grouped according to their genetic changes and clinical history. Secondary GBM, meaning 
GBMs which arise through continuous progression from lower grade gliomas, show distinct 
mutational patterns from primary GBM. Grade II astrocytomas often have mutated p53 and 
PDGFR over-expression. Through additional mutations like CDK4/6 amplification, RB 
mutation or loss of chromosome 19q or 1p, these tumors become more aggressive and 
develop into grade III anaplastic-astrocytomas. Additional loss of chromosome 10q, or in 
rare cases (~10%) PTEN mutations, lead to the progression to grade IV GBMs. This process 
takes 5-10 years and is typically found in younger patients (<45 years of age). The prognosis 
is around 9-14 months. Secondary GBM account for ~5-10% of all GBM cases [21].  
 
 Primary GBM are the rule (~90%) and these tumors normally have different genetic 
alterations. Mutations are often found in INK4aARF, EGFR and PTEN (~40%) and over-
expression of EGFR, Cyclin D and MDM2. Loss of heterozygosity (LOH) is commonly found in 
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10p and 10q and even total loss of chromosome 10 occurs. Average survival is 9-12 months 
[21]. Since these alterations only describe the most common mutations in primary or 
secondary GBM and do not offer a functional classification, a more recent analysis of 206 
GBM offers a signaling pathway based classification [3]. These classes are functionally 
related and offer a rational for targeted therapies although they are significantly overlapping 
(Figure 4).  
 
 The RTK/RAS/PI3K pathway is affected in 88% of GBM (Figure 4). Gain-of-function  
alterations are mostly found in EGFR, PDGFRa, PI3K and ErbB2. Loss-of-function changes in 
this pathway are found in PTEN and NF1. The hyper-activation of this pathway induces cell 
proliferation, survival and translation. It is also linked to cell migration and invasion. 87% of 
GBM have frequent genetic alterations in the p53 pathway. Gain of function of MDM2 or 
loss of function of INK4aARF and p53 make glioma cells more apoptosis resistant and prevent 
cellular senescence. Cell cycle control is affected in 78% by alterations of the RB pathway 
thereby releasing the G1/S-phase block of normal cells regulated by this system. Gain of 
function mutations are found in the CDK4 gene but are relatively rare. However, loss of 
function mutations which affect the CDKN2 locus are about 50% [22]. RB itself is mutated in 
~10% of GBM [3]. 
 
The RTK/RAS/PI3K group can be further subdivided into three distinct subclasses by 
the activity among signal transduction pathways and associated genomic alterations [23]. 
These three classes associate with EGFR over-expression, PDGFB over-expression, and loss of 
NF1 (Figure 5). 
 
These three distinct patterns were revealed by proteomic analysis of protein 
expression and activation in glioma-relevant signaling pathways. The EGFR signaling class has 
significant Notch signaling activation measured by elevated expression of Notch ligands, 
cleaved Notch receptors and down-stream target Hes1 [23]. The PDGFRA class shares 
features with the ‘proneural’ group of gliomas previously identified using transcriptional 
analysis [24], and is characterized by genes expressed during normal cortical 
oligodendrocyte development such as Olig2, Sox2 and doublecortin and signaling pathways 
involved in that process as well, such as PDGF and SHH. Initial data show no relevant clinical 
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or histological differences between these three groups. However, other studies did identify 
Notch signaling and its genetic status as a prognostic marker in gliomas [25]. Although the 
alternative classification into ‘proneural’, ‘proliferative’, or ‘mesenchymal’ gliomas does have 
predictive value it does not offer refined strategies for treatment. The prognostically most 
favorable sub-class ‘proneural’ includes also lower grade gliomas and stereotypic alterations 
of GBM like PTEN loss, however EGFR activation or amplification are not found in this group. 
Therefore, a classification system based on pathway activity rather than transcription level 
seems to be more informative. 
 
 
 
 
Figure 4. Frequent genetic alterations in three critical signaling pathways [3].  
 
Primary sequence alterations and significant copy number changes for components of the RTK/RAS/PI(3)K (a), 
p53 (b) and RB (c) signalling pathways are shown. Red indicates activating genetic alterations, with frequently 
altered genes showing deeper shades of red. Conversely, blue indicates inactivating alterations, with darker 
shades corresponding to a higher percentage of alteration. For each altered component of a particular 
pathway, the nature of the alteration and the percentage of tumours affected are indicated. Boxes contain the 
final percentages of glioblastomas with alterations in at least one known component gene of the designated 
pathway. 
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Figure 5. Clustering of gliomas by signature-defining proteins [23].  
 
Unsupervised k-means clustering of 27 gliomas by 44 core proteins. 3-way clustering was determined to be the 
best fit by consensus matrix stability and cophenetic correlation. Right: summary of array-CGH, sequencing and 
clinical information is given for each tumor. Red denotes copy number gain or focal amplification as specified; 
green marks deletion of at least one copy. Blue denotes mutations. Gray marks samples for which DNA was 
unavailable. 
 
 
Notch receptors in GBM. Notch receptors are evolutionary conserved trans-membrane 
receptors conveying cell to cell signals (Figure 6). They play a key role in developmental 
processes regulating proliferation, cell fate decisions and survival in various tissues and 
species, including neural stem cells [23, 24]. In mammals, a total of four Notch receptors are 
known (Notch1-4) having partially redundant functions. Five ligands (Dll1, 3, 4 and Jagged1, 
2) bind to the receptors inducing proteolytic cleavage of the intracellular domain by gamma-
secretase to the active form Notch-ICD (Notch-intracellular domain). Notch-ICD translocates 
to the nucleus and forms a protein complex with RPBJk, MAML1 and other co-factors. This 
complex leads to the activation of Notch activator genes like Hairy and Enhancer of Split 
homologs (eg. Hes1 and Hes5). Hes genes counteract bHLH genes and thereby act as 
transcriptional repressors. For example, Hes genes counteract the transcription factor Mash-
1 and thereby block neuronal differentiation in neural precursor cells [26]. Deregulation of 
Notch signaling is implicated in various neoplastic disorders [16, 27, 28]. It can either act as 
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an oncogene, like in T-ALL (T-cell acute lymphoblastic leukemia) where translocation of 
Notch1 and its aberrant activation leads to the uncontrolled expansion of immature T-cells 
and subsequently to leukemia, or as a tumor suppressor as in the mammalian skin where 
Notch loss-of-function leads to the development of basal-call-carcinoma-like tumors [29]. 
Interestingly, different Notch receptor variants can have opposing effects on cancer 
development. For example, in the childhood brain tumor medulloblastoma, Notch2 clearly 
promoted tumorigenesis whereas Notch1 had an inhibitory effect on tumor growth [30].  
 
There is accumulating evidence for Notch-signaling through RBPJκ but independent 
of Hes or Hey factors. Potential targets which all contain RBPJκ binding sites in their 
promoter regions are CyclinD1, p21 and GFAP [31-33]. The RBPJκ independent Notch 
signaling through Deltex will be further described below (Introduction and Chapter 1). The 
down stream signaling of Notch receptors is highly cell context dependent. During brain 
development Notch has been described in glial specification as well as progenitor-cell self 
renewal. Hereby, active Notch signaling drives astrocytic differentiation and inhibits 
neuronal and oligodendroglial development. Furthermore, Notch signaling is known to be 
involved in cellular responses to hypoxia and angiogenesis, two processes which are 
characteristic for human gliomas and HGG in particular [34].   
 
Primary GBM display elevated levels of Hes1 expression indicating active Notch 
signaling whereas low grade astrocytoma and secondary GBM show high levels of Hash-1, a 
sign of inactive Notch signalling [35, 36]. Both Hash-1 and Dll-1 expression (which is 
controlled by Hash-1) also correlated with lower grade gliomas and secondary GBM in an 
independent study [24]. Given the role of Notch signaling in maintaining an undifferentiated 
and proliferative state in NSC this is indicative of an oncogenic role of Notch in gliomas and 
primary GBM in particular [37]. Loss of Notch2 in oligodendrogliomas and GBMs was 
associated with favorable patient prognosis in a cohort of 26 OG and 118 GBM patients [25]. 
siRNA against Notch1 induced cell death, decreased proliferation and blocked cell cycle 
progression in transfected glioma cell lines. Mice orthotopically injected with siRNA-Notch1 
cells survived significantly longer than animals injected with control cells. Both these results 
indicate an oncogenic role for Notch in gliomas by maintaining an undifferentiated and 
proliferative state in cancer cells. A proteomic study emphasized such a function in Ras-
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mediated GBM [38]. However, other surveys could not link the functional role of Notch in 
gliomas to other genetic alterations. The Notch downstream genes Hey-1 and Deltex1 
nevertheless correlate with worse patient prognosis [39].  
 
 Notch signaling interacts with other signaling pathways known to be altered in GBM. 
For example, the RTK/RAS/PI3K pathway via EGFR cross talks with Notch signaling [37]. 
Different studies indicate a tight coupling of both pathways and down-stream targets in 
normal development and cancer; particularly well studied is this link in tumor angiogenesis 
[40-44]. Ras transformed astrocytes express more Notch and were more sensitive to GSI 
treatment. Over-expression of K-Ras together with Notch-ICD leads to periventricular brain 
lesions with active proliferation and elevated Nestin expression [38]. Notch was activated by 
Ras and PKB in a mouse glioma model. In addition, the stem cell marker Nestin was under 
direct transcriptional control of Notch [45, 46]. Together these findings indicate a direct link 
of EGFR/Ras, Notch, and Nestin. Furthermore, Notch can also induce the expression of EGFR 
in glial cells potentially pointing to a vicious circle of cross stimulation.  
  
 The mechanism by which quiescent cells, including adult stem cells, preserve their 
ability to resume proliferation after weeks or even years of cell cycle arrest are not known. 
This reversibility is not a passive property of non-dividing cells since forced cell cycle arrest 
of only 4 days induces premature and irreversible cell senescence. The Notch down-stream 
target Hes-1 is required for cellular quiescence to be reversible by preventing cell 
senescence or terminal differentiation. Therefore, active Notch signaling in GBM via Hes-1 
was suggested to safeguard against irreversible cell cycle exit both during normal cellular 
quiescence and pathologically in the setting of tumorigenesis [47]. 
 
Non-canonical Notch signaling through Deltex1. Deltex is a Notch interacting protein 
which contains a basic region at the N-terminus which binds to the Ankyrin repeats of the 
intracellular domain of Notch in Drosophila. Deltex has been proposed to regulate Notch 
activity by antagonizing the interaction between Notch and Suppressor of Hairless [48]. In 
mammalian cells, DTX1 has been shown to be a transcription target of Notch itself 
suggesting a positive feedback loop between Notch and DTX1. However, Deltex protein 
family members contain a RING finger domain at their C-terminus with E3 ubiquitin ligase 
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activity. Deltex forms part of a three protein complex (containing Notch, Deltex and non-
visual beta-arrestin) mediating the degradation of intracellular Notch through a 
ubiquitination-dependent pathway [49]. Loss-of-function mutations provided in vivo 
evidence for the functional relation of Deltex, Notch and non-visual beta-arrestin in 
Drosophila wing development. Therefore, Deltex appears to act as a signal repressor or as 
negative feedback regulator of Notch signaling in mammalian cells.  
 
Deltex also exerts its function on Notch independent targets. DTX1 exerts E3 
ubiquitin ligase activity on other protein substrates, such as the mitogen-activated protein 
kinase signaling component MAP kinase kinase kinase (MEKK1). Targeted MEKK1 
degradation by Deltex suppresses the activation of T-cells [50]. In mouse, three novel ligands 
to the Notch receptor family have been identified which signal specifically through the DTX1 
pathway [51-53] independently of RBPJκ and MAML1. However, the genes involved in this 
pathway are still ill defined [54, 55]. In summary, Deltex constitutes a distinct, cell context-
dependent Notch signaling pathway working in parallel or independently of canonical Notch 
signaling via RBPJκ.  
 
 
Figure 6. Notch signaling in mammalian cell [56]. 
 
Two families of transmembrane ligands and four Notch receptors exist in mammals. After ligand binding, Notch 
receptors are cleaved first by an ADAM metalloproteinase and then by the presenilin-γ-secretase complex. The 
resulting Notch intracellular domain (NICD) translocates to the nucleus, where it associates with the DNA 
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binding protein RBPJk (also known as CSL), converting it from a repressor to an activator of transcription. This 
induces the transcription of Hes family genes, which encode basic helix–loop–helix transcriptional repressors, 
and genes of the Herp family. Cell cycle regulatory genes, such as MYC, CCND1 (which encodes cyclin D1) and 
CDKN1A (which encodes p21) are induced in a cell type-specific manner. The Notch transcription-activating 
complex is terminated by phosphorylation of NICD by cyclin-dependent kinase 8 (CDK8), with subsequent 
recognition by ubiquitin ligases and proteasomal degradation. Negative regulatory mechanisms are also 
provided by the E3 ubiquitin ligases Deltex 1 (DTX1), ITCH, and NUMB. 
 
Inauguraldissertation  Roland M. Huber 
 - 19 - 
Animal Models of High Grade Gliomas (HGG) 
 
 In vitro cancer studies are limited in their informative value due to the fact that they 
consist of isolated cancer cells without tissue context or micro-environment. Metabolic 
processes, the blood-brain-barrier, or the interaction of tumor cells with the tumor stroma 
are missing. Animal models are powerful tools to investigate tumors in complex biological 
settings and enable the analysis of processes which do not take place in a culture dish (eg. 
angiogenesis, tissue invasion, metastasis, cancer-stroma interaction, etc.). Archetypical 
mutations in gliomas are known and through the help of animal models it is possible to 
identify the functional role of any such mutation and to probe for potential counter-
measures. Animal glioma models will hopefully provide methods for identifying promising 
therapeutic strategies and insight into basic biological processes of gliomas in vivo. 
Furthermore, the question of the cell of origin of high grade glioma (HGG) has not been 
resolved yet. The genetic profiles of gliomas are quite well established [3]. Mimicking the 
glioma specific mutations in different cell types could clarify the cell of origin question and 
thereby would identify the most reliable model for gliomagenesis. Several strategies are 
used to obtain such in vivo models and are summarized below (Table 1) [57].   
 
 
Table 1. Summary of strategies used to model gliomas in vivo (adapted from [57]) 
Strategy Principles Primary genetic 
modifications 
Cell-of-origin Secondary 
mutations 
Mutagens DNA alkylation unknown unknown likely 
Transplantation xeno- or allografts into 
immunocompromised animals 
unknown / known unknown less likely 
GM (germline) transgene or gene targeting known depending 
unknown or 
known 
more likely 
GM (somatic) replication competent virus known unknown more likely 
GM (somatic) replication deficient virus known known less likely 
 
Table 1. Listed above are the mechanisms that have been used to generate experimental gliomas in animals. All 
entail modulation of gene expression by one method or another.  
 
 
 All of these four (Table 1) methods have their specific advantages and disadvantages, 
and are utilized depending on the specific question at hand. Below, the different principles 
and methods are discussed according to their individual strengths and weaknesses. 
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Gliomas can be induced by DNA damaging agents (eg. nitrosurea derivates) which 
induce mutations in the host DNA. Although the lesions induced by such procedures bear 
similarities with gliomas, they are poor experimental instruments [58]. First of all, the 
mutations in the lesion are unknown as is the cell of origin. Secondly, the mutagens often 
induce additional neoplasms which compromise the analysis of the brain lesion. Thirdly, 
tumors have to be genetically characterized at the end of the experiment, making this model 
extremely time- and labor-intensive. Therefore, the value of such a model remains rather 
limited.  
 
Orthotopic and ectopic xeno- and allografts of glioma cells in nude or SCID mice are 
the most commonly used in vivo models of HGG. Compared to the above model using 
mutagens, this method offers several important advantages. The cells used for the 
implantation are often genetically characterized (mutations, LOH, over-expression of 
proteins etc.) and can be modified prior to the implantation. Standardized conditions make it 
possible to compare results. The use of different cell lines also gives insights into the effects 
of individual mutations compared to the genetic background of the cells. However, this 
model is also handicapped by several disadvantages: the recipient animal normally has no 
adaptive immune system. Adaptive immune reactions taking place in the tumor stroma are 
therefore absent and may compromise the entire study. Cells routinely used in these models 
are usually cultured for hundreds of passages selecting clones most competent of growing 
under culture conditions rather than reflecting the multi-clonal character of original tumors. 
Additionally, most of these grafts are dissimilar to human gliomas in respect of their 
histology as well as in their infiltrative behavior.   
 
Several large scale studies have characterized the mutation patterns in GBM [3, 24]. 
Although the cell of origin is not clearly identified yet, these patterns can be used to 
generate glioma models with defined genetic backgrounds. These genetic modifications 
(GM) can either be applied locally by means of virus injections or using a germline strategy. 
The later offers several options: oncogenes – in the case of HGG this could be EGFR, PDGFRA 
or constitutively active PI3K – can be over-expressed in general or even in a tissue specific 
manner. The same applies for loss of function of tumor suppressors which can be deleted by 
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gene targeting strategies or blocked in their function through the expression of dominant-
negative proteins. A combination of gain and loss of function give the possibility to generate 
almost any desired genotype in a specific tissue or cell type. However, it is often not 
sufficient to introduce such alterations to induce glioma growth but additional, spontaneous 
mutations are needed in the altered but still functional cells [57]. The last strategy for 
modeling gliomas is somatic cell genetic modification using retroviral vectors using either 
replication competent or incompetent viruses. When replication competent viruses are used 
a large number of cells are infected. This increases the probability to induce a glioma, 
however, it makes it also very difficult to control and analyze. More sophisticated systems 
use viruses which can only infect cells expressing a specific receptor (eg. avian leukosis virus 
which needs the tv-a receptor). The receptor can be expressed through tissue or cell type 
specific promoters defining the cell type which will be infected [57].  
 
In summary, the orthotopic implantation of glioma xenografts into immuno-deficient  
rodents is the only method available which gives reproducible results to date. Unfortunately, 
these models have proven to be poor predictors of therapeutic efficacy in humans [59]. 
Therefore, a model with better predictive power is urgently needed. 
 
Different allo- and xenograft models. Several graft models of HGG use allogenic material 
where gliomas have been induced through administration of mutagens to induce glial 
neoplasms. These are then cultured, analyzed and evaluated for experimental use. Due to 
the bigger body size, most of these models have been established in rats. These models 
include the C6, F98, 9L/LacZ and RG2 rat glioma cell lines which can be implanted into 
recipient animal brains. Although these cell lines are used for allo-transplantation, the 
animals usually receive a choline-deficient diet to reduce their immune-response [60]. The 
mouse glioma cell line GL261 and the human U87MG cell line can either be injected into 
immuno-compromised mice (eg. nude or SCID) or into inbred mice (eg. C57BL/6) fed with a 
choline-deficient diet. Additionally, low passage cultures can be xeno-transplanted from 
patient biopsies into immuno-compromised animals which give highly related pheno-copies 
of the initial lesion. 
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The question of the appropriate cell line for a glioma model relies on two main 
factors: which genetic background and which mutations should be present? If potential 
treatments are to be tested, most researchers favor human cell lines. Established cell lines 
are mostly genetically defined and specific mutations can be taken into account. Low 
passage ex vivo implants give pheno-copies of the original lesions and show a pronounced 
phenotype of infiltration, a trait often reduced in cell lines. However, these cell lines can 
neither be genetically modified (over-expression of a certain gene, for example) nor are the 
results comparable to other studies. Established cell lines on the other hand enable genetic 
modifications prior to implantation but often lack some of the glioma specific characteristics 
in the recipient animal (infiltration, ev. neo-vascularization).   
 
Work on the orthotopic brain tumor model established at the FMI and the evaluation 
of different anit-cancer drugs will be presented in chapter 2 of this thesis.  
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The Cell of Origin – A Stem Cell gone Awry?  
 
Totipotent embryonic or multipotent adult (or somatic) stem cells have several 
defining key features: i) they have a limitless replicative potential and telomerase activity, ii) 
they can self-renew and give rise to more committed progenitor cells in what is known as a 
stem cell division, and iii) they can give rise to all (embryonic) or several (adult) different cell 
types. Somatic stem cells are committed to a defined set of tissues their progenitor cells can 
differentiate into. In the brain the Neuronal Stem Cells (NCS) produce both neuronal 
progenitors which give rise to neurons as well as glial precursors which give rise to 
oligodendrocytes and astrocytes (Figure 3). These NSC are mostly localized in the sub-
ventricular zone (SVZ) or the Dentate Gyrus (DG) of the hippocampus. The NSC, like all 
somatic stem cells, are tightly regulated and controlled by their cellular niche. More recently, 
the principle of stem cells has been applied to cancer biology in what is referred to as “the 
cancer stem cell hypothesis”. The central tenet of this hypothesis is that solid and liquid 
tumors alike are composed of i) a relatively small subset of slowly cycling cells that undergo 
self renewal for an indefinite period of time and ii) a larger population of cells that have 
committed to a particular fate and have finite division capacity [16]. It is often speculated 
that unsuccessful therapies are related to a lack of effectiveness towards these Cancer Stem 
Cells (CSC) [61]. 
 
 
Table 2: Milestones in the History of the Glioma Stem Cell Hypothesis (adapted from [16]). 
mid 19
th
 century Lobstein, Cohnheim, and others comment on similarities between embryogenesis and the 
biology of cancer cells.  
1926 Bailey and Cushing develop the brain tumor classification system from which modern 
taxonomies derive. The system emphasizes the histological resemblance of brain tumor 
cells to cells of the developing CNS.  
mid 1960s Metcalf, Sachs, and others develop in vitro clonogenic assays to display the cellular 
progenitors of blood.  
1966 Altman and Das describe postnatal neurogenesis in rats.  
1988 Weissman et al. isolate the multipotent hematopoetic stem cell. 
1992 Reynolds and Weiss identify postnatal neural progenitors (in neurosphere cultures). 
1994 Dick et al. isolate malignant stem cells from human acute myeloid leukemia. 
2000 Prospective isolation of human CNS stem cells. 
2002 – 2004 Cancer stem cells isolated from adult and pediatric astrocytomas.  
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Although the similarities in embryogenesis and the biology of cancer have been 
described as early as the mid 19th century, it was in the late 1980s when the discovery of 
adult stem cells offered a functional link between the two (Table 2). The concept of stem-like 
cells in neoplastic diseases was first proposed in 1994 for leukemia [62]. After the discovery 
of adult NSC this model was then tested in gliomas identifying sub-populations of glioma 
cells with stem-like characteristics and elevated tumorigenic potential [63-66]. These 
findings suggest that a small fraction of the glioma cells are the driving force behind HGG. 
They are believed to – just as their adult stem cell counterparts – have the ability to 
proliferate infinitely, cycle slowly and additionally to be the mediators of both chemo- and 
radio-resistance. However, they significantly differ from normal SC in the way that they can 
only give rise to genetically abnormal progeny. An operational definition of glioma stem cell 
is a tumor cell sub-population that can self-renew in culture, perpetuate a tumor in 
orthotopic transplantation in vivo, and generate diversified neuron-like and glia-like 
postmitotic progeny in vivo or in vitro [16].  
 
However, important questions concerning this hypothesis remain elusive. Different 
studies use different methods to identify glioma stem-like cells rendering unclear if the same 
cell population was analyzed [66, 67]. Furthermore, most studies use the cell surface marker 
CD-133 to identify GSC form fresh surgical isolates. However, it has been demonstrated that 
CD-133 negative cell populations can have a more stem-like phenotype than their CD133+ 
counterparts challenging the idea of using a single cell surface marker to indentify glioma 
stem-like cells [68]. Also, endothelial cells and endothelial precursor cells express CD133. 
These cells are radio-resistant and could explain some of the features attributed to glioma 
stem-like cells if the samples were contaminated with such cells particularly in studies using 
fresh tumor biopsies. Thirdly, experiments with tumor xenograft models may lead to 
underestimation of the percentage of glioma stem-like cells due to interspecies barriers, 
questioning the idea of only few, tumor perpetuating cells [69]. 
 
Experimental analysis of GSC could be further distorted when using neurosphere 
cultures. Free floating neurospheres are highly mobile and readily fuse with other spheres as 
shown by time lapse microscopy. This mechanism could account for some of the 
heterogeneity of cells derived from single spheres under differentiating conditions rather 
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than the pluripotency of the neurosphere cells [70]. A similar kind of contamination with 
differentiated cells has, at least to some extent, to be expected in surgical isolates. Adjacent 
cells or tumor infiltrating cells could be co-cultured or even co-injected in xeno-
transplantation experiments which could account for the heterogeneity found in the 
resulting tumor. Together, these caveats show that there are important technical questions 
to be resolved before the CSC hypothesis can be further transferred to gliomas. It appears 
rather peculiar to apply the concept of stem cells – probably the most strictly regulated and 
most heavily shielded cell type of all – to cancer biology, unless the actual source of gliomas 
was a malignant adult stem cell. However, the cell of origin of gliomas remains unknown. 
Several possible cells of origins are currently debated in the literature and shall be briefly 
resumed below.  
 
Mature Glia Cells. Prior to the discovery of adult neural stem cells, mature astrocytes and 
astrocyte precursors were believed to be the only proliferation competent cells in the adult 
brain and therefore the most likely, if not the only possible source of gliomas. The fact that 
these cells would have to de-differentiate in order to produce the GBM specific histology 
presented a major question to this model. More recently it was shown that only a few 
transcription factors ectopically expressed in differentiated cells can lead to de-
differentiation into cells with ESC characteristics [71-73]. Targeting early cortical astrocytes 
in vitro and in vivo with oncogenes or activated signal generating proteins (eg. EGFRvIII or 
PDGFRA) can produce tumors in animal models with reliable glioma histology [74, 75]. 
However, the astrocyte marker used in these targeting experiments was GFAP, a protein 
expressed in various other types of progenitor cells as well. Therefore, the results obtained 
leave open the possibility that cells other than mature astrocytes had been targeted. 
Furthermore, this glioma inducing capacity has not been shown for mature astrocytes 
derived from adult brains suggesting that the intrinsic proliferation potential of the cells is a 
key determinant, at least in this experimental setup. In order to reach more reliable data on 
the de-differentiation hypothesis genetic methods which exclusively target adult astrocytes 
need to be developed.  
 
Neural Progenitor Cells. These cells are actively proliferating or at least have the intrinsic 
potential to do so. Therefore, less mutational ‘hits’ are needed to generate a glioma cell of 
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origin. NPC are usually cell lineage restricted and proliferate only at low rates. Activation of 
Sox2 in oligodendroglial precursors is sufficient to induce stem-like characteristics [76]. 
Similar mechanisms could also be involved in gliomagenesis. The NG2 progenitor cell 
population is the most actively cycling cell type in the adult brain. They have been reported 
to have multipotent qualities [77]. Furthermore, they can undergo epigenetic 
reprogramming in culture to produce neurons and astrocytes rather than oligodendrocytes 
[78]. Therefore, several modes of transformation are possible which require only few 
mutational alterations to give rise to a glioma initiating cell. Again, the lack of precise 
experimental tools allowing targeting precisely defined progenitor cell populations at a 
defined time point restricts the experimental design to cells manipulated in vitro.   
 
Multipotent Neural Progenitors. Adult stem cells and multipotent progenitors hold all traits 
required to become a glioma initiating cell in case of malignant transformation. Although 
there are important differences among the different classes of these cells (for review see 
[79]), they are all capable to proliferate and to give rise to glioma-histology-like tumors. In 
fact, several lines of evidence currently hint to these cells as the most likely cell of origin of 
gliomas without ruling out retrograde de-differentiation as an occasional way of CNS tumor 
development [19].  
 
 Both NSCs as well as GSCs are driven by the same signaling pathways. For example, 
the Notch signaling regulates the proliferation and differentiation of precursor cells during 
development. Several studies have shown now that Notch is constitutively active in high 
grade gliomas and that blocking it might have a positive effect on patient prognosis. 
Furthermore, other mitogens, such as PDGF, EGF, FGF etc., promote the growth of NPC and 
are often found to be active in glioma cells. Loss of PTEN, amplification of EGFR or mutations 
rendering this receptor constitutively active, and LoF of NF1 are frequently found in gliomas. 
However, these pathways are widely used even in the adult brain. Cell cycle regulating 
proteins like p16/p19, p53, or Rb are mutated in the majority of gliomas. Again, this does not 
indicate adult stem cells as source of gliomas since these proteins are also present in adult 
astrocytes. However, the transcription factor Olig2, which is not expressed in astrocytes, is 
often found in all types of glial tumors [27].   
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 At first clinical presentation gliomas are found in almost all brain regions, but most 
typically in the subcortical white matter, along blood vessels and in subpial collections [16]. 
Both glioma cells and NPC are highly motile and both white matter as well as blood vessels 
are established lines of migration for these cells. Clinical observations of GBM patients 
treated with brachy-therapy show a necrotic trail from the tumor towards the SVC along 
suspected migratory routes (A. Merlo, personal communication). It is appealing to suggest 
that this area indicates the general migratory behavior of glioma cells indicating cells in the 
SVC as cell of origin. 
 
 In summary, the current data favors the hypothesis of an adult stem or progenitor 
cell as source of gliomas. Mutations disrupt the tight control mechanisms usually in place 
ultimately leading to uncontrolled growth. However, this model does not answer the 
question why individual cells within a tumor (often referred to as cancer stem cells) have 
different tumorigenic potentials. Work on the function, signaling and targeting of such cells 
will be presented in chapters 1, 3, and 4. 
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Results 
 
Part 1 
 
 
The alternative Notch pathway via Deltex-1 is an oncogenic factor in 
malignant glioma. 
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Summary 
 
  Glioblastoma multiforme is the most malignant tumor of the central nervous system 
and results in more years of life lost than any other cancer type. Deltex1 is part of an 
alternative Notch pathway distinct from the canonical cascade. We show that DTX1 activates 
the RTK/PI3K/PKB and the MAPK/ERK pathway and induces anti-apoptotic Mcl-1. The 
clonogenic and growth potential of glioma cells correlated with DTX1 levels. DTX1 controlled 
the tumorigenic potential in vivo, and over-expression of DTX1 increased cell migration and 
invasion. Microarray gene expression analysis identified a DTX1-specific, MAML1-
independent transcriptional program - including microRNA-21. Patients with low DTX1 levels 
have a favorable prognosis. Therefore, we propose the alternative Notch pathway via DTX1 
as an oncogenic factor in glioblastoma.  
 
Significance 
 
 Glioblastoma multiforme (GBM) is a primary brain tumor of glial origin with poor 
prognosis and cancer related death in almost all patients. Low levels of Notch receptor 
expression correlate with prolonged survival in GBM and other gliomas. Different down 
stream pathways of Notch receptors are known; however, research has mainly focused on 
the canonical RBPJκ/MAML1-pathway. Here we show the alternative, or non-canonical, 
pathway functioning through Deltex1 (DTX1) to mediate key features of tumor 
aggressiveness. Proliferation, invasion, clonogenic potential and patient survival correlate 
with DTX1 levels. We identify a DTX1 specific gene expression profile which is functionally 
linked to the changes in tumor aggressiveness. These findings describe the role of 
NOTCH/DTX1 signaling in glial tumors and offer potential therapeutic targets. 
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Introduction 
 
Glioblastoma multiforme (GBM) is the most common primary tumor of the central 
nervous system. This malignant neoplasm occurs with an incidence of 3-7 cases per 100’000 
inhabitants per year in Western Europe and North America [1]. Despite continuing efforts to 
improve treatment over the last two decades and considerable advances in microsurgery, 
radio- and chemotherapy, median survival of patients remained limited around 14 months 
after diagnosis [2]. GBM is a highly aggressive tumor characterized by rapid growth and 
extensive infiltration of adjacent brain areas. Overall, GBM results in more years of life lost 
than any other cancer type as cancer related death is the case in nearly all patients.  
 
Notch receptors are evolutionary conserved transmembrane receptors which convey 
extracellular signals across the cell membrane and trigger signal cascades regulating gene 
expression. Best known for their role in development, Notch signaling has also become a 
major field of interest in cancer research. Notch activation has been implicated as a positive 
determinant of cancer formation in T cell acute lymphoblastic leukemias (T-ALL), primary 
melanomas, breast cancer and gliomas [3]. Furthermore, loss-of-function and gain-of-
function mutations of Notch receptors and their ligands have been related to the 
pathogenesis of various diseases [4] and Notch1 signaling was shown to control proliferation 
and apoptosis in gliomas [5]. Previous studies have also shown that loss of Notch2 positively 
predicts patient survival in subgroups of high grade glial brain tumors, including GBM [6]. A 
possible mechanism by which Notch mediates tumor aggressiveness is by the induction of 
Tenascin-C – an extracellular glycoprotein which correlates with malignancy in glioblastoma 
and other cancers [7] – by the Notch canonical co-activator RBPJκ. This indicates a 
mechanism by which Notch signaling modulates tumor invasiveness, one of the hallmarks of 
GBM [8, 9]. The role of canonical Notch signaling in cancer development, progression and 
metastasis is intensively studied. However, the role of the non-canonical signaling pathway 
via Deltex is still unknown. 
 
Deltex is a Notch interacting protein which contains a basic region at the N-terminus 
where it binds to the ankryn repeats of the intracellular domain of Notch in Drosophila. 
Deltex has been proposed to regulate Notch activity by antagonizing the interaction 
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between Notch and Suppressor of Hairless [10]. In mammalian cells, DTX1 has been shown 
to be a transcription target of Notch itself suggesting a positive feedback loop between 
Notch and DTX1. However, Deltex protein family members contain a RING finger domain at 
their C-terminus with E3 ubiquitin ligase activity. Deltex has been shown to be part of a 
three protein complex (containing Notch, Deltex and non-visual beta-arrestin) mediating the 
degradation of the intracellular Notch receptor through a ubiquitination-dependent pathway 
[11]. Loss-of-function mutations provided in vivo evidence for the functional relation of 
Deltex, Notch and non-visual beta-arrestin in Drosophila wing development. Therefore, 
Deltex appears to act as a signal repressor or as negative feedback of Notch signaling in 
mammals.  
 
Deltex also exerts its function on Notch independent targets. DTX1 has been shown 
to exert E3 ubiquitin ligase activity on other protein substrates, such as the mitogen-
activated protein kinase signaling component MAP kinase kinase kinase (MEKK1). Targeted 
MEKK1 degradation by Deltex suppresses the activation of T-cells [12]. In mouse, three new 
ligands to the Notch receptor family have been identified which signal specifically through 
the DTX1 pathway [13-15] independently of RBPJκ and MAML1. However, the genes 
involved in this pathway are ill defined [16, 17]. In summary, Deltex constitutes a distinct, 
cell context-dependent Notch signaling pathway. 
 
Regarding the cellular origin of gliomagenesis, several findings suggest progenitor or 
adult stem cells as possible founder cells of intracranial neoplasms. Most interestingly, 
Deltex has been shown to block the transcription factor MASH1 in neural progenitor cells by 
binding to p300 and thereby blocking differentiation of these cells. This differentiation block 
was shown to be independent of canonical Notch signaling via RBPJκ [18]. Furthermore, a 
Deltex mediated block of neural differentiation has been shown in microchaetae sensory 
precursors in Dorsophila indicating a conserved role for Deltex as a regulator of 
differentiation [19].  
 
In this study we provide evidence that DTX1 has an oncogenic role in high grade 
gliomas. We provide molecular insight in how a modulation of DTX1 levels changes the 
signaling network in cancer cells and relate this finding to changes in the proliferative, 
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migratory and clonogenic potential. We identify a set of genes specifically controlled by this 
non-canonical Notch signaling and its impact on the in vitro and in vivo tumor phenotype.  
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Results 
 
Deltex 1 is expressed in primary gliomas and glioma-derived cell lines 
 
 We analyzed Deltex1 (DTX1) expression both at the transcript and at the protein level 
in tumor biopsies and glioma-derived cell lines. First, we performed semi-quantitative RT-
PCR with cDNA derived from established glioma cell lines, tumor biopsies directly derived 
from the operating room and with low passage ex vivo glioma cell lines generated in our 
laboratory. All established cell lines showed DTX1 expression at varying levels. All tumor 
biopsies and all ex vivo cell lines showed robust DTX1 expression at the transcript level 
(Figure 1, A). We performed RT-PCR based transcript mapping, confirming in all probes full 
length transcripts by the presence of exon 1, 2, 3-5, 6-8, and 9 as well as of the 3’UTR of the 
mRNA with individual primer sets (data not shown). We found expression of DTX1 at varying 
levels in all glioma cell lines, tumor biopsies and ex vivo cell lines expressed by western 
blotting (Figure 1, B), confirming transcript analysis.  
 
To further validate our results, total RNA was isolated from two normal human brain 
controls, three normal human astrocyte cultures, 15 glioblastoma multiforme, seven 
astrocytomas (grade II-III) and six oligodendrogliomas, and processed for gene expression 
analysis by microarrays [20]. Two independent probes detecting DTX1 mRNA (1559618_at 
and 227336_at, Affymetrix) confirmed DTX1 expression in all samples analyzed. Most glioma 
samples with different histologies showed elevated levels of DTX1 expression (p=0.094) 
compared to controls (Figure 1, C). Altogether, we found DTX1 to be expressed in glioma 
biopsies and cell lines both at the transcript and protein level. 
 
 To further investigate the role of DTX1 in gliomas, we generated cell lines over-
expressing DTX1 (pcDNA3-DTX1-myc) and glioma cells with reduced levels of DTX1 through 
shRNA interference (pLKO.1-shRNA-DTX1) (Figure 1, D). Cell line U373 expresses high 
endogenous levels of Notch1 and Notch2, whereas cell line LN18 shows low expression 
levels for these two receptors [8]. Furthermore, U373 and LN18 differ in their p16/p14 status 
thereby representing the two major subclasses of GBM (U373: p16/p14 wild type; LN18: 
p16/p14 homozygous deletion) [21]. 
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Figure 1. DTX1 is expressed in gliomas, ex vivo cell lines and established glioma derived cell lines.  
 
(A) Semi-quantitative RT-PCR probing for exon 1 of DTX1 in established glioma derived cell lines, glioma tumor 
biopsies and ex vivo cell lines. Ex vivo cell lines were derived from tumor biopsies as indicated by the 
numbering and were maintained as low passage cultures. Fetal brain (FB) was used as positive control. (B) 
Western Blot analysis of glioma derived cell lines, glioma tumor biopsies and ex vivo cell lines probing for DTX1 
and β-actin. (C) Microarray gene expression analysis of tumors and control tissue. Two non diseased normal 
brain samples and three normal human astrocyte cultures were used as control (ctrl), 15 GBMs, seven 
astrocytomas and six oligodendrogliomas were analyzed. Bars represent average expression values per group 
±SEM. Results for both probes on the chip detecting DTX1 mRNA are shown. (D) Western blot analysis of 
transfected cell lines U373 and LN18 probing for DTX1, Myc-tag and β-actin demonstrating DTX1 over-
expression and down regulation as indicated according to the genotype.  
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Deltex 1 regulates signaling pathways of cell growth and survival.  
 
 
 Unlimited replicative potential of tumor cells is a hallmark of aggressive 
cancers. Notch acts as a switch-like signaling mechanism controlling the transition from 
proliferation to differentiation and vice versa depending on the cellular context. We 
therefore analyzed several signaling pathways in relation to the DTX1 status of the cell which 
are known to control proliferation and are often altered in GBM. 
 
 
 
Figure 2. Proliferation and signaling pathways are modified by DTX1 in glioma cell lines. 
  
(A) Western blot analysis of signaling proteins. Blots for total EGFR (t-EGFR), phosphorylated Akt/PKB (p-
Akt/PKB), total Akt/PKB (t-Akt/PKB), phosphorylated Erk (p-Erk), total Erk (t-Erk), Mcl-1 and beta actin (actin) 
are shown. (B) Proliferation analysis by BrdU incorporation assay. Relative average values of 5 individual 
experiments are shown per genotype. (C) Proliferation analysis by cell counting. Equal numbers of cells were 
seeded, grown for 3d under standard conditions and counted afterwards. (D) Apoptosis in U373 cells after 
treatment with 100μM temozolomide (TMZ) or DMSO vector control. Relative values of sub-G1 cells are shown 
normalized to control cells treated with vector control. Averages of at least three independent experiments are 
shown. Values are normalized to controls. Error bars: ±SEM. * p<0.05, ** p<0.01, *** p<0.001.  
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In gliomas, the PI3K/PKB/mTOR and the MAPK/ERK pathways are upregulated by 
specific mutations [22]. We analyzed the effect of DTX1 on the expression level of EGF 
receptor (EGFR), a receptor tyrosine kinase frequently over-expressed in gliomas. In the 
EGFR-expressing glioma cell line LN18, DTX1 over-expression increased EGFR protein levels. 
However, shRNA-DTX1 only marginally reduced EGFR levels (Figure 2, A). In the U373 cell 
line that does not express EGFR, we could not induce de novo expression of EGFR by DTX1 
(Figure 2, A). In both LN18-DTX1-myc and U373-DTX1-myc we observed a massive increase 
of the phospho-Akt/PKB (p-Akt/PKB) levels. In contrast, we detected a moderate reduction 
of p-Akt/PKB levels in the LN18-shRNA-DTX1 and U373-shRNA-DTX1 cells. In both glioma cell 
lines analyzed, down-regulation of DTX1 reduced the levels of phosphorylated Erk (p-Erk). 
On the other hand, DTX1 over-expression induced p-Erk (Figure 2, A). The changes observed 
for p-Akt/PKB and p-Erk levels were paralleled by changes in the total amounts of the 
proteins. The anti-apoptotic protein Mcl-1 was reduced by shRNA-mediated DTX1 down-
regulation and induced in DTX1-myc over-expressing cells in both cell lines (Figure 2, A).  
 
To determine how these changes in MAPK and PI3K/PKB signaling affect 
proliferation, we performed BrdU incorporation assays to detect alterations in tumor cell 
proliferation in relation to DTX1 levels. U373-DTX1-myc cells showed a slight increase in 
proliferation of 15% (p=0.15) whereas U373-shRNA-DTX1 cells displayed a significant 
reduction by 35% (p<0.001, ***) (Figure 2, B). In LN18 cells, over-expression of DTX1 
increased proliferation by 14% (p<0.01, **). However, down-regulation did not significantly 
change the proliferative behavior of LN18 cells (Figure 2, B). In accordance with the results 
obtained in the BrdU incorporation assay, we observed a reduction by 35% (p<0.01, **) 
when analyzing cell numbers after 3 days of unchallenged growth in U373-shRNA-DTX1 cells 
(Figure 2, C). In LN18-DTX-myc cells, we observed 14% more cells compared to controls after 
3 days of growth (p=0.26) (Figure 2, C). Background apoptosis was not changed in any of the 
cell lines compared to controls as analyzed by sub-G1 cell content (data not shown). When 
challenged with 100μM temozolomide relative apoptosis in U373-EGFP increased to 305% of 
control but only to 143% in U373-DTX1-myc cells (p < 0.01, **) (Figure 2, D). There was no 
significant difference between U373-shRNA-scr and U373-shRNA-DTX1 cells regarding TMZ 
sensitivity (data not shown).  
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 These results show that two major survival and growth promoting signaling pathways 
and the anti-apoptotic protein Mcl-1 are positively regulated by DTX1 in glioma cell lines. 
Proliferation and drug resistance correlated with these findings. A direct link between DTX1 
and the MAPK and PI3K/PKB pathways has so far not been described, we therefore wanted 
to identify the molecular mediators involved.   
 
Deltex 1 controls gene expression in glioma cells and regulates genes independently of the 
canonical Notch signaling cascade 
 
 We compared U373-EGFP GBM control cells to U373-DTX1 cells by microarray gene 
expression experiments that allow the identification of genes controlled by non-canonical 
Notch signaling. Given the tight interaction of DTX1 with Notch and the proposed negative 
feedback loop on the canonical pathway, we aimed to exclude genes which are altered due 
to a secondary inhibitory effect of DTX1 on the canonical pathway. Therefore, we compared 
the first dataset to the gene expression profiles of U373 cells expressing a dominant negative 
form of MAML1 (MAML1-dn) mimicking the negative feedback of DTX1 on canonical Notch 
signaling.  
  
 We identified 763 annotated genes to be differentially expressed in U373-DTX1 cells 
(665 up, 98 down) and 991 in U373-MAML1-dn (872 up, 119 down) when compared to EGFP 
control cells (Supplementary Table 1; Supplementary Figure 1, A). 572 genes were commonly 
affected in both cell lines compared to U373-EGFP control cells, 419 uniquely in U373-
MAML1-dn and 191 uniquely in U373-DTX1 cells (Supplementary Figure 1, B). Out of the 191 
annotated transcripts unique to U373-DTX1 cells (Supplementary Table 3), 121 were 
significantly up-regulated and 70 were significantly down regulated more than 2 fold 
compared to EGFP cells (Supplementary Table 1).  
 
 Unsupervised clustering based on overall gene expression profiles pointed 
towards a high similarity between MAML1-dn and DTX1 transcriptomes. This indicates a 
negative feedback role for DTX1 on canonical Notch signaling resulting in correlated effects 
(p<0.05) on overall gene expression (Supplementary Figure 1, A and 2, A). Unsupervised 
clustering based on the annotated 191 genes specifically altered in U373-DTX1 cells showed 
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high specificity for this DTX1 gene set compared to both EGFP and MAML1-dn expressing 
cells (p<0.05; Supplementary Figure 2, B). To confirm the validity of these two clusters, we 
assessed the uncertainty in hierarchical cluster analysis. For each cluster, p-values were 
calculated via multiscale bootstrap resampling [23]. These results confirmed that both 
clusters (Supplementary Figure 2, A, B) are strongly supported by data (p < 0.05). 
  
 
 
Table 1 
 
Accession ID Gene 
Symbol 
 
Protein Name fold 
change 
examples of genes up regultated >2-fold and related to cancer 
 
 
NM_004416 DTX1 deltex homolog 1 1) 47.20 
NM_005264 GFRA1 GDNF family receptor alpha 1 3.00 
AY699265 MIRN21 microRNA 21 2.85 
NM_001018159 NAE1 NEDD8 activating enzyme E1 subunit 1 2.54 
NM_018131 CEP55 centrosomal protein 55kDa 2.49 
NM_012096 APPL1 adaptor protein, phosphotyrosine interaction, PH domain and 
leucine zipper containing 1 
2.37 
NM_003238 TGFB2 transforming growth factor, beta 2 2.16 
NM_001025366 VEGFA vascular endothelial growth factor A 2.14 
NM_005921 MAP3K1 mitogen-activated protein kinase kinase kinase 1 2.05 
ENST00000321331 HIGD1A HIG1 domain family, member 1A 2.04 
NM_175866 UHMK1 U2AF homology motif (UHM) kinase 1 2.02 
   
 
 
examples of genes down regulated >2-fold and related to cancer 
 
 
NM_001040058 SPP1 secreted phosphoprotein 1 0.27 
NM_003811 TNFSF9 tumor necrosis factor (ligand) superfamily, member 9  0.28 
NM_002346 LY6E lymphocyte antigen 6 complex, locus E 0.30 
NM_001946 DUSP6 dual specificity phosphatase 6 0.41 
NM_020645 NRIP3 nuclear receptor interacting protein 3 0.43 
NM_016086 STYXL1 serine/threonine/tyrosine interacting-like 1 0.45 
NM_002231 CD82 CD82 molecule 0.46 
NM_030964 SPRY4 sprouty homolog 4 0.47 
NM_001964 EGR1 early growth response 1 0.48 
 
1) DTX1 over-expressing cell line 
 
 
 
Next we analyzed the functional groups of DTX1-specific genes according to their 
gene ontology (GO). Most genes belong to metabolic (23 genes) or signal transduction (22 
genes) networks. Among others, the GO categories cell cycle control, cell motion, 
extracellular matrix and apoptosis also contained 30 genes controlled by DTX1 suggesting a 
Inauguraldissertation  Roland M. Huber 
 - 40 - 
direct mechanistic link between the phenotypes observed and gene expression 
(Supplementary Table 2). We next performed an extensive literature search for all 191 genes 
specific for DTX1 with respect to their functional role in cancer and GBM in particular. Some 
20 genes with described functions in cancer specifically controlled by DTX1 are shown in 
Table 1. Interestingly, we observed an induction of miR-21, a microRNA which has previously 
been shown to target a network of tumor suppressive pathways in GBM cells [24].  Taken 
together these results identify a set of genes specifically controlled by non-canonical Notch 
signaling through DTX1 including known oncogenes and oncomirs.  
 
miR-21 expression is controlled by DTX1 and is p300 dependent 
 
 To evaluate the results obtained by microarray analysis, we performed quantitative 
PCR measurements of miR-21 levels. We found a reduction of miR-21 in U373-shRNA-DTX1 
to only 30% of the control levels (p< 0.001, ***) whereas over-expression of DTX1 resulted in 
an increase of miR-21 to 951% of the control (p < 0.001, ***) (Figure 3, A). 
 
Previous studies have identified the histone acetyl-transferase p300 as a binding 
partner of DTX1 which in turn modulates p300’s co-activator activity in various contexts [18]. 
Therefore, we analyzed the effect of p300 knock down on the DTX1 induced miR-21 
expression. We transiently transfected U373-DTX1-myc cells with siRNAs targeting p300 
(sip300) or scrambled control siRNAs (siCTRL) alongside a GFP vector. After 2 days, >80% of 
the cells showed GFP expression indicating high transfection efficiency (data not shown). 
p300 levels were analyzed by qPCR showing effective targeting of p300 (Figure 3, B). DTX1-
myc cells transfected with sip300 showed reduced miR-21 expression remaining with 23% of 
DTX1-myc control or 31% of siCTRL levels (p < 0.001, ***) (Figure 3, C). Transfection of U373-
DTX1-myc cells with miR-21 inhibitor (α-miR-21) reduced miR-21 levels to 25% compared to 
DTX1-myc cells (Figure 3, D) (p < 0.001, ***) and to 32% compared to cells treated with an 
inhibitor control (α-CTRL) (Figure 3, D) (p < 0.01, **).  
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Figure 3. DTX1 controls miR-21 expression in glioma cells in a p300 dependent manner. 
 
(A) Real time quantitative PCR analysis of miR-21 expression in U373 cells with modified DTX1 levels. (B) p300 
and (C) miR-21 expression levels in U373-DTX1-myc cells transfected with siRNA targeting p300 (sip300, red) or 
control siRNA (siCTRL, blue) analyzed by qPCR. (D) miR-21 expression in U373-DTX1-myc cells treated with miR-
21 inhibitor (α-miR-21, green) or an inhibitor control (α-CTRL, yellow). Average relative expression values of at 
least four independent experiments are shown. Error bars: ±SEM. * p<0.05, ** p<0.01, *** p<0.001. (E) 
Western blot analysis of signaling cascades in U373-DTX1-myc cells transfected with sip300 or siCTRL. Blots 
were probed for phosphorylated and total Akt/PKB, phosphorylated and total Erk, Mcl-1 and actin.  
 
  
 
Inhibition of miR-21 resulted in a reduction of p-Akt/PKB levels in DTX1-myc cells 
whereas the down-regulation of p300 did neither affect phosphorylation nor total Akt/PKB 
protein levels (Figure 3, E). Similarly, Erk phosphorylation and total amounts were not 
affected either upon inhibition of miR-21 (Figure 3, E). Mcl-1 expression was reduced in 
U373-DTX1-myc cells treated with sip300 but was unchanged in α-miR-21 treated cells 
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(Figure 3, E).  Taken together, these data demonstrate that miR-21 expression is controlled 
by DTX1. The induction of miR-21 and Mcl-1 is p300-dependent while activation of Akt/PKB 
depends on miR-21.   
 
The clonogenic potential of glioma cells is regulated by Deltex 1 
 
The ability to initiate clonogenic growth – a determinant of tumorigenicity – is 
reflected by the potential to form colonies in vitro when seeded at very low density, 
minimizing cell-cell contact or when grown in an anchorage independent manner in low 
density soft agar or as floating spheres. We therefore analyzed the clonogenic potential of 
glioma cell lines with modified DTX1 expression. 
 
Cells transfected either with EGFP, DTX1-myc, shRNA-DTX1 or shRNA-scr were 
seeded, grown for 3 weeks, fixed and stained with Cresyl violet. Over-expression of DTX1 
significantly increased the number of colonies compared to the EGFP control. We observed 
43% more colonies and 358% more colonies in U373 and LN18, respectively (p<0.001, ***) 
(Figure 4, A, B). U373-shRNA-DTX1 cells showed a significant reduction in colony formation 
by 42% (p<0.001, ***). Down regulation of DTX1 in LN18 cells resulted in a reduction by 73% 
(p<0.001, ***). The overall area covered by individual colonies appeared smaller in DTX1 
over-expressing LN18 cells. However, cell density was massively increased in these colonies. 
Furthermore, LN18-DTX1 cells showed a pronounced phenotype of aggregation and grew in 
multiple layers, which was not observed in control cells (Supplementary Figure 3).   
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Figure 4. DTX1 regulates the clonogenic capacity of glioma cells. 
 
 (A) Low density cell seeding of glioma cells with showing positive correlation between colony 
formation potential and DTX1 levels in glioma cell lines U373 and LN18. (B) Quantification of colonies formed in 
the low density seeding assay after 21d. All colonies were included irrespective of size. (C) Soft agar colony 
formation assay shown as light microscopic overview images (1, 3) or detailed close up images (2, 4) of a 
representative individual colony showing surface independent growth in 0.3% agar.  Scale bars: overview 
400μm; detailed view 80μm. (D) Quantitative analysis of the number of colonies formed after 15d of incubation 
in soft agar shown in (C). (E) Floating cancer spheres grown in NBE medium for 24d (shRNA-scr and shRNA-
DTX1) or 15d (EGFP and DTX1-myc) shown as light microscopic images. (F) Low density seeding of U373-DTX1-
myc cells treated with miR-21 inhibitor (α-miR-21) or control inhibitor (α-CTRL). (G) Quantification of low 
density seeding shown in (F).  Average values are shown. Error bars: ±SEM. *** p<0.001. 
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Anchorage-independent cell growth was also dependent on the DTX1 status. While 
the shRNA-scr control cells readily formed spheres with considerable density, the shRNA-
DTX1 cells only formed very few colonies. On average, these colonies were also smaller than 
the control spheres (Figure 4, C). In total, a reduction of around 90% of growing spheres was 
observed in the case of DTX1 down regulation in U373 (p < 0.001, ***) (Figure 4, D). Over-
expression of DTX1 in LN18 cells resulted in a 68% increase in colony number (p < 0.001, ***) 
(Figure 4, D).  Over-expression of DTX1 in U373 or shRNA-DTX1 in LN18 did not significantly 
change sphere formation. miR-21 inhibition did not change the clonogenic potential of 
glioma cells when plated at low density (Figure 4, F, G).  
 
Cells were seeded in serum-free neurobasal medium to check for differences in 
floating cancer sphere formation as an additional measure for the oncogenic effect of DTX1. 
Down-regulation of DTX1 reduced both colony numbers and size in both cell lines. U373-
DTX1-myc cells formed more and larger spheres when compared to EGFP control cells. 
Likewise, LN18-DTX1-myc cells formed larger spheres while control cells did only form few 
and small spheres (Figure 4, E). Taken together, these results show a significantly reduced 
aggressiveness of glioma cells with down regulated DTX1 as shown by the reduced ability to 
give rise to cell colonies or spheres in all assays performed. This effect was insensitive to 
miR-21 inhibition.  
 
Deltex 1 controls cell migration and invasiveness in glioma cells 
 
GBM are highly invasive neoplasms. We have previously shown that Notch signaling 
induces Tenascin C (TnC), a marker for tumor malignancy which stimulates glioma cell 
migration and invasion through the canonical Notch pathway. This induction was RBPJκ-
dependent and could be blocked by using a dominant negative form of the Notch canonical 
co-activator MAML1 (Sivasankaran et al., 2009). However, it remained unanswered if the 
non-canonical Notch pathway also has a regulatory role in cell migration and invasiveness.  
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Figure 5. Migration and invasion potential of glioma cells is regulated by DTX1. 
 
(A) Boyden chamber trans-well migration assay with U373 and LN18 glioma cells on collagen coated 
membranes with 8μm porosity. Counts were performed after 24h. (B) Scratch test wound healing assay. A 
scratch wound was inflicted and immediately imaged (time 0h). Follow up images were taken after 24 and 48 
hours. Dashed lines indicated border of cell layer. (C) Western blot analysis of known pro-migratory factors in 
glioma probing for Snail-1, Akt2/PKBβ, and beta-actin. (D) Boyden chamber trans-well migration assay with 
U373-DTX1-myc cells not treated (white), treated with a miR-21 inhibitor (α-miR-21, green) or an inhibitor 
control (α-CTRL , yellow). (E) Western blot analysis of known pro-migratory factors in glioma probing for Snail-
1, Akt2/PKBβ, and beta-actin after transfection with siRNA targeting p300 (sip300) or control construct (siCTRL) 
and after miR-21 inhibition (α-miR-21) or application of control inhibitor (α-CTRL). Average values are shown 
from at least three individual experiments. Error bars: ±SEM. * p<0.05, *** p<0.001. 
 
 
To determine this role, we performed transmembrane invasion assays with the two 
GBM cell lines U373 and LN18 by modifying DTX1 expression. DTX1 over-expression did not 
significantly alter the invasive behavior of U373 cells whereas the U373-shRNA-DTX1 cells 
showed an average reduction of invasion by 63% compared to control cells (p < 0.001, ***) 
(Figure 5, A). Cell invasion was elevated in LN18-DTX1 cells to 188% of the EGFP controls (p < 
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0.001, ***) whereas shRNA-mediated knock-down of DTX1 did not influence the invasive 
potential of LN18 cells (Figure 5, A). Again we observed a strong effect upon down-
regulation of DTX1 in the U373 cell line with high endogenous Notch levels. Similarly, up-
regulation of DTX1 in LN18 cells with low endogenous Notch levels increased migration.  
 
To confirm these results in an independent experimental setup, we performed 
scratch test wound healing assays. Wounds were imaged immediately after the scratch 
wound was inflicted as well as 24 and 48 hours later. Wound closing, which is a measure for 
cell motility, was massively reduced in U373-shRNA-DTX1 cells compared to controls (Figure 
5, B) confirming the initial finding of the transwell migration assay.  
 
 Elevated levels of p-Akt/PKB have been shown to positively correlate with migrating 
glioma cells, and reduction of total Akt2/PKBβ has been shown to inhibit the migratory as 
well as the invasive potential of glioma cells [25, 26]. To determine if the alterations in the 
invasive and migratory potential observed could be explained by these mechanisms, we 
analyzed the expression pattern of Akt2/PKBβ in our cell lines. We found a positive 
correlation of Akt2/PKBβ and DTX1 in both cell lines analyzed (Figure 5, C). The elevated 
levels of p-Erk in DTX1 over-expressing cells (Figure 2, C) pointed towards pathway know to 
regulate the migratory potential of cells through an Erk/NFκB/Snail1 pathway controlling 
epithelial to mesenchymal transition (EMT) in primary human mesothelial cells [27]. We 
therefore analyzed the levels of Snail1 in our glioma cell lines and found a positive 
correlation with DTX1 which is in accordance to the observed increase in p-Erk levels (Figure 
2, C).  
 
 Besides targeting a network of tumor suppressor genes, miR-21 has also been 
described as a migration and invasion promoting factor in gliomas [28]. Therefore we aimed 
at determining the effect of miR-21 on migration in DTX1 over-expressing cells. DTX1-myc 
cells treated with miR-21 inhibitors migrated 19% less than DTX1-myc cells (p < 0.05, *) and 
28% less than DTX1-myc cells treated with a control inhibitor (p < 0.001, ***) (Figure 5, D). 
Snail-1 upregulation was slightly p300, but not miR-21 dependent (Figure 5, E). Akt2/PKBβ 
induction through DTX1 was neither affected in cells with sip300 nor in cells treated with a 
miR-21 inhibitor (Figure 5, E). Taken together, we have demonstrated that DTX1 positively 
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correlates with glioma cell migration and invasiveness. Furthermore, we have shown that 
this effect could be mediated by alterations in known pro-migratory signaling pathways in 
GBM.  
 
Deltex 1 controls the tumorigenic potential of glioma in vivo 
 
  We analyzed the data publicly available at the REMBRANDT database 
(REpository of Molecular BRAin Neoplasia DaTa, NCI, NIH, USA) to determine if the in vitro 
findings could be brought forward to tumor behavior in patients. GBM patients with 
intermediate DTX1 expression levels had a median survival time of 402 days. Patients with 
low levels (reduced by 2 fold or more of intermediate) had a median survival time of 544 
days, an increase of more than 35%. Furthermore, the expression of DTX1, PKBβ, Snail-1 and 
EGR1 significantly correlated with patient survival in GBM patients (Supplementary Figure 4) 
(p < 0.05, *). To assess whether this finding was conferrable to other cancers, we analyzed a 
data set of early breast cancer samples [29] for the correlation of DTX1 expression levels and 
patient survival. Again, prolonged survival in the group with sub-reference DTX1 expression 
was detected throughout the period of observation (data not shown).  
   
 In summary, we found DTX1 expression levels to correlate with patient survival. Low 
DTX1 expression favors better prognosis in GBM patients. This is in accordance with our in 
vitro data and identifies DTX1 as an oncogenic factor in HGG.   
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Discussion 
 
The functional role of Notch has been intensively studied in human gliomas over the 
last years. Notch-signaling through distinct receptors regulates critical aspects of glioma 
biology such as differentiation, proliferation, tumor stroma and angiogenesis [30]. For 
example, Notch2 status has been identified as a highly significant prognostic marker in GBM 
and oligodendroglioma independent of other mutation patterns [6]. The role of DTX1, the 
mediator of non-canonical Notch signaling, has not been elucidated yet in cancer. DTX1 has 
been linked to invasiveness in osteosarcoma [31], however, its role in glioma remains 
elusive.   
 
 In this study we demonstrated an oncogenic role of DTX1 in high grade glioma. DTX1 
increased tumor aggressiveness, seen by elevated clonogenicity, increased the migratory 
and invasive potential of glioma cells and induced several signaling pathways protecting 
cancer cells form apoptosis and stimulating survival and proliferation. These effects are 
linked to a set of genes whose expression is specifically controlled by DTX1. We will discuss 
our results in the context of DTX1 as a regulator of gene expression, the regulation of DTX1 
itself and of DTX1 as a novel oncogenic factor.  
 
DTX1 has an oncogenic role in glioma 
 
 Oncogenes have the potential to induce malignant growth by conveying uncontrolled 
proliferation, insensitivity to growth limiting and pro-apoptotic signals, by inducing cell 
migration, invasion and neo-vascularisation. DTX1 aggravates several of these mechanisms 
in glioma cells. The ability to grow when seeded at low density, as floating spheres or in soft 
agar indicates abnormal growth potential and increased resistance to anoikis. These 
phenotypes are enhanced in glioma cells by high DTX1 levels. Our in vivo data further 
demonstrate that growth is enhanced in tumors with DTX1 over-expression. Furthermore, 
GBM patients with low DTX1 expression levels have a better prognosis and have a >35% 
longer median survival than controls. The increased levels of RTK/PI3K/PKB and MAPK/ERK 
activation observed in DTX1-myc cells offer a mechanistic explanation for this enhanced 
tumorigenic potential. The elevated protein levels of the anti-apoptotic factor Mcl-1 point to 
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a second mode of action. Interestingly, a link between Notch receptors and Mcl-1 had been 
demonstrated [32]. However, this effect could not be assigned to the canonical factors 
MAML1 and RBPJκ. Taken together, these findings suggest that Mcl-1 is specifically 
controlled through the non-canonical Notch pathway. DTX1 mediated effects may be 
conferrable to other solid tumors. For example, the better prognosis of early breast cancer 
patients with low DTX1 expression levels points in this direction.  
 
 Massive tumor cell migration and brain invasion are hallmarks of GBM. These 
migrating cells pose a major obstacle to any successful therapy, thwarting complete surgical 
resection. DTX1 positively correlates with the migratory and invasive potential of glioma 
cells. This effect is depending on the levels of endogenous Notch. For example, in U373 cells, 
which have high levels of endogenous Notch, DTX1 only alters the migratory behavior upon 
down-regulation. In low Notch expressing LN18 cells the opposite is true. Although the pro-
migratory factors Snail-1 and Akt2/PKBβ are influenced by DTX1 in both lines, high Notch 
activity appears to saturate the migratory behavior and cannot be further induced by over-
expressing DTX1 whereas low Notch levels readily induce migration. The MAPK/ERK pathway 
has previously been linked to proliferation and migration in glioblastoma [33]. DTX1 levels 
strongly correlate with the levels of p-Erk in all cell lines analyzed independent of Notch 
levels. Furthermore, MMP-9, an endopeptidase that digests basement membrane type IV 
collagen, is induced by p-Erk in glioma cells [34]. Therefore, elevated levels of p-Erk could 
explain the increased invasive potential while the elevated levels of Akt2/PKBβ act on cell 
adhesion and cytoskeleton rearrangement [26] leaving the cells with significantly aggravated 
invasive and migratory behavior as observed in our experiments.  
 
DTX1 controls the expression of oncogenes, tumor suppressors and oncomirs in glioma 
 
 Deltex has been shown to be a negative regulator of Notch signaling in cancer cells by 
targeting the Notch-ICD for ubiquitination and degradation [31]. Notch signaling itself 
induces Deltex which thereby leads to a negative feedback loop. The high degree of 
similarity in our overall gene expression profiles between MAML1-dn and DTX1-myc cells 
further supports this model. However, DTX1 also controls genes which are not regulated by 
the canonical Notch pathway and have a direct impact on cancer progression, e.g. miR-21 
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which has a well established role as an oncomir through several modes of action [24, 35, 36]. 
Our results demonstrate miR-21 activation through non-canonical Notch signaling to depend 
on p300 levels. In C. elegans LIN-12/Notch signaling has previously been linked to microRNA 
expression [37]. The two Notch signaling pathways may represent an evolutionary conserved 
mechanism of microRNA regulation.  
 
 DUSP6, a gene down regulated in DTX1 over-expressing cells, belongs to a 
class of dual-specificity phosphatases which dephosphorylate MAPK pathway proteins ERK, 
JNK, and p38 [38]. This offers a direct functional link between DTX1 specific gene expression 
and p-Erk levels. Additionally, we found APPL1, a co-activator of Akt2/PKBβ [39], to be up-
regulated by DTX1. Both have a similar activating effect on cell migration in glioma cells. It is 
not clear to which extent the change in the invasive potential of the cells is mediated by 
these pathways or by miR-21, which also has been described as a regulator of invasiveness. 
However, inhibition of miR-21 alone did not reduce migration as much as down regulation of 
DTX1 did, indicating an additive, combinatorial effect of several mechanisms controlled by 
DTX1.  
  
 Altogether, DTX1 activates a set of transcripts with oncogenic functions and 
down regulates tumor suppressors in parallel. How these different aspects interact and to 
which extent the changes in expression are direct or indirect remain to be established. An 
additional layer of complexity is added by the fact that not all changes in gene expression or 
signaling are p300 dependent in our experiments. Whereas miR-21, Snail-1 or Mcl-1 
expression was reduced in cells with diminished p300 levels this was not the case for 
Akt2/PKBβ or Erk. Several modes of action could explain this finding. DTX1 has been shown 
to bind to p300 and thereby sequester it from its previous binding partners. This effect leads 
to the inhibition of the transcription factor MASH1 which controls differentiation in neural 
progenitor cells [18]. If the change induced by DTX1 is caused by reducing p300 availability at 
a certain site, a further reduction of p300 by siRNA would not further enhance the initial 
alteration. Non-canonical Notch signaling also inhibits E47, a widely expressed transcription 
factor [40]. Therefore, DTX1 could regulate gene expression directly by forming a DNA 
binding complex with p300 and thereby reducing its availability and/or by changing the 
activity of other transcription factors.  
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Deltex can be activated by Notch and other signaling cascades  
 
If the DTX1 specific transcriptional program is activated by specific ligands of Notch 
receptors as it was shown for oligodendrocyte maturation which is induced by F3/Contactin 
[13], remains to be determined. The NB-3/Notch1 pathway also has been reported to signal 
specifically through DTX1 but not through the canonical pathway [41].  
Although Notch receptors are the best established activators of Deltex, there are also 
other mechanisms described. The transcription factor NFAT (nuclear factor of activated T 
cells) was shown to induce DTX1 expression in T cells where DTX1 then acted as a 
transcriptional regulator independently of Notch [42]. Granule cell precursors of the 
cerebellum increase DTX1 expression when stimulated with Shh [43]. If this induction of 
Deltex occurred directly or if this was a secondary effect due to overall changes in gene 
expression remained unaddressed. Regarding GBM, DTX1 is induced by Notch signaling, 
however, alternative pathways like SHH may also contribute to direct activation of DTX1. It 
remains to be shown in glioma if NB3, F3/contactin and other specific ligands to Notch 
receptors exclusively signal through the non-canonical pathway. In conclusion, we propose 
the alternative Notch pathway via DTX1 as an oncogenic factor in malignant glioma. We 
found low DTX1 expression levels to correlate with prolonged survival in solid tumor 
patients.   
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Experimental Procedures 
 
Cell culture and cell lines 
 
Glioma cell lines (LN18, U373) with defined genetic status for TP53, p16/p14 and 
PTEN were cultured in Eagle’s medium supplemented with 25mM glucose, glutamine, 
standard antibiotics, and 10% fetal calf serum. All cells were maintained at 37°C in 5% CO2 in 
a humified chamber (standard conditions). If not stated otherwise in the figure legends, cells 
were seeded at 5’000-10’000 cells/cm2 in 94mm culture dishes (Sarsted, Nümbrecht, 
Germany). For cell counting, the cells were cultured and treated as stated in the figure 
legends and counted using a ‘Neubauer’-chamber (hemacytometer).  
 
Plasmids and transfections 
 
 The lentiviral vectors pLKO.1-puro-scrambled-shRNA (Addgene, Cambridge, MA, USA) 
and pLKO.1-puro-shRNA (Sigma, sh1938: CCGGC CACTG CTATC TACCC AACAA CTCGA GTTGT 
TGGGT AGATA GCAGT GGTTT TT) targeting DTX1 were transfected into HEK293 cells 
together with plasmids encoding the packaging (pCMV_dr8_91) and envelope proteins 
(pMD2-VSV-G) using CaCl2 precipitation. The concentration of infectious particles in the 
supernatant was titrated using HeLa cells. Glioma cells were transduced with infectious viral 
particles. Stably transfected clones were selected with 2 µg/ml puromycin. DTX1 over-
expression was obtained with pcDNA3-IRES-EGFP as control and pcDNA3-DTX1-myc-IRES-
EGFP (kind gift form Prof. Kimie Ohta, Keio University, Japan) using CaCl2 precipitation for 8 
hours. Stably transfected clones were selected with 100 µg/ml geniticin (Gibco, Invitrogen, 
San Diego CA, USA).  
 
RT-PCR and qPCR  
 
 RNA was extracted using TRI-Reagent (Sigma, St.Louis MO, USA), phenol/chloroform 
extraction and were purified with RNeasy spin column kit (Qiagen, Venlo, The Netherlands). 
cDNA synthesis was performed using the ‘Thermo Script RT-PCR System’ and random primer 
hexameres (Invitrogen, San Diego CA, USA). DTX1 primers: fwd (5’- GGGCT GATGC CTGTG 
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AATG-3’), rev (5’- CCTGG CGAAA CTGGT GC-3’). RNA and cDNA amounts were measured on a 
NanoDrop ND-1000 Spectrophotometer and equalized prior to synthesis reactions. qPCR for 
p300 was performed as described elsewhere [44]. microRNAs were isolated using miRNeasy 
Mini Kit (Qiagen) according to manufacturer’s instructions. Taqman MicroRNA Reverse 
Transcription Kit and Megaplex RT Primers human pool A v 2.1 (Applied Biosystems) were 
used for cDNA synthesis of microRNAs and Taqman Pri-miRNA Assay for the measurement of 
miR-21 levels according to manufacturer’s instructions (Applied Biosystems).  
 
Cell proliferation analysis  
 
 Cell proliferation was analyzed using the ‘Amersham Cell Proliferation Biotrak ELISA, 
version 2’ system (GE Helathcare, UK) according to manufacturer’s instructions. In short, 
5’000 cells were seeded in the well of a 96-well plate and grown for two days, labeled with 
BrdU for 3-4h, fixed and labeled with a peroxidase-labeled anti-BrdU antibody. After coloring 
reaction the optical density was measured with a ‘SpectraMAX 250’ plate reader and 
analyzed with accompanying ‘Soft Max Pro’ software (Molecular Devices, MDS Analytical 
Technologies, Toronto, Canada). For cell counting, equal amounts of cells were seeded in 
triplicates and grown under standard conditions. Cells were then harvested and each 
biological replicate was counted ≥8 times using a ‘Neubauer’-chamber (hemacytometer).  
 
Colony formation, shpere and soft agar assay 
 
 In colony formation experiments for each cell line 1’000 cells were plated in 
triplicates into 94-mm Petri dishes containing 10 ml of standard culture medium. Cells were 
then fixed with 4% formaldehyde in 1x PBS and stained with crystal violet. For sphere 
formation, cells were seeded in Neurobasal medium (Invitrogen) supplemented with basic 
FGF (20 ng/ml, Invitrogen), EGF (20 ng/ml, R&D Systems), B27 supplement (1x) and N2 
supplement (0.5x) (Invitrogen) and grown under standard conditions for different times: 
shRNA-scr and shRNA-DTX1 for 24d, EGFP and DTX1-myc cells for 15d. In soft agar 
experiments for each cell line 1’000 cells were seeded in 0.3% agar (Nobel Agar, Becton 
Dickinson, USA) in DMEM supplemented with 10% FCS without phenol red (Gibco, 
Invitrogen, San Diego CA, USA) and grown for 15 days under standard conditions. All spheres 
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were documented with an ‘Olympus IX50’ microscope using the ‘Color View Soft Image 
System’ controlled by ‘cell^P’ software (Olympus, Tokio, Japan).  
 
Transwell migration and scratch test assay 
 
Transwell migration assays were performed using modified Boyden chamber units 
with polycarbonate filters of 8μm porosity (Costar, Vitaris, Switzerland). The lower side of 
the filter was coated with 25 μg/ml collagen 1 (Sigma, St.Louis, USA) for 2h at 37°C. The 
bottom chamber was filled with DMEM containing 10% FCS. Cells (2x104 per well in serum-
free DMEM) were plated in the upper chamber in 100μl medium and incubated for 24h in 
standard conditions. After removal of the remaining cells from the upper surface of the filter 
insert, migrated cells at the bottom of the filter were fixed with 3.7% formaldehyde in PBS 
and stained with 0.1% crystal violet. For every individual filter, the cells in 9 fields of view 
were counted. Every experiment was conducted in triplicates.  
For scratch test analysis, cells were grown to ~90% confluency under standard 
conditions. A wound was inflicted by scratching a 200μl pipette tip (Starlab, Milton Keynes, 
UK) over the surface of the culture flask. The wounds were documented as described above 
for the soft agar immediately after scratching, after 24 and 48 hours.  
 
Western blot analysis and antibodies 
 
Cells were grown to 80-90% confluency, washed twice with 1x PBS, lysed in buffer 
containing 2% sodium dodecyl sulfate (SDS), 50mM Tris pH 6.8, 0.1M dithiothreitol (DTT), 
boiled at 95°C for 5min and used either immediately or frozen at -20°C. Protein lysates were 
resolved on denaturing 8-12% SDS-polyacrylamide gels and transferred to nitrocellulose 
membranes (iBlot Gel transfer stacks, Invitrogen). The following primary antibodies were 
used: anti-Actin (Sigma-Aldrich, St. Louis, USA), anti-phospho-Akt/PKB and anti-total-Akt/PKB 
(Ser-473) (Millipore), anti-Akt2/PKBβ (Cell Signaling), anti-DTX1 (ABBiotech), anti-EGFR 
(Santa Cruz Biotechnology), anti-phospho-Erk and anti-total-Erk (Santa Cruz Biotechnology), 
anti-Mcl-1 (Santa Cruz Biotechnology), anti-Myc Tag (Millipore) and anti-Snail1 (Abcam). 
Decorated proteins were revealed using horseradish peroxidase-conjugated anti-mouse, 
anti-rabbit, anti-rat (New England Biolabs) or anti-goat (Pierce) secondary antibodies and 
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visualized by the chemoluminescence detection system SuperSignal West Pico (Thermo 
Scientific).  
 
Microarray analysis of patient biopsies and cell lines 
 
Microarray gene expression analysis of patient biopsies has been reported earlier 
[20]. This data set was reanalyzed in respect of DTX1 expression. For cell lines, total RNA was 
extracted from U373-EGFP, U373-DTX1-myc and U373-MAML1-dn cells in triplicates and 
amplified once. Samples were hybridized to Affymetrix chips HuGene 1.0 ST v1. The data 
analysis and gene filtering was performed using R/Bioconductor [45]. Signal condensation 
was performed using only the RMA from the Bioconductor Affy package. Differentially 
expressed genes were indentified using the empirical Bayes method (F-test) implemented in 
the LIMMA package and adjusted with the False Discovery Rate (FDR) method [46]. We 
selected those probe sets with a log2 average contrast signal of at least 4, an adjusted p 
value <0.01 and an absolute linear fold change of >2. The gene expression data has been 
deposited at the Gene Expression Omnibus Databank (accession ID: GSE22772) according to 
MIAME standards. Hierarchical clustering and visualization was performed in R software. The 
scripts are available upon request. Assessment of the uncertainty in hierarchical cluster 
analysis was performed with “pvclust” package as described elsewhere [23] based on all 
annotated genes or 191 annotated genes specifically alerted by DTX1 as described in the 
text. 
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Supplementary Material 
 
 
 
Supplementary Figure 1. Heat map of differential gene expression in glioma cell lines with modified Notch 
canonical and non-canonical signaling.  
 
(A) Gene expression values are shown as color coded heat map with red representing low and white 
representing high expression values. The three samples are listed on the x-axis, individual genes on the y-axis. 
Gene clustering was performed according to similarity in expression pattern. All genes shown are differentially 
expressed in at least one sample (fold change of expression >2, p-value < 0.01). Asterisks indicate example 
areas with unique expression patterns in DTX1-myc cells. (B) Venn-Diagram of gene expression analysis. Genes 
differentially expressed in U373-DTX1-myc are shown in red, genes differentially expressed in U373-MAML1-dn 
are shown in blue, genes altered in both cell lines are shown in purple. 
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Supplementary Figure 2. Dendrograms based on gene expression profiles of glioma cell lines. 
 
Dendrograms based on the gene expression profiles of the glioma cell lines used visualizing relatedness of 
samples based on (A) overall gene expression pattern including all 22’000 genes annotated on the microarray 
and (B) based on the 191 genes indentified to be specifically controlled by DTX1. p-values were calculated via 
multiscale bootstrap resampling.  
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Supplementary Figure 3. Colony size and cell density are changed in LN18-DTX1-myc cells. 
 
(A) Low density seeding colonies shown as light microscopic pictures demonstrating the aggregation phenotype 
in LN18-DTX1-myc cells. Arrows point to the center of individual colonies indicating the area of aggregation in 
LN18-DTX1-myc cells. Close up images show borders of colonies at higher magnification.  
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Supplementary Figure 4. Kaplan-Meier survival plots for samples with differential gene expression in GBM 
and early breast cancer. 
 
Survival plots based on the expression levels of DTX1, PKBβ, Snail-1, and EGR1 in color coded graphs. Red: up 
regulated by 2 fold or more; green: down regulated by 2 fold or more; yellow: intermediate gene expression. P-
values for all four samples up to 1’500 days in study are below 0.05 . Data derived form the Repository for 
Molecular Brain Neoplasia Data, NCI, NIH.  
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Summary 
 High grade gliomas (HGG) are tumors of the central nervous system with unmet 
medical needs. Grade IV HGG, known as glioblastoma multiforme (GBM), are rapidly growing 
and highly infiltrative, making large volume tumor resection and irradiation impossible. 
Effective chemo/bio-therapeutic strategies which can be applied systemically and reach all 
tumor cells irrespective of their localization are therefore urgently needed. Previous work in 
our lab has identified a combination of histone deacetylase inhibitors (HDI) and glycolysis 
inhibitor 2-deoxy-D-glucose (2DG) as potent strategy inducing cell death in glioma and other 
cancer cell lines in vitro. The synergistic effects of epigenetic remodulation of cancer cells 
paralleled by energy deprivation induced apoptosis at high levels without negative effects on 
control cells. Here we report the evaluation of this combination therapy in an in vivo model 
of GBM. Treatment of orthotopic glioma in nude mice with high levels of 2DG in combination 
with the HDI sodium butyrate (NaB) significantly reduced tumor growth without detectable 
side effects. Treated tumors displayed areas of necrosis not found in control tumors and 
increased levels of apoptosis. In contrast, these were not found in control tumors. Overall, 
the combinatorial use of HDIs and 2DG has anti-tumor properties in vivo. We suggest this 
therapy to be evaluated in a clinical setting in order to determine the efficacy in HGG 
patients.   
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Introduction 
The treatment of malignant high grade gliomas consists of three major lines of 
attack. The late detection of most gliomas and the fast growth rate make surgical resection 
of the tumor bulk, which leads to increased intracranial pressure, imperative in basically all 
cases. Removal of the tumor mass alleviates neurological symptoms. However, given the 
highly infiltrative phenotype of gliomas and GBMs in particular, a complete surgical resection 
is not possible and recurrence is usually the case within a 2 cm margin of the original tumor 
edge in 95% of cases [1]. The second line of attack is radiotherapy, which can be applied 
both before (experimental) and after surgery (standard). Preoperative irradiation helps to 
demarcate the tumor-brain border and facilitates surgical resection. Postoperative 
irradiation mainly aims at eradicating residual tumor cells adjacent to the resection site or 
even in whole brain applications. The side effects of whole brain irradiation can be 
substantial, particularly in young patients. Radio-sensitizers, such as temozolomide, and 
occasionally 2-deoxy-D-glucose, are applied to increase the effectiveness of radiotherapy [2]. 
Thirdly, glioma patients are treated with chemotherapy aiming at eliminating residual tumor 
cells. The drug most commonly used is the DNA-alkylating agent Temozolomide, which is 
also used as a radio-sensitizer. However, the effectiveness of this compound is under intense 
debate [3].    
 
  Numerous potential drug targets and therapeutic compounds targeting GBM cells 
have been published. However, no therapy which improved patient prognosis by more than 
a few weeks has been reported up to date [3]. A major bottleneck hampering progress is the 
translation of in vitro into in vivo results. This still is a prerequisite for any clinical trial 
although in vivo models of GBM have proven to be of poor prognostic value for the 
effectiveness in patients [4]. We aimed at establishing an in vivo GBM model enabling us to 
evaluate our previous in vitro data and to potentially provide in vivo data for subsequent 
clinical trials. We choose a model of human glioma cells (U87MG) transfected with firefly 
luciferase which can be implanted into immuno-compromised nude mice [6]. The tumor can 
be visualized by injecting luciferin which will be cleaved by the luciferase enzyme in a 
luminescent reaction. The cleaving of luciferin sets photons free which can be recorded with 
super-sensitive digital cameras. It was shown, that tumor size is reliably represented by the 
bioluminescence of the implant, making tumor measurement very quick and comparatively 
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easy [5].  Furthermore, the treatment effects can be evaluated in human tumor cells, 
however in an artificial environment without an operative adaptive immune system. 
Immunological effects are therefore absent in this setting. On the other hand, using a model 
well established in the field make the results comparable to other studies.  
 
We previously reported a study on the use of Histone Deacetylase Inhibitors (HDI) in 
combination with 2-deoxy-D-glucose as a potential cancer therapy [6]. Because HDIs induce 
re-expression of tumor suppressor genes in several distinct pathways [6] and cancer cells 
critically depend upon continuous energy supply, we explored the therapeutic potential of a 
combination of these two compounds that simultaneously target the epigenetic status and 
the energy demand of cancer cells. Synergistic effects may even allow reducing the drug 
dosage of potentially toxic HDIs [7] although HDIs of the new generation are well tolerated 
[11]. We found that the combination of 2-DG and HDIs lead to a strong synergistic effect 
resulting in widespread apoptosis of tumor cells of the brain, breast, and cervix, while 
sparing normal rat astrocytes in vitro [6].  
  
 The aim of the study reported here was: i) to evaluate the in vivo efficacy of the HDI + 
2DG combination therapy as chemo-therapeutic approach targeting gliomas in vivo, ii) asses 
the toxic effects of the combination therapy on the host animal, and iii) compare the anti-
tumor potential of selected dosing regimens and drug concentrations. We show that HDI 
(sodium butyrate) in combination with 2DG applied at high concentration for 4 consecutive 
days significantly reduces tumor growth in vivo without having acute toxic effects. We 
suggested the treatment of high grade gliomas with the HDI + 2DG combination therapy as a 
novel strategy which should be evaluated in a clinical setting.  
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Results 
 
Bioluminescence of different glioma cell lines expressing firefly luciferase analyzed for in 
vivo suitability  
 
 A bioluminescent cell line used for tumor growth analysis needs to meet several 
criteria: i) the cell line has to be tumorigenic in the host animal, particularly at the site of 
implantation (subcutaneous, in the brain, etc.), ii) BL has to be a reliable representation of 
tumor size, and iii) the generated tumor should closely reproduce the original tumor 
histologically, anatomically, and biochemically. The well established cell line U87-luc [7] 
routinely used in orthotopic in vivo GBM models meets most of these requirements, except 
that it does not generate a tumor with particular GBM-like histology. We therefore aimed at 
generating luciferase expressing cell lines derived from GBMs attempting to generate a 
model which would reflect the clinical situation more precisely. We transfected U373 and 
LN18 cells with a luciferase expression vector, and analyzed individual, stable clones in 
respect of their suitability as an orthotopic glioma model.   
  
U87-luc cells show linear correlation of BL and cell number (Figure 1, A) and a linear 
correlation of signal intensity and tumor size in vivo was reported previously [5]. This cell line 
was used as reference in the subsequent analysis. Stable U373-luc and LN18-luc clones were 
analyzed for luciferase expression by Western blot analysis (Figure 1, B) and clones with high 
Luc-protein levels were evaluated in a luminometer (Figure 1, C). Four clones showed linear 
correlation over a wide concentration range and were therefore used in pilot orthotopic in 
vivo experiments. Only one clone (U373-pLuc) resulted in detectable tumors. However, BL 
was only significantly above background levels 5-8 days prior to the onset of illness in the 
host animal; a time period which does not allow to perform adequate experiments. In 
comparison, U87-luc cells are detectable 5-7 days post implantation with an observation 
period of up to 35 days prior to the onset of symptoms. The late signal detection could be 
explained by the lower Luc activity in the newly generated cell lines (Figure 1, D). The 
subsequent experiments were therefore performed with the reference cell line U87-luc.  
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Figure 1. Bioluminescence of different luciferase transfected glioma cell lines 
 
(A) BL of U87-luc cells. Dashed line shows best-fit curve (R
2
 = 0.9744) demonstrating linear proportionality of BL 
and cell numbers. (B) Western blot probing for luciferase in transfected U373 cells. Seven stable clones are 
shown. (C) BL of clones #3 and #6 from (B) are shown. Dashed lines show best fit curve (R
2
 > 0.98) indicating 
direct proportionality between BL and cell numbers. (D) BL of different glioma cell lines transfected with 
luciferase compared to U87-luc reference cell line. 5x10
5
 cells were measured each. BL is shown on an arbitrary 
scale corresponding to photons/time in panels (A), (C) and (D).  
 
 
Orthotopic U87-luc tumors show exponential growth in the brains of Foxn1
nu
 nude mice 
  
 Nude mice (Crl:Nu) were implanted with 5*105 U87-luc cells in 10μl of sterile PBS 
3mm caudal and 2mm lateral to the bregma of the scull and 3mm below the dura. After 7 
days of recovery, the animals were injected with the luciferin substrate and analyzed in an in 
vivo bioluminescence imager (Figure S1, A-E). Unchallenged growth resulted in exponential 
signal increase in asymptomatic host animals for up to 4 weeks (Figure 2, A). A signal 
intensity of more than 108 photons per second (ph/s) for a given tumor was soon paralleled 
by pain related behavior. In a pilot group we found that animals with tumors above this 
threshold did not survive for more than 3-4 days during which they showed overt signs of 
pain and uneasiness. Therefore, 108 ph/s was defined as termination criteria for all following 
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experiments.  Following this rule, untreated control animals reached a median survival of 28 
days post implantation (Figure 2, B).  
 
 
 
 
 
Figure 2. Bioluminescence of control tumors 
 
(A) BL of untreated control U87-tumors. Error bars: ±SD. Dashed line shows best-fit curve (R
2
 = 0.9918) 
indicating exponential growth. (B) Kaplan-Meier plot of animals with control tumors shown in (A). Dashed line 
at 50% survival: 28 days. (C) BL of a single U87-luc tumor measured over time after luciferin administration. 
Dashed line shows best-fit curve (R
2
 = 0.933) indicating approx. linear decay of BL. (D) Relative tumor signal 
intensities of different experimental batches normalized to the overall average per time point. BL is shown on 
an arbitrary scale in panels (A) and (C).  
 
 
 
To determine the optimal time point for luminescence imaging, we performed time 
lapse imaging experiments. Individual tumors were imaged every 5 min after a single dose of 
luciferin. The first 5 min resulted in highly variable luminescence kinetics, but from 7 min up 
to 77 min an almost linear decay of the signal intensity was observed (Figure 2, C). To avoid 
the variable start phase but to use the signal at high intensity, animals were routinely 
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imaged 10min after the substrate was injected. A control study comparing imaging results at 
10 and 20 min post substrate injection showed, that the signal was proportionally the same 
after 20 min but overall intensity, and therefore also sensitivity, was markedly reduced (data 
not shown). Different tumor batches (tumors implanted at the same time) showed 
considerable variation (Figure 2, D). Therefore, tumors were always compared to batch 
matched control tumors rather than to an overall average. This batch matched approach 
yielded highly reproducible results.  
 
Sodium Butyrate (NaB) and 2-deoxy-D-glucose reduce tumor growth in vivo  
 
  The histone deacetylase inhibitor NaB in combination with the glycolysis inhibitor 
2DG has been shown to synergistically induce apoptosis in glioma and other cancer cells [9]. 
We analyzed the effect of a combinatorial treatment with NaB (1 mg/g) + 2DG (0.8 mg/g) 
administered daily by i.p. injection. Treated tumors showed a non-significant signal increase 
compared to control from day 10 to 24 (end of observation), but no difference in survival 
time could be observed (Figure 3, A-B). Although the signal variance was considerable and 
intermittent signal-loss was observed in the treatment group, we were unable to find any 
signs of tumor reduction or necrosis (Figure 3, C and data not shown). However, histological 
analysis showed ~3% apoptotic cells in the treated tumors versus <1% in the controls. All 
tumors were highly positive for the proliferation marker Ki67 with 35-45% actively 
proliferating cells in all tumors analyzed.  
 
The finding of accelerated tumor growth in the treatment group could not be related 
to batch differences, differences in proliferation rates or changes in body weight due to 2DG 
treatment. Therefore, we analyzed the effect NaB and 2DG had on the bioluminescence of 
U87-luc cells in vitro. When treated with 2DG, a slight drop in relative BL was observed 
(Figure 4, A-B). This is in accordance with the observation that glioma cells treated with 2DG 
have reduced levels of ATP [9] which is needed for the luminescence reaction. Therefore, a 
reduction of the relative BL was to be expected. However, U87-luc cells treated with NaB 
showed a highly significant increase of relative BL by >2-fold (Figure 4, A-B). A panel of 
additional compounds was analyzed in respect to their impact on relative BL. The mTOR 
inhibitor Rapamycin reduced relative BL significantly to ~60% of the control whereas 
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RAD001, an alternative mTOR inhibitor, did not affect BL (Figure 4, C). The Mnk inhibitor 
CGP57380 and the Syk inhibitor QAB205 did not significantly change BL although there was a 
trend towards reduced signal intensity (Figure 4, C). The alterations in the relative BL could 
not be related to changes in luciferase expression since the protein levels of the enzyme 
were not affected in any of the treatment groups (Figure 4, D). It therefore appears likely 
that the observed increase in BL is related to a change of enzymatic activity of the luciferase 
rather than an actual increase in tumor growth. This is further supported by the unchanged 
survival time of the experimental animals and the histological tumor presentation, which is 
indiscriminate between treated and control tumors.   
 
 
 
 
Figure 3. Treatment of U87-tumors with NaB and 2-DG 
 
(A) BL of control (red) and treated (blue; NaB + 2-DG) U87-tumors. Error bars: ±SD. (B) Kaplan-Meier survival 
curve of control mice (red) and treated mice (blue). 50% survival: 28 days for both groups. (C) H&E staining of 
ortotopic tumor implants (U87-luc) with (NaB + low 2DG) or w/o treatment (control) indicating absence of 
tumor necrosis.  
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Figure 4. Bioluminescence of U87-luc cells is changes by NaB and 2-DG 
 
(A) Relative BL of U87-luc cells treated as indicated for 24h and normalized to control. Error bars: ± SD. ** 
p<0.01. (B) Color coded BL image of 5*10
5
 living U87-luc cells per tube treated as follows: top row: control 
cells; middle row: treated with 2-DG (2.4 mg/kg); bottom row: treated with NaB (1 mg/kg). (C) Relative BL of 
U87-luc cells treated with additional compounds: RAD001  (10nM); Rapamycin (10nM); QAB205 (1ug/ml); CGP 
(10μM). Error bars : ± SD. * p<0.05. (D) WB analysis of luciferase expression in U87-luc cells treated as indicated 
and actin as loading control.  
 
To determine if the percentage of apoptotic cells in the treated tumors could be 
further increased, we performed a dose escalation study showing that short term treatment 
with a maximum of NaB (1 mg/g) + 2DG (2.4 mg/g) during 4 consecutive days was well 
tolerated by the animals. Higher concentrations of either drug were not tolerated, 
particularly if administered in combination. Treatment of tumor bearing animals from day 7-
10 post implantation with this regimen resulted in a significant reduction of tumor growth 
(Figure 5, A). Treated animals showed stable disease from day 10 to 17 and tumor size was 
reduced to approximately one third of the control afterwards. Control animals had a median 
survival of 28 days whereas treated animals had a median survival of 31 days (Figure 5, D).  
NaB (1mg/g) alone did not significantly reduce implant growth (Figure 5, B) although there 
was a reduction of BL in the second half of the observation period. The survival time was not 
affected with a median of 28 days. 2DG (2.4 mg/g) alone resulted in increased BL compared 
to control from day 17 onwards (Figure 5, C). This group showed the strongest signal 
variation and overall health was greatly reduced (weight loss, reduced nesting behavior, 
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etc.). A link between 2DG and the increased signal intensity could not be found (Figure 4, A-
B, D). Histological analysis of tumors treated with NaB (1 mg/kg) and 2DG (2.4 mg/kg) in 
combination revealed increased apoptosis and areas of tumor necrosis which was never 
observed in control or single compound treated samples (Figure 5, E) indicating a pro-
apoptotic effect in vivo and offering a possible mode of action for reducing tumor growth as 
observed (Figure 5, A).  
 
 
 
Figure 5. Treatment of U87-tumors with NaB and high 2-DG 
 
U87-tumors BL: control (red) and (A) treated (blue; NaB + high 2-DG), (B) NaB alone, and (C) 2DG alone. Error 
bars: ±SD. * p < 0.05; ** p < 0.01. (D) Kaplan-Meier survival curve of control mice (red) and treated mice (blue). 
50% survival: control 28 days, treated 31 days. (E) H&E staining of U87-luc tumors shown as light microscopic 
images treated as indicated. Arrows indicate necrotic areas.  
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Evaluation of genetically modified glioma cell lines in vivo in different genetic mouse 
backgrounds 
 
 Not all molecules of interest can be evaluated in the orthotopic model due to 
limitations in the experimental set-up. In short, transfection and stable expression of 
additional genetic constructs to study their role in tumor growth within the U87-Luc cell 
lines has proven to be difficult, particularly because the different clones have varying 
luminescence efficiencies. In addition, U87-luc cells do not express all proteins currently 
under investigation. Thus the use of corresponding inhibitors is not always possible. 
Therefore, we evaluated several genetically modified cell lines in an alternative in vivo 
model, wherein cells are implanted subcutaneous and growth is monitored by measuring the 
palpable tumor nodule rather than by BL. As a control, U87-Luc cells, which readily grow in 
the brains of nude mice, were injected s.c. at the body flanks. The cells formed large, fast 
growing nodules after 10-14 days post inoculation (data not shown). Genetically modified 
U373 and LN18 cells, two cell lines reported to be tumorigenic in nude mice [13], did not 
give any detectable tumor nodules in Crl:Nu mice (Swiss Webster background) over an 
observation period of >9 weeks. Even the parental cell lines which were not transfected or 
genetically modified did not form tumors. Increased cell number per implant or the 
additional use of extracellular matrix proteins to facilitate tumor initiation did not change 
these results. Therefore, we aimed at evaluating the growth behavior in two alternative 
mouse lines. The Hsd:Nu (Hsd:Nu-Foxn1nu, athymic BALB/c, Harlan) which have the 
alternative BALB/c genetic background was recommended by Novartis having used this 
particular line in their brain tumor studies. Furthermore, these mice seem to be less 
sensitive to anesthesia, which was a major problem of the orthotopic brain tumor model. 
Additionally, we aimed at evaluating s.c. tumor growth in Hsd:BNX mice (Hsd:NIHS-
Lyst
bg
Foxn1
nu
Btk
xid, Harlan). These triple mutant animals have neither adaptive nor innate 
immune cells (no NK-, B- or T-cells) and have been recommended to be used in studies with 
cells not growing in other immuno-compromised mice (eg nude, NOD-Scid, etc.). The growth 
behavior of all GBM cell lines evaluated in the different mouse lines is summarized in Table 
1.  
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Table 1. 8 glioma derived cell lines were evaluated for their tumorigenic potential in three different immuno-
compromised mouse lines. Implants were either orthotopic (brain) or subcutaneous on the flank of the animal 
(flank). (+) tumor formed growing nodules; (-) no tumor nodule was detectable after prolonged observation; 
n/a not assessed; blank fields indicate cell line/mouse combinations which are still pending. Tumor growth was 
assessed by bioluminescence in the brain and palpable nodule size in the flank.  
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Discussion 
 
 Previous work in our lab identified HDIs in combination with 2DG as an effective, pro-
apoptotic cancer therapy in vitro. Epigenetically reprogrammed glioma cells were more 
sensitive to the glycolysis inhibitor 2DG inducing high levels of cell death at concentrations 
leaving normal rat astrocytes, HEK293 and RASMC cells unaffected [8]. This is in accordance 
with other studies reporting low toxicity for HDIs even when used in combination strategies 
in clinical settings [8]. Animals exposed to NaB on a daily basis by i.p. injection did not show 
overt signs of toxicity, unwanted side effects or behavioral changes in our study. However, in 
vivo efficacy of the HDI/2DG regimen has not been analyzed up to date. 
 
 Long term exposure to low concentrations of HDI and 2DG in combination did not 
reduce tumor growth although it was able to induce apoptosis in a limited number of cells 
(~3%). Short term exposure to higher concentrations, however, was able to induce both 
apoptosis and tumor necrosis and reduced tumor growth significantly. Therefore, the 
combinatorial use of epigenetic modulators and energy deprivation seems a therapeutic 
approach with considerable potential in clinical settings. Furthermore, the finding of 
increased BL in U87-luc cells treated with NaB in vitro could indicate that the anti-tumor 
effect of the HDI/2DG combination is underrepresented in our model. This also holds true 
for the effect the regimen has on the overall survival. Since the termination criteria was 
defined by BL (at 108 ph/s), it is unclear if the animals were not sacrificed prematurely due to 
the increased BL after NaB treatment. Adding an additional layer of complexity, we found 
animals treated with NaB only to have similar BL increase and survival times as control 
animals. If the anti-tumor effect and the increase in BL are just kept in balance in this setting 
is unclear. However, the control tumor cannot be differentiated from NaB treated samples 
when analyzed histologically. The question how NaB influences BL in vivo can only be 
addressed in a setting in which animals remain in the experiment until they die 
spontaneously or until they show overt signs of illness. Without these experiments the 
primary endpoint of overall survival will remain non-distinctive in our study. Experiments to 
answer this question are currently ongoing.   
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 NaB, TSA, Depsipeptide, and Apicidin are HDIs from natural sources [8] and NaB has 
been reported to cross the blood brain barrier in mice [9]. Synthetic HDI, for example AN-9 
or FK-228, are currently in clinical phase I/II studies in leukemia patients showing increased 
HDI activity in vivo compared to natural HDIs [10, 11]. The synthetic HDI LAQ824 [9], which is 
in clinical phase I/II studies for solid tumors, lymphomas and leukemia, has increased HDI 
activity compared to NaB and also crosses the blood brain barrier [8]. Therefore, it will be 
interesting to see how HDIs with optimized activity will perform in combination with 2DG in 
glioma and potentially other cancer models. Optimized bio-availability and target specificity 
lead to fewer side effects and allow for higher target concentrations. In sum, this should 
further improve the therapeutic effect of our strategy. In addition, our dosing regimen was 
constricted to 4 days with an overall observation period of ~31days. The main impact (loss of 
total BL or reduction thereof) was observed immediately after the therapy followed by an 
increase in BL at reduced levels after approx. another 7-10 days. Pharmacokinetics are highly 
variable between species. Therefore such a regimen can not be immediately translated to 
humans. However, it points to a regimen that should include expanded or recurrent 
exposures to the combination therapy.   
 
 2DG at high concentrations administered as single agent for 4 days did not reduce 
tumor growth; instead, a slight increase in BL was observed compared to the control group. 
Our in vitro results showed that 2DG does not induce increased BL in U87-luc cells nor did it 
have a growth promoting effect. To the contrary, 2DG had a cytostatic effect in vitro. We 
cannot exclude the possibility, that 2DG (2.4 mg/kg) acts differently in vivo. However, given 
the fact that 2DG is used in several tumor models without ever being related to increased 
tumor growth [10, 11], we find it rather unlikely that there is an unknown, growth promoting 
effect. Furthermore, the increase in BL was not significant and showed huge variation. 2DG 
by itself can have a negative effect on overall health and body weight in particular due to 
energy deprivation or reduced metabolism [12]. Therefore, the combined effect of tumor 
burden and energy reduction may lead to additive effects reducing overall life expectancy. 
Animals treated with the HDI/2DG combination apparently profit significantly from the anti-
tumor effect fully compensating for the adverse effect of 2DG. Combined application of HDI 
and 2DG has a favorable effect compared to 2DG alone due to epigenetic reprogramming. 
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The single Foxn1nu mutation background did not allow s.c. tumor growth in our 
experimental set up when using U373 or LN18 parental cells. Orthotopic growth was 
observed for several cell lines irrespective of subcutaneous growth in all genetic 
backgrounds analyzed (Table 1). Several reasons could cause this effect: the nude mutation 
was found to be leaky in our colonies. A fraction of the animals would develop coat hair over 
time indicating some residual Foxn1 activity or compensatory mechanisms (at least in the 
hair follicles). Furthermore, this mutation only impairs T-cell maturation rendering the 
adaptive immune system inactive [13]. The innate immune system is not affected leaving the 
Natural Killer cells (NK) active. These NK cells (which have the natural ability to kill tumor 
cells) recognize non-self proteins presented on MHC-I like molecules highly up regulated in 
tumor cells and kill cells presenting such on the cell surface [14]. Tumor cells and particularly 
xenogenic tumor cells display a plethora of non-self markers and are therefore prime targets 
of NK cells. Furthermore, the cell lines used in these experiments were cultured on plastic 
dishes for hundreds of passages selecting for “on-plastic” growth capacity rather than for 
tumorigenic potential. The combined effect of long term culturing and the innate immune 
system of the host animal are likely to explain the lack of xenogenic tumor growth in the 
nude mutants. The mouse line Hsd:NIHS-LystbgFoxn1nuBtkxid is devoid of NK cells (beige 
mutation), T-cells (nude mutation), and mature B-cells (xid mutation) and therefore lack 
major components of both the adaptive and the innate immune system [18]. The 
experiments determining the growth potential of our experimental cell lines described 
above in these animals are currently ongoing. If the modified cell lines do not form palpable 
tumor nodules in these immuno-compromised animals, we have to assume that the cells 
(particularly after repeated transfection and selection) have lost their tumorigenic potential. 
Strategies to overcome this problem in an in vivo setting are currently unclear.  
 
The orthotopic GBM model is currently the only in vivo model of HGG we have at 
hand. Therefore, we aim at analyzing several additional regimens and inhibitors in this 
experimental setup. The rational of these projects as well as a short scientific introduction 
are listed below.  
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Future Perspectives and Outlook 
 
The possibility of continuously monitoring tumor growth in an orthotopic model of 
high grade gliomas will provide us with the ability to evaluate novel inhibitors and 
combination therapies. In the near future several such treatments shall be analyzed which 
have shown promising results in vitro. These experiments are focused around three main 
findings and the corresponding inhibitors: 
 
MNK1 inhibitor CGP57380. MAP kinase-interacting kinase 1 (MNK1), which is downstream 
of the MAP kinase pathway [16] and which is over-expressed in GBM, was found to have a 
critical funciton in GBM malignancy. It was shown that MNK1 regulates the SMAD2-
dependent TGF-β pathway and also cell motility in glioma cells. In addition, targeting MNK1 
with the inhibitor CGP57380 together with an mTOR inhibitor (eg. Rapamycin) induced cell 
cycle arrest and strongly inhibited global translation and GBM cell proliferation [15]. Based 
on these findings, we aim at evaluating a combination therapy of CGP57380 and Rapamycin 
(or its derivative RAD001) in our in vivo model. Acute toxicity screening has been completed 
with no negative effects detected. Therefore, the CGP57380 (25 mg/kg) + RAD001 (3 mg/kg) 
combination will be evaluated in the next batches of tumor bearing animals. Primary 
endpoints will be tumor growth (measured by BL) and overall survival. Secondary endpoints 
will be toxcicity and generalized adverse effects.  
 
Spleen Tyrosine Kinase (SYK) inhibitors. Recently, the spleen tyrosine kinase SYK, SRC kinase 
LYN and the immunoreceptor molecule CD32 (exclusively activating SYK or ZAP70 through 
SRC’s) were identified to be highly over expressed in GBM [16] and increased expression of 
these molecues correlates with significantely reduced patient survival time (REMBRANDT). 
Further investigation confirmed the expression of SYK/LYN/CD32 in GBM derived cancer 
spheres and cell lines. To study the role of SYK in glioblastoma, cell lines were treated with 
three small molecule inhibitors of SYK. All of these inhibitors showed a strong inhibition in 
basal and EGF induced proliferation and migration (Gerald Moncayo, personal 
comunication).  After the acute toxicity screening, upon which at least one compound had to 
be excluded from this study allready, we aim at evaluating the anti-cancer potential of the 
remaining SYK inhibitors in the orthotopic glioma model as well as the effect genetic 
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modification of cell lines (either by over-expressing or down-knocking of SYK) has on their 
tumorigenic potential in the s.c. flank model. In the orthotopic assay the primary and 
secondary endpoints are similar to the ones described for CGP57380. In the flank model the 
primary endpoint is palpable tumor size and the secondary endpoint is ulceration-free 
progression. Toxicity and generalized adverse effects will be included as third endpoint.  
 
Proto-oncogene tyrosine-protein kinase MER (MerTK). In the same screen as we have 
identified MNK1 and SYK, we also found MerTK to be elevated in GBM samples when 
compared to normal brain or human astrocyte controls [18]. MerTK has an anti-apoptotic 
function in glioma cells but is only consistently expressed in cancer spheres or sphere 
derived adherent cells (Yuhua Wang, personal communication). Therefore, the experimental 
set up differs from the two others in several aspects. First, we aim at analyzing the tumor 
growth in the flank model using cancer spheres transfected either with shRNA-luc (as 
control) or shRNA-MerTK as implants and to compare growth behavior. Secondly, since U87 
cells do not express MerTK, the specific inhibitor ‘compound 52’ [17] can not be applied to 
the current orthotopic model. However, cancer spheres could be injected orthotopically 
[18]. The readout would be asymptomatic survival as well as overall survival of treated 
versus untreated animals. However, these experiments would require substantial amounts 
of animals per group to correct for individual variation. Furthermore, only post mortem 
analysis would give conclusive insight on tumor invasion, growth, vascularization, and 
apoptosis. Since it is not possible to control for tumor formation prior to necropsy, the 
evaluation would be even further complicated. The establishment of luciferase expressing 
cancer spheres (controlled for MerTK expression) therefore appears as a more feasible, 
however, still difficult approach.  
 
 Regimens with a growth inhibiting and life prolonging effect in vivo have the 
potential to induce comparable effects in patients. Although results obtained in rodents are 
difficult to translate into clinical outcome [5] such results represent the groundwork for any 
clinical trial. Hopefully we will be able to identify regimens with high anti-tumor efficacy in 
the GBM model based on drugs which are already safety approved by the EMEA or FDA, 
making the initiation of a phase I clinical trial comparatively easy.  
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Materials and Methods 
Cell Lines 
 
 U87MG-Luc [19], U373 and LN18 cells were grown in Dulbecco’s Modified Eagle 
Medium (DMEM, Invitrogen) supplemented with 10% (v/v) fetal bovine serum (FBS, No: 
S1810, Labforce, Basel, Switzerland), 1% glutamax solution (v/v) (Invitrogen) and 1% (v/v) 
penicillin/streptomycin solution (Invitrogen). Cells were suspended by proteolysis with 1x 
trypsin-EDTA (Invitrogen) for 5 minutes at 37°C and transfected with Firefly Luciferase 
expression plasmids (pcDNA3.1-Luc-IRES-GFP) using CaCl2 precipitation. Stably transfected 
cells were maintained in 100µg/ml Geneticin® or G418 (Invitrogen Corporation, California, 
USA) for U87-luc and 0.2μg/ml Puromycin (Invitrogen) for U373 and LN18.   
 
Western blot analysis and antibodies 
 
Cells were grown to 80-90% confluency, washed twice with 1x PBS, lysed in buffer 
containing 2% sodium dodecyl sulfate (SDS), 50mM Tris pH 6.8, 0.1M dithiothreitol (DTT), 
boiled at 95°C for 5min and used either immediately or frozen at -20°C. Protein lysates were 
resolved on denaturing 8-12% SDS-polyacrylamide gels and transferred to nitrocellulose 
membranes (iBlot Gel transfer stacks, Invitrogen). The following primary antibody was used: 
polyclonal goat anti-luciferase Ab (Chemicon). Decorated proteins were revealed using 
horseradish peroxidase-conjugated anti-goat (Pierce) secondary antibodies and visualized by 
the chemoluminescence detection system SuperSignal West Pico (Thermo Scientific).  
 
Mouse Lines and Brain Injections 
 
 Immuno-compromised mice were used in the orthotopic brain injections: Crl:Nu(loc)-
Foxn1nu (CRL, France). The strain was maintained in a Swiss Webster Background as an 
outbred line by crossing heterozygote females with homozygote males. Hsd:Nu athymic 
Nude-Foxn1nu (Harlan, Netherlands) generated in a BALB/c background and maintained as 
an outbred strain were also evaluated in orthotopic injections. Hsd:NIHS-LystbgFoxn1nuBtkxid 
(Hsd:BNX) maintained as an inbred colony were used as indicated above. All animals were 
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housed in IVC settings with food and water ad libitum. For orthotopic injections the mice 
were anesthetized with Ketamine/Xylozine/Acepromazin (75/13/2 mg/kg) by i.p. injection 
and kept on a 37°C heating pad. 5*105 U87-luc cells in 10μl sterile PBS were injected 3 mm 
caudal and 2 mm lateral of the bregma, 3 mm below the dura with a 100μl Hamilton syringe 
using a 25 Gauge needle mounted in a stereotactic frame. Animals received 0.3 mg/kg 
Buprenorphine i.p. or s.c. as analgesic treatment post implantation for 3 days.     
 
Bioluminescence Imaging 
 
 Mice were injected with 10μl/g (body weight) of D-luciferin in PBS (15mg/ml) i.p. 
Animals were immobilized with 2.5% Isoflurane via individual face masks. Imaging was 
performed in a NightOwl BL imager (Berthold Technologies) at 560 nm emission wavelength 
after 10 min incubation time of the substrate for 30 sec. Integrated signal intensity was 
normalized to background and calculated for individual tumors. Cell lines were imaged with 
the same settings and same substrate concentration at 25°C in 1.5 ml tubes (Eppendorf).  
 
Histology 
 
 Tumor bearing brains were fixed in 4% Formalin at RT over night, washed and 
embedded in paraffin. Thin sections (2-4 um) were cut and dried at 37°C o/n. Stainings were 
performed as indicated in the figure legends.   
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Supplemental Material 
 
 
 
Figure S1. Bioluminescence signal of a defined tumor followed over time 
 
A single U87-tumor was measured at time points (A) 7 days post implantation, (B) 14 days, (C) 21 days, (D) 24 
days, and (E) 28 days. All images were taken 10 min after application of 300 μl luciferin solution (15mg/ml) i.p. 
BL is shown color coded with blue representing low and red high signal density as a heat map. 
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Abstract  
Cancers are driven by a population of cells with the stem cell properties of self-
renewal and unlimited growth. As a subpopulation within the tumor mass, these cells are 
believed to constitute a tumor cell reservoir. Pathways controlling the renewal of normal 
stem cells are deregulated in cancer. The polycomb group gene Bmi1, which is required for 
neural stem cell self-renewal and also controls anti-oxidant defense in neurons, is 
upregulated in several cancers, including medulloblastoma. We have found that Bmi1 is 
consistently and highly expressed in GBM. Downregulation of Bmi1 by shRNAs induced a 
differentiation phenotype and reduced expression of the stem cell markers Sox2 and Nestin. 
Interestingly, expression of glycogen synthase kinase 3 beta (GSK3β), which was found to be 
consistently expressed in primary GBM, also declined. This suggests a functional link 
between Bmi1 and GSK3β. Interference with GSK3β activity by siRNA, the specific inhibitor 
SB216763, or lithium chloride (LiCl) induced tumor cell differentiation. In addition, tumor cell 
apoptosis was enhanced, the formation of neurospheres was impaired, and clonogenicity 
reduced in a dose-dependent manner. GBM cell lines consist mainly of CD133-negative 
(CD133-) cells. Interestingly, ex vivo cells from primary tumor biopsies allowed the 
identification of a CD133- subpopulation of cells that express stem cell markers and are 
depleted by inactivation of GSK3β. Drugs that inhibit GSK3, including the psychiatric drug 
LiCl, may deplete the GBM stem cell reservoir independently of CD133 status. 
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Introduction  
Recent studies suggest that cancer stem cells are the driving force behind 
tumorigenesis [1]. CD133 (also known as Prominin 1) was identified as a surface marker of 
cancer stem cells in brain tumors [2]. As few as 100 CD133-positive (CD133+) cells were 
shown to induce tumors in transplantation experiments giving rise to a phenocopy of the 
initial neoplasia [2], [3]. CD133+ cells, which express multi-drug resistance and DNA repair 
proteins [4], are highly resistant to chemo- and radiation therapy. However, stemness is not 
restricted to the expression of the CD133 marker, since CD133-negative (CD133−) cell 
populations were also found to be tumorigenic [5]. Cancer stem cells have also been 
detected in glioblastoma (GBM), the most malignant human brain tumor, with an annual 
incidence of 36 per million and a mean survival of less than 1 year [6]–[8]. GBM, a highly 
invasive and proliferative tumor, manifests itself as a de novo lesion or progresses from less 
undifferentiated low-grade astrocytoma. 
Bmi1 is a member of the polycomb group of proteins involved in brain development 
[9]. Polycomb group proteins maintain embryonic and adult stem cells by forming multi-
protein complexes that function as transcription repressors [10]–[17]. Bmi1 is also involved 
in cancer by cooperation with Myc in lymphoma formation [18] and blocking of senescence 
in immortalized mouse embryonic fibroblasts through repression of the Ink4a/Arf-locus [19]. 
It is also amplified and/or overexpressed in non-small-cell lung cancer, colorectal carcinoma, 
nasopharyngeal carcinoma, medulloblastoma, lymphoma, multiple myeloma and primary 
neuroblastoma [9], [13], [19]–[22]. Whether Bmi1 is expressed in GBM is controversial [9]. In 
a mouse glioma model, Bmi1 was implicated in tumorigenesis in an Ink4a/Arf-independent 
manner [23]. Furthermore, it was shown recently that microRNA-128 inhibits proliferation 
and self-renewal in glioma at least partially by downregulating Bmi1 [24]. 
Glycogen synthase kinase 3 (GSK3), a serine/threonine kinase, regulates numerous 
signaling pathways involved in cell cycle control, proliferation, differentiation and apoptosis 
[25], [26]. The mammalian isoforms GSK3α and GSK3β are functionally independent as 
GSK3α cannot rescue the embryonically lethal phenotype of GSK3β (−/−) mice [27]. GSK3 has 
been described as a pro-survival factor in pancreatic cancer [28] and as a pro-apoptotic 
factor in colorectal cancer [29] and is interconnected with several pathways and implicated 
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in Alzheimer's disease [30], diabetes [31], bipolar disorder [32], and more recently cancer 
[33]. 
We have analyzed the role of GSK3 in malignant gliomas and its links to critical 
signaling proteins. Downregulation of Bmi1 reduced GSK3β levels and induced the 
differentiation of malignant glial cells. Direct inhibition of GSK3β by lithium chloride (LiCl), 
SB216763 and siRNA decreased Nestin and Sox2 levels and induced the cell differentiation 
markers CNPase, glial fibrillary acidic protein (GFAP) and β-tubulin III. In addition, LiCl and 
SB216763 depleted cancer stem cells grown as human GBM ex vivo cell cultures, induced 
differentiation and inhibited neurosphere formation. Thus, GSK3 may represent a novel 
therapeutic target for malignant gliomas. 
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Results  
Bmi1 is overexpressed in GBM, oligodendroglioma and astrocytoma 
Bmi1 overexpression has been reported in several different tumor types including 
medulloblastoma and neuroblastoma. In an analysis of Bmi1 mRNA and protein expression 
in GBM cell lines and primary brain tumors, all GBM cell lines expressed high Bmi1 levels, 
with the LN319 line having the highest expression comparable to the reference line DAOY [9] 
(Figure 1A and data not shown). In primary brain tumor samples, Bmi1 expression was 
marked in 16/19 (84%) of GBM, 5/7 (71%) of oligodendroglioma and 3/7 (42%) of 
astrocytoma. In contrast, fully differentiated normal brain tissue had no Bmi1 protein (Figure 
1B, C). 
 
Figure 1. Bmi1 was highly expressed in GBM. 
Bmi1 expression in (A) GBM cell lines and (B) primary brain tumors. (C) Ratio of Bmi1-positive primary tumors. 
NB: normal brain. EPEN: Ependymoma. 
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shRNA against Bmi1 downregulates GSK3β 
To study the role of Bmi1 in GBM, Bmi1 expression was knocked down using 
lentiviral-mediated delivery of shRNAs. Bmi1 was efficiently downregulated in the Hs683, 
U373, U87, and U343 GBM cell lines (Figures 2A and S1A and data not shown) using different 
shRNA sequences (Figure S1B). Since the Polycomb group gene Bmi1 is involved in the 
regulation of development and tumorigenesis, the effect of Bmi1 downregulation in GBM 
cells was screened by analysis of proteins involved in key cellular pathways of the cell cycle, 
development, metabolism, apoptosis and growth, including Erk, Akt, GSK3β, p16 and p14, 
Bcl-2, c-Myc, Nestin and Sox2. In contrast to non-neoplastic cells in Bmi1 knockout mice [19], 
Bmi1 downregulation in GBM cells did not affect Ink4a/Arf protein levels (Figure 2A). Bmi1 
downregulation induced cell differentiation associated with morphological changes and 
decreased expression of the stem cell-related proteins Nestin and Sox2, accompanying 
induction of an astrocytic fate in U373 glioma cell line, determined by increased levels of the 
astrocyte-specific marker GFAP, and decreased levels of oligodendrocyte-specific marker 
CNPase (Figures 2A–D and S2B). In contrast, Bmi1 overexpression accompanied 
dedifferentiation as shown by increased Nestin expression (Figure S1C). Interestingly, GSK3β 
levels were markedly reduced (Figures 2A and S1A–B). This raised the question of whether 
GSK3β mediates the effects observed on cell differentiation. To this end, we used the small 
molecules LiCl and SB216763 as well as siRNA to interfere with GSK3β activity in GBM cells. 
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Figure 2. GSK3β was downregulated by reduction of Bmi1 expression. 
(A) GBM cell lines U373 and Hs683 transduced with shRNA against Bmi1 (sh1061) or with scrambled shRNA 
(scr). Bmi1 downregulation induced downregulation of the following proteins: p-AKT, Nestin (in U373), Bcl2, 
and GSK3β. No effects are evident on the p16/p14
ARF
, or p-ERK protein levels. (B) Scrambled control or U373 
Bmi1-downregulated cells at subconfluency (sub-con) or confluency (con). Bmi1-downregulated cells show 
differentiated morphology (arrow: long, branched processes). (C) The glial fibrillary acidic protein (GFAP) levels 
in U373scr and U373sh1061 cells measured by flow cytometry. (D) Relative CNPase protein levels in U373scr 
and U373sh1061 measured by western blotting, quantified using ImageJ software and normalized to β-actin 
levels. (E) GSK3β mRNA values from a series of primary brain tumors (GBM and astrocytoma) and normal brain. 
(F) GSK3β protein is expressed in primary GBM. *P<0.05; one-way ANOVA (Newman-Keuls Multiple 
Comparison Test). 
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GSK3β is expressed in GBM 
Thirty-two primary tumor tissues obtained from patients diagnosed with GBM were 
studied using microarray and western blot analysis to measure GSK3β mRNA and protein 
levels. GSK3β mRNA were higher in GBM and astrocytoma patients compared with the 
control (Figures 2E, F and S2) and protein was found to be expressed in the majority of the 
tumors analyzed. The high GSK3β expression in astrocytoma was most probably due to 
greater necrosis in the GBM, with increased protein degradation (Figure S2B). 
siRNA- and drug-induced inhibition of GSK3 increases differentiation markers 
The effect of the inhibition of GSK3 on protein levels of progenitor (Nestin and Sox2) 
and differentiation (CNPase, GFAP, and β-tubulin III) markers in GBM cell lines U373, LN319, 
BS125 and LN18 was analyzed using the drugs LiCl and SB216763 or siRNAs. β-catenin is 
targeted for degradation upon phosphorylation by GSK3β [25]. Blocking GSK3β therefore 
leads to accumulation of β-catenin, which was used as a read-out for the effects of LiCl and 
SB216763 on GSK3 activity (Figure 3B). After 72 h treatment with LiCl and SB216773, Nestin 
protein level decreased in the Nestin-expressing U373, LN319 and LN18 cell lines (Figures 3A, 
B), which was confirmed by immunocytochemistry (Figure 4B). Nestin and Sox2 were not 
expressed in the “ex vivo” BS125 GBM cell line. Sox2 levels were reduced in LN18, U373 and 
LN319 upon GSK3 inhibition (Figure 3A, B). The oligodendrocyte specific marker 2′, 3′-cyclic 
nucleotide 3′-phosphodiesterase (CNPase) and the neuronal marker β-tubulin III increased in 
BS125, LN18 and LN319, (Figure 3A, B). GSK3 inhibition also increased the protein levels of 
the astrocytic lineage-specific marker GFAP in LN319 and BS125 (Figure 4A). Downregulation 
of GSK3 activity in LN18 by siRNA reduced Nestin and Sox2 protein levels (Figure 4C), 
confirming the specificity of the inhibitory drug SB216763 in blocking GSK3β. The effect of 
the specific GSK3 inhibitor SB216763 was more pronounced and consistent than the effect of 
LiCl, which is known to target other signaling molecules [26]. Thus GSK3 inhibition 
specifically decreased the expression of progenitor markers (Nestin and Sox2) and induced 
the expression of differentiation markers (neuronal marker β-tubulin III, oligodendrocyte-
specific marker CNPase and the astrocytic marker GFAP) in a cell line-dependent manner. 
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Figure 3. GSK3 inhibitors specifically induced differentiation in GBM cell lines. 
Western blot analysis of Nestin, Sox2, CNPase, β -tubulin III and β -actin (loading control) protein levels after 
treatment of GBM cell lines with GSK3 inhibitors (10 mM LiCl; 20 µM SB216763). Each cell line showed a pro-
differentiation response to GSK3β inhibitor application. (A) Protein bands quantified with ImageJ software. 
Protein levels were normalized to β-actin for each cell line. (B) Corresponding western blots. 
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Figure 4. GSK3β downregulation by siRNA treatment induced differentiation. 
(A) The intensity of GFAP, an astrocyte-specific marker, was measured by FACS analysis of GBM cell lines 
treated with 10 mM LiCl for 72 h. (B) Nestin immunostaining of cell lines U373 and LN18 after GSK3β inhibition 
by LiCl (Li) or SB216763 (SB) for 72 h. (C) GSK3β siRNA reduced Sox2 and Nestin expression in the LN18 cell line. 
*P<0.05; one-way ANOVA (Newman-Keuls Multiple Comparison Test). Scale bar in B is 30 µm. 
 
Inhibition of GSK3 depletes GBM cells with a stem cell signature 
The phenotypic switch towards differentiation in GBM cells following inhibition of 
GSK3 raises the question of whether GSK3 activity regulates cancer stem cell populations. 
CD133+ and CD133− cancer stem cells have been described in GBM [2], [3], [35]–[37]. In an 
analysis of eight different tumorigenic GBM cell lines (LN18, LN215, LN319, U373, LN229, 
U343, BS125 and Hs683) [34] for the presence of CD133+ cells, only LN319 contained 
CD133+ cells, at approximately 12%. To test whether the CD133+ population possessed a 
cancer stem cell-like character, the expression levels of stem cell markers were analyzed in 
the CD133-enriched population. Nestin, Notch2 and Bmi1 were highly expressed relative to 
the CD133− fraction (Figure 5C). GSK3β and β-catenin protein levels were also higher in the 
CD133+ population than in the control (Figure 5C). Inhibition of GSK3 in cell line LN319 with 
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either LiCl or SB216763 showed a selective effect on the cancer stem cell-like population. 
LiCl at 10 mM and SB216763 at 20 µM induced a 50–60% depletion of CD133+ cells (Figure 
5A). The effects of GSK3 inhibitory drugs were found to be specific in that the epidermal 
growth factor receptor inhibitor (AEE788) and the γ-secretase inhibitor (DAPT) did not 
significantly alter the CD133+ population (data not shown). To further consolidate this 
observation, we enriched the LN319 CD133+ population by FACS sorting, obtaining a CD133+ 
cell population of approximately 80%. This was maintained for several passages and then 
subjected to inhibition of GSK3 by LiCl or SB216763, which depleted the CD133+ fraction 
(Figure 5B). 
    
Figure 5. GSK3β inhibition reduced the CD133+ cell population of a GBM cell line. 
(A) LN319 GBM cell line was treated for 72 h with 10 or 20 mM LiCl or with SB216763 at 10 or 20 µM. GSK3β 
inhibition reduced the CD133-positive (CD133+) population. (B) LN319 CD133+ cells were enriched to 80% 
purity by cell sorting. The enriched population was treated for 72 h with 10 or 20 mM LiCl or with SB216763 at 
10 or 20 µM. (C) Western blot analysis of Notch2, Nestin, Bmi1, β-catenin, GSK3β and β-actin in CD133+ and 
CD133-negative (CD133-) enriched populations compared with the control. **P<0.01; ***P<0.001; one-way 
ANOVA (Newman-Keuls Multiple Comparison Test). 
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It has been argued that GBM cells grown for many passages in standard medium do 
not mirror the stem cell compartment within the original tumor [38]. To examine this, the 
“ex vivo” cell line BS287 was analyzed which had been isolated from a fresh tumor biopsy 
and directly grown as neurospheres in neurobasal medium supplemented with bFGF and 
EGF, thus favoring expansion of cancer stem cells. Interestingly, the population with a stem 
cell-like signature in this cell line was represented by the CD133- and not by the CD133+ 
population (Figure 6A–C). Only the CD133− population expressed elevated levels of Nestin, 
Sox2 and Bmi1 and formed neurospheres (Figure 6B, C). Inhibition of GSK3 decreased the 
stem cell like (CD133−) population (Figure 6D) and also altered protein levels of stem cell and 
differentiation markers, mainly decreased Sox2 levels (Figure S3). Induction of 
differentiation impairs the ability of precursor cells to form neurospheres. Inhibition of GSK3 
significantly reduced the number and volume of neurospheres in BS287 cells (Figure 6E, F). 
The results show that inhibition of GSK3 reduces the cancer stem cell pool and that CD133 
may not be a reliable cancer stem cell marker. 
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Figure 6. GSK3β inhibition reduced stem cell characteristics in an “ex vivo” GBM cell line. 
(A) CD133 sorting of the BS287 “ex vivo” GBM cell line. (B) Growth characteristics of the CD133+ and CD133- 
populations in BS287. (C) Western blot analysis of Nestin, Sox2, Bmi1 and β-actin in BS287. The CD133- 
population showed stem cancer-like characteristics. (D) Cells in the CD133+ population with a more 
differentiated geno/phenotype increased after GSK3β inhibition. (E, F) Inhibition of GSK3β led to a reduction in 
the number and volume of neurospheres in the BS287 “ex vivo” cell line. 
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GSK3 inhibition reduces colony formation and induces apoptosis in GBM cells 
The effects of GSK3 inhibition on cell proliferation and apoptosis in the GBM cell lines 
LN18, U373, LN215 and LN319 were analyzed using colony formation, relative cell number 
and cell death as readout. In a colony formation assay, both the number and size of colonies 
formed after 14 days of drug treatment were measured. GSK3 inhibitors significantly 
reduced colony formation in all GBM cell lines tested compared with the untreated control 
(Figure 7A). The GSK3 inhibitor concentrations used were in the non-toxic range; cell 
proliferation and survival of the human adipose tissue-derived progenitor cells (A111) were 
not negatively affected (Figure 7A). GSK3 inhibition by LiCl or SB216763 induced a slight 
increase in cell death for GBM cell lines LN319, LN18, U373 and BS125 after 72 h (Figure 7B). 
Induction of cell death was significantly elevated when GSK3 inhibitor LiCl was combined 
with the standard GBM therapeutic temozolomide in the LN18 cell line (Figure 7D). Cell 
death was dose-dependent and varied from cell line to cell line. Direct cell counting after 
exposure of cells to LiCl or SB216763 for 72 h showed inhibition of the proliferation of LN18, 
LN319, U373 and LN215 cells (Figure 7C). G2-M accumulation was recorded in LN319, LN18, 
U373 and G2-M arrest in LN215 (Figure S4). In a migration assay, LN319 showed a significant 
reduction in cell migration following GSK3 inhibition (Figure 7E). These results show that 
GSK3 strongly reduces colony formation and induces cell death in GBM cell-lines. 
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Figure 7. GSK3β inhibition reduced colony formation of GBM cells. 
(A) A colony formation assay was performed on GBM cell lines treated with 10 mM LiCl or 20 µM SB216763 for 
14 days. (B, C) GBM cell lines treated with LiCl or SB216763 for 72 h. (B) Percent cell death and (C) relative cell 
number relative to the initial seeding. (D) Cell death determined by PI staining of the LN18 cell line after 
treatment with 10 mM LiCl with or without 50 µg/ml temozolomide (TMZ) for 72 h. *P<0.05, for the 
combination of LiCl and TMZ compared with each drug alone. (E) GSK3β inhibition significantly reduced 
migration of the LN319 cell line. (B, C and E) Treated samples were compared to the corresponding control: 
*P<0.05; **P<0.01; ***P<0.001; one-way ANOVA (Newman-Keuls Multiple Comparison Test). 
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Discussion  
Bmi1, a member of the polycomb group proteins, is required for self-renewal of 
neural stem cells and is upregulated in several cancers. It is also known to repress Ink4a/Arf 
locus inhibiting progenitor cell proliferation during neural differentiation [39]. In 
differentiated cells, Bmi1 levels decrease while Ink4a/Arf protein levels increase [40]. As the 
Ink4a/Arf locus is frequently deleted in brain tumors [41], the role of Bmi1 overexpression in 
GBM cells appears to be distinct from its repression of the Ink4a/Arf locus. For example, 
downregulation of Bmi1 did not influence Ink4a/Arf protein levels in tumor cells that 
retained the Ink4a/Arf locus. Thus, in GBM cells, Bmi1 targets a different pathway. Screening 
of several key proteins controlling cell cycle, development, metabolism, apoptosis and 
growth, including Erk, Akt, GSK3β, p16 and p14, Bcl-2, c-Myc, Nestin and Sox2, showed that 
downregulation of Bmi1 reduced GSK3β protein levels and induced differentiation in cancer 
cells. In addition, tumor cell proliferation, survival, migration and clonogenicity were 
markedly reduced. 
Discovered some 25 years ago [42], GSK3 has been considered only recently as a 
therapeutic target for cancer [33]. It has been shown that this enzyme negatively regulates 
the Wnt, Hedgehog and Notch pathways, which are aberrantly activated in several cancers 
[33], [43]. This suggests that GSK3 inhibitors could exert a therapeutically negative, pro-
survival effect on tumor cells. However, the long-term medical use of the GSK3 inhibitor LiCl 
for the treatment of psychiatric disorders did not lead to an increase in cancer incidence 
[44], arguing against an oncogenic effect of GSK3 inhibitors. On the contrary, Cohen et al. 
demonstrated that cancer prevalence in psychiatric patients on long-term LiCl medication 
was lower than in the general population [44], suggesting even a protective effect of LiCl. 
The results presented here offer a molecular explanation of this epidemiological 
observation: administration of LiCl induces differentiation and inhibits proliferation and, 
thereby, might effectively inhibit tumor formation and progression. Furthermore, the 
plethora of clinical data on LiCl offer solid information about potential side-effects and it 
appears safe to assume that normal adult stem cells are not negatively affected, even by 
long-term use of the drug. The very similar phenotypic and functional alterations induced by 
either inhibiting GSK3 or by downregulating Bmi1 in the present study points to a functional 
link between Bmi1 and GSK3. However, further studies are needed to analyze whether there 
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is a direct interaction between Bmi1 and GSK3. Downregulating GSK3 specifically decreased 
the subpopulation of cancer cells that contained a cancer stem cell-like signature by driving 
them into differentiation. 
Sox2 protein is widely expressed in the early neural plate and early neural tube of 
several species [45]. In the developing central nervous system, Sox2 expression becomes 
restricted to the neuroepithelial cells of the ventricular layer, which continue to divide and 
exhibit an immature phenotype. Cells that leave the ventricular layer lose Sox2 expression 
[45]. Interestingly, Sox2 has also been implicated in GBM [46], [47] as downregulation of 
Sox2 reduced cell proliferation and tumorigenicity in GBM cells. Therefore, Sox2 was 
proposed as a new GBM therapeutic target [46]. At present, inhibitors of Sox2 are not 
available but the data presented here show that inhibition of GSK3 strongly downregulates 
Sox2 in GBM cells. This raises the possibility that LiCl or more specific GSK3-inhibitory drugs 
could be used to decrease the Sox2-dependent tumorigenic potential of GBM cells. 
Two main strategies are currently being exploited to eradicate the cancer stem cell 
(CSC) pool: i) chemotherapeutic regimens that specifically drive CSC into apoptosis and 
thereby deplete the CSC reservoir of the tumor, and ii) strategies aiming to drive CSC into 
differentiation and thereby increase their susceptibility to pro-apoptotic treatments [1]. 
Given the high degree of drug resistance and the shared cellular and gene expression 
profiles of adult and cancer stem cells [48], targeting CSC has proven to be difficult. 
However, induction of differentiation remains a therapeutic strategy for CSC as Piccirillo et 
al. showed that bone morphogenetic proteins can induce differentiation of CD133+ GBM 
cells, thereby reducing their tumorigenic potential [49]. However, the use of morphogens 
bears the risk of interfering with the tightly regulated adult stem cell niches. Any strategy to 
induce differentiation in cancer stem cells must be carefully assessed for any adverse effects 
on the adult stem cell population. 
Our results show GSK3 inhibition to be an attractive strategy for specifically targeting 
a subpopulation of cancer cells with stem cell-like characteristics. Expression of stem cell and 
differentiation markers more accurately defined the subpopulation of cells within GBM cell 
lines and ex vivo tumor cells than expression of the CD133 marker. Inactivation of both Bmi1 
and GSK3 depleted precursor cells required for tumor maintenance and progression. These 
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data add another facet to the many effects of GSK3 as a regulator of cancer cell identity. 
Here, GSK3 activation is identified as a key element in maintaining stem cell-like 
characteristics in a subset of cancer cells, providing these cells with a higher self-renewal 
capacity. Recently, downregulation of GSK3 was shown to induce apoptosis in glioma cells 
and to have an anti-migratory effect in glioma sphreoids [50], [51]. The role of GSK3 
inhibiton on differentiation was not analyzed. Optimal therapies for cancer aim to spare 
normal cells with minimal or no general toxicity while depleting malignant cells. The Wnt 
pathway is involved in regulating cell processes as proliferation, apoptosis, differentiation, 
mobility and stem cell self-renewal and has been described also as a major regulator of adult 
neurogenesis in the hippocampus [52]. In the Wnt/β-catenin pathway GSK3β mediates β-
catenin degradation. Use of GSK3 inhibitors leads to the accumulation of β-catenin, which 
then drives cells into proliferation but this effect was not observed in the present study. This 
may be explained by the constitutive activation of several growth-promoting pathways, such 
as EGFR and PI3K, commonly found in GBM. This could lead to maximal Wnt signaling target 
activation masking additional activation. Conversely, differentiation- and apoptosis-inducing 
programs, which are low in cancer cells, could be influenced by GSK3 inhibition and are, 
therefore, directly detectable. On the opposite in normal system as in the A111 cells GSK3 
inhibition lead to an increased cell proliferation in accordance with the previously described 
results in neural progenitor cells [53]. 
shRNA against Bmi1 downregulated not only GSK3 but also Bcl2, Nestin, Sox2 and not 
p16 and p14 (Figure 2A). The microarray data showed higher levels of GSK3 expression in 
brain tumors than in normal brain tissue, and protein was found to be expressed in the 
majority of the tumors analyzed indicating a role for GSK3 in GBM (Figure 2). GSK3 can thus 
be regarded as an important regulator of tumor cell identity in GBM. 
In conclusion, we propose GSK3 inhibitory drugs, e.g. LiCl, as possible first- and/or 
second-line treatments complementing standard cancer therapy. 
The additive effect of combining the GSK3 inhibitor LiCl and the standard GBM 
therapeutic temozolomide suggests possible sensitization due to the induction of 
differentiation by interference with GSK3 activity. In addition, the vast clinical experience of 
this drug with psychiatric patients indicates safe application and the lower cancer prevalence 
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in LiCl-treated patients than in the general population suggests a protective effect of the 
drug [44]. Clinically, LiCl could be tested in patients receiving standard treatments in an 
additional therapeutic arm, the clinical hypothesis being that long-term LiCl therapy in 
stabilized GBM patients may delay tumor recurrence from the residual cancer stem cell pool 
by driving cancer stem cells into differentiation and apoptosis. 
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Materials and Methods   
Patients 
Tumor samples obtained from patients during a neurosurgical procedure were 
immediately frozen and kept at −80°C. All patients gave their written consent for the 
neurosurgical procedure and for anonymous scientific analysis of diseased tissue according 
to the guidelines of the Ethics Committee of Basel, Switzerland (EKBB). 
Cell culture and reagents 
LN319, LN18, LN215, U373, LN229, LN401, U343, U87, BS125 and Hs683 glioma cell 
lines with defined genetic status of TP53, p16/p14 and PTEN [34], DAOY medulloblastoma 
and B104 neuroblastoma cell lines were cultured in Eagle medium supplemented with 25 
mM glucose, glutamine, standard antibiotics, and 10% FCS. BS287 cells were cultured in 
Neurobasal medium (Invitrogen) supplemented with basic fibroblast growth factor (20 
ng/ml, Invitrogen), epidermal growth factor (20 ng/ml, R&D Systems), B27 (1x) and N2 
supplement (0.5x) (Invitrogen). All cells were maintained at 37°C in 5% CO2. The cell lines 
were seeded in 6-cm plates at 5’000–10’000 cells/cm2 and grown for 24 h prior to 
treatment. For cell counting, cells were treated for 72 h as described in the figure legends 
and counted by hemocytometer. Lithium chloride (LiCl) was obtained from MERCK and 
SB216763 from Tocris. Drug concentrations used are indicated in the figure legends. LiCl was 
dissolved in PBS and SB216763 in DMSO and stored at −20°C. The EGFR inhibitor AEE788 was 
provided by Novartis Pharma. The γ–secretase inhibitor DAPT was obtained from Roche. 
Colony formation assay 
For each cell line, 500 cells were plated in triplicate into 94-mm Petri dishes 
containing 10 ml of culture medium with 10% FCS. Cells were grown for 14 days at 37°C and 
5% CO2, during which period the medium was not changed. Cells were then fixed with 4% 
formaldehyde in 1x PBS and stained with crystal violet. 
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BS287 “ex vivo” cell line formation and neurobasal medium 
Following informed consent, a tumor sample classified as GBM based on the WHO 
criteria was obtained from a patient undergoing surgical treatment at the University 
Hospital, Basel, Switzerland. Within 1–3 h after surgical removal, the sample was treated 
with the Neural Tissue Dissociation Kit (Miltenyi Biotec GmbH) according to the 
manufacturer's protocol. Tumor cells were cultured in NBE media. Uncoated plastic dishes 
were used for neurosphere culture of NBE cells. 
Plasmids, lentiviruses and transfection 
The lentiviral vectors pLKO.1-puro-scrambled-shRNA (Addgene) and pLKO.1-puro-
shRNA (Sigma, sh1061: CCGGCCTAATACTTTCCAGATTGATCTCGAGATCAATCTG G 
AAAGTATTAGGTTTTT, sh693: CCGGCCAGACCACTACTGAATATAACTCGAGTTATA 
TTCAGTAGTGGTCTGGTTTT) targeting Bmi1 were transfected into HEK293 cells together with 
plasmids encoding the packaging (pCMV_dr8_91) and envelope proteins (pMD2-VSV-G) 
using CaCl2 precipitation. The concentration of infectious particles in the supernatant was 
titrated using HeLa cells. Glioma cells were transduced with infectious viral particles. Stably 
transfected clones were selected with 2 µg/ml puromycin. Bmi1 overexpression was 
obtained with pBABE-puro and pBABE puro-Bmi1 using CaCl2 precipitation for 8 h. Stably 
transfected clones were selected with 2 µg/ml puromycin. siRNA transfection for GSK3 was 
performed using the GSK-3α/β siRNA SignalSilence Kit (Cell Signaling Technology) according 
to the manufacturer's instructions. Cells were transfected using the Amaxa Nucleofector 
device (Lonza). Cells transfected with non-specific siRNA were used as a control. 
Transwell migration assays 
Transwell migration assays were performed using modified Boyden chamber units 
with polycarbonate filters of 8-µm porosity (Costar). The lower side of the filter was coated 
with 10 mg/ml fibronectin for 2 h at 37°C. The bottom chamber was filled with DMEM 
containing 10% FCS. Cells (104 per well in serum-free DMEM) were plated in the upper 
chamber and incubated for 24 h with or without GSK3β inhibitors. After removal of the 
remaining cells from the upper surface of the filter, migrated cells at the bottom of the filter 
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were fixed with 3.7% formaldehyde in PBS and stained with 0.1% crystal violet. For each 
treatment, cells in 10 fields of view were counted in three independent experiments. 
Western blot analysis and antibodies 
Cells were washed with 1x PBS, lysed in buffer containing 2% sodium dodecyl sulfate 
(SDS), 50 mM Tris pH 6.8, 0.1 M dithiothreitol (DTT), boiled and used either immediately or 
frozen at −20°C. Protein lysates were resolved on denaturing 8–12% SDS-polyacrylamide gels 
and transferred to nitrocellulose membranes (iBlot Gel transfer stacks, Invitrogen). The 
following primary antibodies were used: anti-Bmi1 (Upstate), anti-β-catenin and anti-Nestin 
(Santa Cruz Biotechnology); anti-β-tubulin III and anti-GFAP (Sigma); anti-CNPase 
(Chemicon); anti-GSK3β (Cell Signaling); anti-Notch2 (Developmental Studies Hybridoma 
Bank); anti-Sox2 (R&D systems); anti-CD133 (Miltenyi Biotec); anti-Akt and phospho-Akt 
(Ser-473) (Millipore, Billerica MA, USA), anti-p16/p14, anti-Bcl2, anti-Erk and anti-phospho-
Erk (Santa Cruz Biotechnology, Santa Cruz CA, USA), anti-Actin (Sigma-Aldrich, St. Louis, 
USA). Decorated proteins were revealed using horseradish peroxidase-conjugated anti-
mouse, anti-rabbit, anti-rat (New England Biolabs) or anti-goat (Pierce) secondary antibodies 
and visualized by the chemoluminescence detection system SuperSignal West Pico (Thermo 
Scientific). Protein bands were quantified with ImageJ software (http://rsb.info.nih.gov/ij/). 
Results were normalized to actin levels. 
Cell sorting and flow cytometry 
Cell DNA content and apoptosis were analyzed by flow cytometry (CyAn ADP 
Analyzer, Beckman Coulter) and the results statistically evaluated with Summit v4.3 
software. Cells were trypsinized, fixed in ice-cold 70% ethanol for 1 h and stained with 50 
µg/ml propidium iodide for FACS analysis. Percent dead cells was determined from the 
proportion of cells in sub-G1 phase. Results are given as mean values from three 
independent experiments. For CD133 analysis, isolated cells were labeled with anti-CD133 
antibody (1:10) for 10 min at 4°C, washed with PBS and sorted (INFLUX Cell Sorter by BD 
Biosciences). 
For BrdU analysis, cells were pulsed with 10 µM bromodeoxyuridine for 2 h and 
processed with the APC-BrdU kit according to the manufacturer's instructions (BD 
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Pharmingen). For fluorescent labeling with GFAP, cells were fixed and permeabilized with 
the Cytofix/Cytoperm kit (BD Pharmingen). Permeabilized cells were incubated with anti-
GFAP (1:200) or matching isotype control antibody for 30 min on ice, washed twice and 
incubated with the corresponding secondary antibody for 30 min on ice and analyzed by 
flow cytometry (CyAn ADP Analyzer, Beckman Coulter). 
Immunocytochemistry 
Cells were grown to 80% confluency as a monolayer as described above. Cells were 
then fixed in 4% PFA in PBS for 15 min at room temperature, washed with PBS and incubated 
with the primary antibody overnight at 4°C in PBS +1% BSA +0.1% Triton X100. After 
thorough washing with PBS, the secondary antibody was added for 3 h at room 
temperature. Cells were imaged by confocal microscopy. All tumor samples analyzed were 
stained with hematoxylin-eosin. 
Microarray analysis of glioma 
BS series are primary tumor tissues obtained from patients diagnosed with primary 
CNS tumors classified according to the WHO grading system. Normal brain tissue used as a 
template for microarray was obtained from samples of brain surgery for non-neoplastic 
disease. Total RNA from two normal brains, 12 GBM and eight astrocytoma samples was 
amplified and labeled using the Affymetrix 2-cycle amplification protocol according to the 
manufacturer's instructions (Affymetrix). Samples were hybridized to Affymetrix U133v2.0 
GeneChips and scanned using an Affymetrix Gene Chip scanner following the manufacturer's 
instructions. Expression values were estimated using the GC-RMA implementation in the 
Genedata Refiner 4.1 (Genedata, Basel, Switzerland) package. Data-mining and visualization 
was performed using the Genedata Analyst 4.1 package. All samples were quantile 
normalized and median scaled to correct for minor variation in expression distribution. All 
microarray data reported in the manuscript are in accordance with the MIAME guidelines. 
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Supporting Information  
 
Figure S1.  
Bmi1 down-regulation reduces GSK3β protein levels. (A) GBM cell line U87 is transduced with shRNA against 
Bmi1 (sh1061) or with scrambled shRNA (scr) (B) Bmi1 down regulation lead to GSK3β reduction in Hs683 using 
a different shRNA sequence. (C) Bmi1 down-regulation in U87 glioma cell line decreased nestin protein levels, 
whereas Bmi1 over-expression increased Nestin protein expression. 
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Figure S2.  
GSK3β is expressed in primary brain tumors. (A) GSK3β protein expression in a series of primary GBM (1–32). 
(B) Photomicrograph of the immunohistochemical study showing extensive necrotic areas in GBM compared to 
Astrocytoma (Hematoxylin-Eosin staining). Arrows point to necrotic areas in GBM. 
 
 
Figure S3.  
GSK3 inhibition induces differentiation of the BS287 “ex vivo” cell line. Nestin, Sox2, β-catenin, CNPase, β-
tubulin III and β-actin protein expression upon GSK3 inhibition (with LiCl and SB216763 for either 24 or 72 
hours) on the BS287 “ex vivo” cell line. 
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Figure S4.  
Cell cycle analysis in GBM cell lines treated with LiCl. The GBM cell lines LN319, LN18, U373 and LN215 were 
treated with 10 or 20 mM LiCl for 24 hours. Percentage of the cells in G1, S and G2-M phase of the cell cycle 
were evaluated by FACS analysis. 
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Abstract 
 
Glioblastoma multiforme (GBM) brain tumors are proposed to originate from neural 
stem cells (NSCs) transforming into glioma stem cells (GSCs). The underlying molecular 
events are poorly understood. Notch2 is frequently amplified in GBMs and correlates with 
poor prognosis, possibly implicating Notch2 into gliomagenesis. Here we generated mice 
expressing the activated intracellular domain of Notch2 in NSCs. We found that Notch2 
signaling triggers NSC differentiation into astrocytes while inhibiting oligodendrocyte and 
neuronal differentiation. Moreover, Notch2 signaling increases NSC proliferation, which 
causes a pronounced hyperplasia of the neurogenic niche. Neurospheres derived from mice 
expressing activated Notch2 show increased proliferation and reduced apoptosis. Likewise, 
high levels of Notch2 expression in GBM cell lines correlate with increased GSC proliferation 
and reduced apoptosis. In GBM biopsies Notch2 mRNA expression levels positively correlate 
with mRNA expression levels of genes controlling stemness (Sox2, Nestin) and astrocyte fate 
(Vimentin, GFAP) while they negatively correlate with the expression levels of genes 
controlling oligodendrocyte fate (Olig2, CNP, PLP1). High Notch2 mRNA expression levels 
also correlate with high and low expression levels of antiapoptotic (Mcl1, BclX) and 
proapoptotic (Bax) markers, respectively. It therefore appears that Notch2 signaling in NSCs 
produces key GSC features, including increased proliferation, astrocytic lineage commitment 
and reduced apoptosis. Aberrant Notch2 signaling may therefore contribute to malignant 
transformation of NSCs. Accordingly, pharmacological blockade of Notch2 signaling may 
represent a promising strategy for therapeutic interference with GBM formation.  
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Introduction 
 
Despite advances in tumor imaging, surgery, chemo and radiation therapy, more 
than 70% of GBM patients die within 2 years of diagnosis [1]. The discovery of a highly 
tumorigenic subpopulation of stem-like GSCs in GBM biopsies [2] led to the proposal GSCs 
arise from developmentally stalled NSCs [3-6]. GSCs have characteristics of NSCs, such as 
multipotency, self-renewal capacity, high motility and robust proliferative potential [4-5]. 
Mutations impairing cell cycle control and apoptosis may therefore promote NSCs to 
become GSCs [7-8]. Intriguingly, Notch2 was found to be amplified in most GBMs and high 
Notch2 mRNA levels strongly correlate with poor prognosis [9]. Moreover, the active form of 
Notch2 increased xenograft GBM tumor growth [10]. Notch signaling regulates proliferation, 
cell fate decisions and survival in various cell types, including NSCs [11-14]. Notch2 may 
therefore represent one of the factors contributing to malignant transformation of NSCs.  
 
Four Notch receptors (Notch1-4) exist in mammals. Binding of ligands triggers a 
proteolytic processing of receptors and translocation of their intracellular domains 
(NotchICDs) to the nucleus. NotchICD binding to RBPjκ leads to transcriptional activation of 
the effector genes Hairy and Enhancer of Split homologs (e.g. Hes1 or Hes5), which can 
prevent neuronal differentiation [12, 15]. Notch1, for example, was shown to control 
proliferation and survival of NSCs during brain development [16-18] and to promote glial 
differentiation [12-14], Notch1 was also implicated in the development of a variety of 
tumors, including GBMs [3, 19-20]. Notch2 signaling is much less understood. Notch2 is 
expressed throughout the embryonic [21-22] and adult NSC niche [18, 22], regulates 
morphogenesis of Bergmann glia cells and inhibits granule neuron differentiation in the 
cerebellum [23]. Because of the strong association of Notch2 with GBMs it is also proposed 
that constitutive Notch2 signaling in NSCs could contribute to gliomagenesis [9]. To test this 
hypothesis, we now generated mice expressing activated Notch2 in NSCs and compared the 
properties of such NSCs with those of GSCs and GBM biopsies. Our data show that Notch2 
expression during development or in adults is sufficient to induce features of GSCs and GBM 
in NSCs, thus further substantiating a role for Notch2 in gliomagenesis. 
Inauguraldissertation  Roland M. Huber 
 - 129 - 
Results 
 
Notch2ICD Expression in Embryos Causes Severe Hyperplasia and Inhibits Neurogenesis  
 
To study the role of Notch2 signaling in the developing brain, we used N2ICD/Nestin-
Cre mice to drive expression of myc-tagged Notch2ICD in NSCs and their progeny (Figure 
1A). N2ICD/Nestin-Cre mice died at birth. Myc-immunostaining in E18.5 mice showed 
widespread expression of Notch2ICD in the brain (Supplementary Figure 1A). Moreover, 
mRNA levels not only for Notch2 but also for its direct downstream target genes Hes1 and 
Hey1 are highly increased in E16.5 N2ICD/Nestin-Cre mice compared to control mice (Figure 
1B), showing and increase in Notch2 signaling. E18.5 N2ICD/Nestin-Cre but not single 
transgenic N2ICD or Nestin-Cre control embryos displayed a hyperplasia of the neurogenic 
region (ganglionic eminence) and enlarged ventricles in cresyl violet stainings (Figure 1C,D) 
when compared to wildtype embryos.. The ganglionic eminence displayed a 3-fold increase 
in size (Figure 1C) and an enlarged zone of Ki67+ (Figure 3E) and Nestin+ NSCs 
(Supplementary Figure 2A). The strata region of E18.5 N2ICD/Nestin-Cre embryos had an 
increased cell density and lacked the striasome, a typical porous structure (Figure 1D,F). 
Moreover, the striatal region lacked immunostaining for substance P and GAD67/67, which 
are commonly used to outline the striatum in the ventral forebrain (Figure 1F). NeuN 
immunostaining showed that the ventral forebrain of N2ICD/Nestin-Cre mice is not only 
devoid of GAD65/67+ interneurons but of mature neurons in general (Supplementary Figure 
2B). It therefore appears that the striatal region is mainly populated by an increased number 
of Nestin+ NSCs that fail to develop into neurons (Figure 1F, Supplementary Figure 2A,B). 
This supports a dual role for Notch2 during embryogenesis in proliferation and inhibition of 
neurogenesis. 
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Figure 1. Activated Notch2 signaling in the developing brain results in a hyperplasia of the neurogenic zone.  
 
(A) Transgenic expression of activated Notch2 in the developing brain. N2ICD mice contain a chicken β-actin 
(pCAG) promoter followed by a LoxP flanked transcriptional Stop cassette and the Notch2 intracellular domain 
(Notch2ICD) with a c-terminal human 5xMyc tag. Crossing N2ICD mice with Nestin-Cre mice yielded 
N2ICD/Nestin-Cre mice in which Nestin-Cre mediated Stop cassette excision enabled Notch2ICD expression 
specifically in the neural lineage. (B) Notch2 signaling is highly upregulated in N2ICD/Nestin-Cre mice. The 
mRNA expression levels for Notch2 and its downstream targets Hes1 and Hey1 are increased in brains from 
E16.5 N2ICD/Nestin-Cre mice when compared to controls mice. (C) Quantification of the ganglionic eminence 
revealed a more than 3-fold increase in size in E18.5 N2ICD/Nestin-Cre mice compared to E18.5 wt controls. (D) 
Coronal cranial sections of E18.5 control and N2ICD/Nestin-Cre mice were stained with cresylviolet. The 
neurogenic zone termed ganglionic eminence (GE; indicated by a dashed line in the corresponding magnified 
panels) showed a dramatic hyperplasia in N2ICD/Nestin-Cre mice, while it appeared normal controls. E18.5 
N2ICD/Nestin-Cre mice also displayed enlarged ventricles (V) and a lack of a properly developed striatum (Str) 
as it was present in E18.5 wt controls.. (E) Immunostaining for the proliferation marker Ki67 reveals a highly 
increased population of proliferating cells in E18.5 N2ICD/Nestin-Cre mice compared to E18.5 wt controls. (F) 
Immunostaining for markers that are present in the striatum of E18.5 wt mice such as Gad65/67 and Substance 
P reveals that N2ICD/Nestin-Cre mice do not express such markers in the ventral forebrain. In addition, DAPI 
staining in E18.5 wt mice shows the typical porous structure of the striasome (asterisks) which was missing in 
N2ICD/Nestin-Cre, further indicating a lack of a properly developed striatum due to the hyperplasia of the GE. 
Bar diagram shows mean±SD, ***=p<0.001, students t-test). Scale bars are (A,C) = 200µm, (D) = 50 µm (D). 
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Notch2ICD Expression in Adult Mice Increases Proliferation and Inhibits Neuronal 
Differentiation in the Dentate Gyrus 
 
GBM mostly occur in adults and therefore Notch2ICD expression in adult NSCs more 
accurately mimics a possible role of Notch2 in gliomagenesis. Unfortunately, perinatal 
lethality of N2ICD/Nestin-Cre mice precludes studying a possible role of Notch2 in malignant 
transformation of adult NSCs. We therefore generated triple transgenic N2ICD/YFP/GCE 
mice by crossing N2ICD mice with double transgenic GFAPCreERT2/R26R-YFP mice [24-25]. 
These mice allow for tamoxifen-induced Notch2ICD and YFP expression in adult GFAP+ NSCs 
and astrocytes [24] (Figure 2A). YFP/GCE mice, which express YFP but not Notch2ICD upon 
tamoxifen induction were used as littermate controls. N2ICD/YFP/GCE mice exhibit a 2-fold 
increase in Ki67+ proliferating YFP+ cells in the subventricular zone (SVZ) and the 
subgranular zone (SGZ), indicating that Notch2ICD increases proliferation in adult NSCs as 
well (Figure 2B,C,D). One year old N2ICD/YFP/GCE mice (n=8) still exhibited hyperplasia but 
had no tumors (data not shown). This suggests that Notch2 is not oncogenic by itself, 
although the number of aged mice is too small to be conclusive. 
 
We next analyzed whether Notch2ICD prevents neuronal differentiation in the adult 
brain (Figure 2C). N2ICD/YFP/GCE and YFP/GCE mice were co-immunostained for YFP and 
NSC (GFAP, Sox2) or neuronal (Dcx, NeuN) markers. The dentate gyrus of N2ICD/YFP/GCE 
mice showed exhibited approximately a 2-fold increase in YFP+ cells expressing GFAP/Sox2 
(Figure 2E,F). Likewise, N2ICD/YFP/GCE mice had a significantly reduced number of YFP+ 
cells expressing Dcx/NeuN (Figure 2E,F). This supports that Notch2 signaling inhibits 
neuronal differentiation in adult mice as well.  
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Figure 2. Notch2 regulates proliferation and differentiation in adult NSCs. 
 
(A) N2ICD mice introduced previously in Figure 1A were mated with GFAPCreER
T2
/Rosa26-YFP (YFP/GCE) mice, 
yielding N2ICD/YFP/GCE
 
mice which allow for Stop excision in adult NSCs upon Tamoxifen injection. Upon Stop 
excision in N2ICD/YFP/GCE, both Notch2ICD and a YFP reporter are expressed. Tamoxifen was administered to 
8 week old mice for 5 consecutive days and analysis was performed 7 days after the last injection. (B) 
Immunostaining for YFP and the proliferation marker Ki67 was performed on N2ICD/YFP/GCE and YFP/GCE 
coronal cryosections, to determine the amount of YFP+ cells that proliferate. Panels show exemplary pictures 
from the SVZ of the lateral ventricle and SGZ of the dentate gyrus. (C) Quantification of YFP+ cells expressing 
Ki67 showed a 2-fold increase of proliferating YFP+ cells in N2ICD/YFP/GCE mice compared to YFP/GCE in the 
SVZ and in the SGZ (D), indicating that activated Notch2ICD increased proliferation in the adult neurogenic 
niche. (E) Immunostaining for YFP in combination with either adult stem cell marker (Sox2, GFAP; left panels) or 
marker for neurons (Dcx, NeuN; right panels) was performed in the dentate gyrus to analyze the effect of 
activated Notch2 on adult NSC differentiation in N2ICD/YFP/GCE and YFP/GCE mice. (F) Quantification of YFP+ 
cells coexpressing Sox2 and GFAP revealed that N2ICD/YFP/GCE mice have almost 2-fold more YFP+ which 
express NSC marker compared to YFP/GCE mice, while the number of YFP+ neurons dramatically decreased. 
This indicates that Notch2ICD expression increased the amount of NSCs while it largely blocked neurogenesis. 
Bar diagrams show mean±SEM, *=p<0.05, **= p<0.01, ***= p<0.01. Statistics were performed using student’s 
t-test.  
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Notch2ICD Expression in Neurospheres Increases Proliferation, Promotes Survival and Glial 
Differentiation 
 
To study NSC proliferation and expansion, we made neurospheres from the 
ganglionic eminence of E14.5 N2ICD/Nestin-Cre and littermate control embryos (Figure 3A). 
Neurospheres from N2ICD/Nestin-Cre NSCs were significantly larger (73µm vs. 42µm 
diameter, p<0.0001), indicating that Notch2ICD increases NSC proliferation in neuropheres 
as well (Figure 3B,C). Next, we used neurospheres to study whether Notch2ICD regulates 
NSC fate decisions. We differentiated neurospheres from E14.5 N2ICD/Nestin-Cre embryos 
in vitro (Figure 3A) and quantified cells expressing the the neuronal marker βIII-Tubulin 
(Tuj1), the oligodendrocyte marker Olig2 and the astrocyte marker GFAP (Figure 3D). A 
significantly reduced number of Tuj1+ cells in N2ICD/Nestin-Cre cultures indicates that 
Notch2ICD prevents NSCs from efficiently differentiating into neurons (Figure 3E). 
N2ICD/Nestin-Cre NSCs efficiently developed into GFAP+ astrocytes (Figure 3F). However, no 
statistically significant increase in the number of GFAP+ astrocytes was observed, 
presumably because most cells already differentiate into astrocytes in the absence of 
Notch2ICD. Intriguingly, the staining intensity for GFAP in differentiated N2ICD/Nestin-Cre 
NSCs was visibly increased compared to control (Figure 3D). Increased GFAP protein levels 
and decrease Tuj1 protein levels were confirmed on immunoblots (Figure 3H). Moreover, 
the number of Olig2+ oligodendrocytes was significantly decreased in N2ICD/Nestin-Cre 
NSCs (Figure 3G). This supports that Notch2 signaling biases fate decisions in NSCs towards 
the astrocytic lineage by inhibiting differentiation into neurons or oligodendrocytes. Notch2 
signaling in NSCs is therefore sufficient to promote and maintain the astrocytic features of 
GSCs. 
 
To test the role of Notch2ICD activity on NSC survival and cell death resistance, 
N2ICD/NestinCre and control neurospheres were treated with etoposide to induce apoptotic 
cell death. Apoptosis induction was assessed by the cleavage of caspase-3 which is part of 
the apoptotic signaling cascade (Figure 3I). Etoposide treatment induced the cleavage of 
caspase-3 in control NSCs. In contrast, NSC overexpressing Notch2ICD showed low levels of 
cleaved caspase-3 compared to controls at the same treatment, suggesting a role of Notch2 
signaling in regulating NSC survival mechanisms. 
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Figure 3. Notch2 signaling controls NSC proliferation and differentiation in vitro.  
 
(A) Scheme depicting the experimental setup used for the analysis of activated Notch2 in NSCs. NSCs were 
isolated from E14.5 N2ICD/Nestin-Cre and control mice and neurospheres were cultured under non-adherent 
conditions in serum-free media. Neurosphere growth was determined to study NSC proliferation. In order to 
study NSC differentiation, neurospheres were dissociated and differentiated into neurons, astrocytes and 
oligodendrocytes under adherent conditions in serum-containing media. (B) Neurospheres derived from 
N2ICD/Nestin-Cre mice and thus overexpressing Notch2ICD showed increased sphere size when compared to 
control spheres. (C) Quantification of neurosphere diameters showed that the median diameter in 
N2ICD/Nestin-Cre spheres was increased by 75% when compared to control spheres, showing that activated 
Notch2 increases NSC proliferation. (D) Immunostainings on differentiated N2ICD/Nestin-Cre and control NSCs 
for markers defining neurons (Tuj1) (arrows), astrocytes (GFAP) and oligodendrocytes (Olig2) (arrowheads) was 
performed and counterstained with DAPI to study the effect of Notch2ICD on NSC fate decisions. 
Quantification of differentiation marker in percent of DAPI+ nuclei showed that Notch2ICD largely blocked 
neuronal differentiation (E) and increased the number of astrocytes (F). Furthermore, N2ICD/Nestin-Cre NSC 
almost completely lost their ability to differentiate into Olig2+ oligodendrocytes (G). Although the increase in 
GFAP+ astrocyte numbers was not statistically significant, the overall GFAP staining was more intense (D) and 
GFAP protein levels were highly increased in western blot analysis from differentiated NSCs, while Tuj1 levels 
diminished (H). (I) NSCs overexpressing Notch2ICD were protected from apoptosis. Lower levels of cleaved 
caspase-3 were detected in the Notch2ICD overexpressing NSCs after etoposide treatment. Box plot diagrams 
show median (red line), boxed 25% and 75% percentiles and whiskers marking minima and maxima, statistics 
were performed using Mann-Whitney test. Scale bar (B, D) = 100µm.  
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Notch2ICD Expression in GSCs Derived from Human Glioblastoma Cell Lines Increases 
Proliferation and Prevents Apoptosis  
 
To activate and inhibit Notch2 signaling in GSCs we stably transfected U373 GBM 
cells with human Notch2ICD (U373-Notch2ICD cells) and dominant-negative mastermind-like 
I (MAML1dn) (U373-MAML1dn cells) [26-27], respectively. Transfected GBM cells were 
cultured in neurosphere media under non-adherent conditions, resulting sphere growth. The 
presence of GSC markers (Nestin, Sox2, CD133) confirmed that spheres derived from GSCs 
rather than non stem-like GBM cells growing under non-adherent conditions 
(Supplementary Figure 3).  
 
Notch2ICD and MAML1dn expression visibly increased and reduced the size of GSC 
spheres, respectively (Figure 4A). Notch2ICD overexpressing GSC spheres had a significant 
approximately 2-fold increase in diameter compared to parental U373 (U373-wt) GSC 
spheres (111±2.4µm vs. 56±1.7µm; mean±SEM, p<0.0001) (Figure 4B). U373-MAML1dn GCS 
spheres had a 33% decrease in diameter when compared to U373-wt cells (41±0.5 µm vs. 
56±1.7µm; mean±SEM, p<0.0001) (Figure 4B).  
 
To evaluate whether Notch2 signaling plays a role on GSCs chemoresistance to cell 
death, U373-Notch2ICD and GFP-transfected (U373-GFP) control GBM cells were treated 
with etoposide. Both cell populations showed a higher resistance to apoptosis induction 
compared to neurospheres (data not shown) since etoposide treatment had to be prolonged 
to 24h to detect an effect. Similarly to the apoptosis assay on neurospheres, the GBM cells 
expressing Notch2ICD showed low levels of cleaved caspase-3 compared to GFP-transfected 
GBM cells (Figure 4C). This result supports a role for Notch2ICD activity on the 
chemoresistance of glioma cells to apoptosis. In addition, U373-Notch2ICD GBM cells 
showed increased levels of anti-apoptotic proteins such as Bcl-2 and Mcl-1 compared to 
U373-GFP GBM control cells, further implicating Notch2 in GBM survival (Figure 4D). Thus, 
Notch2 signaling not only increases GSC proliferation but also induces chemoresistance of 
GBM cells to etoposide treatment by upregulating antiapoptotic pathways. 
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Figure 4. Notch2 signaling controls proliferation and induces survival in GSCs.  
 
(A)  U373 GBM cell were cultured for 7 days in neurospheres media under non-adherent conditions, allowing 
GSCs to form spheres. U373-Notch2ICD GSC spheres overexpressing Notch2ICD showed increased sphere size, 
indicating increased GSC proliferation, when compared to GCS spheres derived from parental (wt) U373 cells. 
U373-MAML1dn GSCs expressing MAML1dn and thus inhibiting canonical Notch signaling, formed only very 
small spheres. (B) Notch2 signaling increases GSC proliferation in vitro. Quantification of the GSC sphere 
diameters derived from U373 GSCs showed a 2-fold increase in proliferation in U373-Notch2ICD GSC spheres 
compared to wt U373 GSC spheres, while U373-MAML1dn GSC spheres showed a decrease. (C) Notch2 
signaling induces chemoresistance to Etoposide. U373-Notch2ICD GBM cells were resistant to etoposide-
induced apoptosis. Cleaved caspase-3 expression was reduced in U373-Notch2ICD GBM cells compared to 
U373-GFP GBM cells. (D) U373-Notch2ICD upregulate antiapoptotic proteins. U373-Notch2ICD GBM cells show 
an increase in Mcl1 and Bcl2 protein levels compared to U373-GFP cells, indicating that Notch2 signaling 
increases the resistance to apoptosis by upregulation of antiapoptotic factors. Actins controls for sample 
loading (C, D). Scale bar (A) = 100µm. 
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Notch2 Levels in Primary Human GBMs Correlate with Antiapoptotic, Stem Cell and Glial 
Markers 
 
Using published microarray data [28], we investigated whether Notch2 expression in 
primary human GBM samples correlates with the expression of genes regulating cell 
differentiation and survival (Figure 5A, Supplementary Figure 4). As a control, Notch2 
expression correlated highly expression of the target genes Hes1 and Hey1. Transcripts for 
the anti-apoptotic proteins Mcl1 and BclX exhibited moderate correlation with Notch2, while 
transcripts for the proapoptotic protein Bax showed a strong negative correlation. This 
further implicates Notch2 into GBM survival. GSC markers (Sox2, Nestin) and FABP7 (also 
known as BLBP) exhibited strong and moderate correlation with Notch2, respectively, 
supporting that Notch2 levels correlate with an increased GSC pool. The astrocyte markers 
vimentin and GFAP highly correlated with Notch2 expression, in line with Notch2 directing 
astrocyte versus oligodendrocyte fate decisions, Likewise, oligodendrocyte markers (CNP, 
Olig2, PLP1) showed a strong negative correlation with Notch2 transcript levels. In summary, 
this correlation analysis further supports that Notch2 signaling determines much of the 
cellular identity of GSCs.  
 
 
Figure 5.  
 
Notch2 expression in primary human GBMs correlates with the expression of genes inhibiting apoptosis, 
promoting stemness (NSCs) and inducing astrocyte differentiation. Correlation coefficients for Notch2 and 
genes involved in apoptosis (blue) and differentiation (red/purple) as well as Notch2 targets (green) were 
calculated using Pearson’s Score. Values 0.3 to 0.5 or -0.3 to -0.5 represent moderate positive or negative 
correlation, whereas values from 0.5 to 1 or -0.5 to -1 indicate high positive or negative 
correlation, respectively. Correlation coefficient (0.98) for another Notch2 probe is shown as a positive control.   
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Discussion 
 
Developmentally stalled NSCs are a possible source of GSCs giving raise to GBMs [3-
6]. NSCs inherently express the cellular machinery necessary for tumor formation (e.g. 
multipotency, self-renewal capacity, high motility and robust proliferative potential) and 
therefore are at risk for malignant transformation [4-5]. Notch2 is amplified in most GBMs 
and high Notch2 levels correlate with poor prognosis. In contrast, loss of Notch2 is 
frequently found in oligodendroglioma and low Notch 2 levels correlates with a much better 
prognosis. Since Notch1 is a critical regulator of neurogenesis [13-14, 29] and implicated in 
tumor formation, we now used a transgenic approach to study whether Notch2 signaling in 
NSCs potentially plays a role in GBM formation. In support of this, we found that Notch2 
signaling in NSCs increases proliferation and causes severe hyperplasia of the neurogenic 
niche. Notch2 expression in cultured NSCs promotes astrocytic differentiation at the expense 
of neuronal and oligodendrocytic differentiation. Moreover, the expression of the activated 
form of Notch2 in NSCs increased the resistance to apoptosis of these cells, rendering them 
insensitive to the cytotoxic drug etoposide. Our findings therefore support that Notch2 
signaling in NSCs is sufficient to induce key features of GSCs, including increased 
proliferation, reduced apoptosis and astrocytic lineage commitment. Given that NSCs with 
constitutively high Notch2 signaling acquire features akin of those of GSCs, we studied 
whether manipulating the level of Notch2 signaling in GSCs from cultured GBM cells 
influences proliferation and cell survival. We found that increasing Notch2 signaling in 
cultured GBM cells significantly increases proliferation, while blocking Notch2 signaling 
reduces proliferation. Increased Notch2 signaling in cultured GBM cells also caused an 
upregulation of anti-apoptotic proteins, which increases cell survival. These results are in line 
with activated Notch2 increasing proliferation and reducing apoptosis in HSR-GBM1 cells and 
xenografts thereof. 
 
Enhanced proliferation and survival of GBM cells with elevated Notch2 levels may 
provide an explanation for the increased aggressiveness of GBMs with high Notch2 levels 
[30]. Finally, we also found that Notch2 expression levels in GBM biopsies positively 
correlate with the expression levels of genes controlling stemness (Sox2, Nestin) and 
astrocyte fate (Vimentin, GFAP) while they negatively correlate with the expression levels of 
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genes controlling oligodendrocyte fate (Olig2, CNP, PLP1). Notch2 expression levels in GBM 
biopsies positively and negatively correlate with the expression levels of antiapoptotic (Mcl1, 
BclX) and proapoptotic (Bax) markers, respectively. In summary, it appears that key features 
of GSCs, such as increased proliferation, astrocytic lineage commitment and reduced 
apopotosis can be induced by Notch2 signaling in NSCs. In particular, the enhanced 
proliferation seen in the presence of Notch2 signaling may stochastically increase the risk of 
NSCs to acquire somatic mutations and to transit to GSCs. It is possible that aberrant Notch2 
signaling occurs after GSCs are formed. In this case high levels of Notch2 expression would 
promote GSCs to give rise to astrocytomas, such as GBMs. In this case, loss of Notch2 
signaling in subsets of expanding GSCs with Notch2 amplification could explain the formation 
of mixed oligodendroglioma. In any instance, blockade of Notch2 signaling may interfere 
with glioma formation and the aggressiveness of tumors and thus be of therapeutic benefit 
for the treatment of GBMs. 
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Materials and methods 
 
Mice 
 
Homozygous N2ICD mice [31] with a floxed STOP cassette in the chicken β-actin 
(pCAG) promoter were crossed with heterozygous Nestin-Cre mice [32]. Cre/LoxP-mediated 
activation of the pCAG promoter in double transgenic N2ICD/Nestin-Cre mice results in 
Notch2ICD expression in the neural lineage [32] (Figure 1A). Single transgenic N2ICD were 
used as littermate controls. Since E18.5 Nestin-Cre mice showed no obvious phenotype, we 
did not further include them as controls. Crossing of homozygous N2ICD mice with GFAPCre-
ERT2 (hereafter GCE) mice [24] containing a Cre/LoxP inducible Rosa26-YFP reporter gene 
(hereafter YFP) [25] resulted in triple transgenic N2ICD/YFP/GCE mice expressing Notch2ICD 
in the adult NSC niche (Figure 2A). YFP/GCE mice were used as littermate controls. 
Intraperitoneal administration of tamoxifen (2 mg, Sigma) once daily for 5 consecutive days 
was used for Cre-mediated excision of floxed STOP cassettes in the promoters of 8-10 week 
old N2ICD/YFP/GCE mice or YFP/GCE mice. Mice were sacrificed 7 days after the final 
injection and perfused with paraformaldehyde. Genotyping was with TaqMan-PCR (YFP 
mice: sense 5`- ACAGCTCGTCCATGCCGA-3`, antisense 5`-ATCACATGGTCCTGCTGGAGT-3`, 
probe 5`-FAM-TGATCCCGGCGGCGGTCA-TAMRA-3`; N2ICD mice: sense 5`- 
ATATCCGCGGTGGAGATCAA-3`, antisense 5`- TAGACCAGGCTGGGCTAAA-3`, probe 5`- VIC-
CGGTACCAGATCTC-MGB-3`; Nestin-Cre/GCE mice: sense 5`- GCCGCGCGAGATATGG -3`, 
primer antisense 5`- GCCACCAGCTTGCATGATC -3`, probe 5`- FAM- 
CCGCGCTGGAGTTTCAATACCGG-TAMRA -3`). Vaginal plugs correspond to embryonic day 0.5 
(E0.5) in timed matings. All animal experimentation was approved by the veterinary office of 
Basel-Stadt. 
 
Immunohistochemistry and Immunoblots 
 
Embryos were fixed overnight at 4°C with 4% paraformaldehyde (PFA) in phosphate 
buffered saline (PBS), cryoprotected at 4°C in 30% sucrose containing PBS for 48h and frozen 
in TissueTEK compound (Sakura Finetec, Netherlands). Mounted cryostat sections (10µm) 
were washed in PBS, incubated for 1h in blocking solution (5% horse serum and 0.15% Triton 
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X-100 in PBS) and incubated overnight with primary antibodies in blocking solution at 4°C. 
Adult mice were intracardially perfused with ice-cold 0.9% saline solution, followed by ice-
cold 4% PFA solution in 0.1 M phosphate buffer (PB). Brains were post-fixed with 4% PFA 
overnight, washed in PB, cryoprotected in 30% sucrose in PB for 48 hrs, embedded and 
frozen in OCT. Free floating coronal sections (30 µm) were collected in multi-well dishes and 
stored at -20°C in antifreeze solution. For immunostaining, sections were washed with PBS, 
incubated for 1 hr in blocking solution (5% horse serum and 0.3% Triton X-100 in PBS) 
followed by overnight incubation with primary antibodies in blocking solution at 4°C. PFA 
fixed cells were incubated for 1 hr in blocking solution (5% horse serum and 0.1% Triton X-
100 in PBS) and incubated with primary antibodies overnight in blocking solution at 4°C. The 
primary antibodies were mouse anti-NeuN (MAB377; Chemicon/Millipore, Billerica, MA), 
rabbit anti-GFAP (ZO334; Dako, Denmark), mouse anti-GFAP (Chemicon) and rabbit anti-
MAP2 (Chemicon), rat anti-Notch2 (C6551.6DbHN; Developmental Studies Hybridoma Bank, 
Iowa City, IA), goat anti-Myc (A-14; Santa Cruz, Santa Cruz, CA), rat anti-Substance-P (NC1/34 
HL; Abcam, UK), rabbit anti-Ki67 (NCL-Ki67p; Novocastra, UK), rabbit anti-Gad65/67 (G5163; 
Sigma, Saint-Louis, MO), rabbit anti-Olig2 (AB9610, Chemicon) goat anti-Sox2 (AF2018; R&D 
Systems, Switzerland), goat anti-Dcx (SC-8066, Santa Cruz), chicken anti-GFP (Molecular 
Probes/Invitrogen Carlsbad, CA), mouse anti-Nestin (sc-23927, Santa Cruz), rabbit anti-
CD133 (sc-30220, Santa Cruz) and mouse anti-βIII-Tubulin (Tuj1) (Sigma). After rinsing in PBS, 
sections were incubated with secondary antibodies in blocking solution for 1 hr and 
counterstained with DAPI. The secondary antibodies used were Cy3-conjugated donkey anti-
rabbit, Cy3-conjugated donkey anti-mouse, Cy3-conjugated donkey anti-goat, Cy3-
conjugated donkey anti-rat, Cy5-conjugated donkey anti-rabbit, Cy5-conjugated donkey anti-
mouse, Cy5-conjugated donkey anti-goat and Cy2-conjugated donkey anti-chicken (Jackson 
Immunoresearch, UK). Imaging was with a Leica DMI6000 fluorescence microscope or a Zeiss 
LSM510 confocal microscope. For detection of proteins on immunoblots, whole protein 
lysates were prepared in lysis buffer from neurospheres or GBM cells. Protein extracts were 
separated by electrophoresis on SDS-PAGE gels (20ug/lane) and transferred onto 
polyvinylidene difluoride membranes (PVDF) (Millipore). Membranes were blocked (10 mM 
Tris-HCl, 150 mM NaCl, 5% milk powder and 0.5% Tween 20) for 1 hour at RT and incubated 
overnight at 4C̊ with primary antibody against:  GFAP (Dako), Tuj1, mouse anti-Myc (SC-40, 
Santa Cruz), rabbit anti-Caspase-3 (#9062, Cell Signaling), mouse anti-beta-Actin (A5316, 
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Sigma), anti-Bcl-2 (Santa Cruz) and anti-Mcl1 (Santa Cruz). After washing, membranes were 
incubated for 1 h at RT with IgG-horseradish peroxidase conjugated secondary antibodies 
followed by the SuperSignal chemiluminescent substrate (Pierce) to detect protein-antibody 
biding.  
 
Neurosphere Cultures 
 
NSC cultures were prepared and maintained as described [33]. Briefly, telencephali of 
E14.5 N2ICD/Nestin-Cre or N2ICD control mice were dissected and the tissue triturated in 
neurosphere medium consisting of DMEM/F12 (1:1), 0.2 mg/ml L-glutamine, 1% 
penicillin/streptomycin, 2% B27, 2 μg/ml Heparin, 20 ng/ml EGF and 10ng/ml FGF2. For adult 
neurosphere cultures, subventricular zones from N2ICD/GFP and GFP control mice were 
microdissected from 300 μm vibratome sections in L15 and the tissue digested with 0.05 % 
Trypsin. After 5 to 6 days in culture neurospheres were split plated at a density of 
105cells/ml. For determination of neurosphere number and size, aliquots of samples were 
pipetted into 96 well plates. For immunoblotting, spheres were lysed in RIPA buffer 
supplemented with complete protease inhibitor cocktail (Roche) and phosphatase inhibitor 
cocktail I and II (Sigma). For in vitro differentiation, cells were seeded at a density of 200,000 
cells/cm² on coverslips coated with 15 μg/ml poly-L-ornithin and 40 μg/ml laminin. Cells 
were differentiated in neurosphere medium lacking FGF2, EGF and heparin and fixed after 5 
days with 4% PFA. For N2ICD or GFP expression in adult NSCs, neurosphere cultures from 
N2ICD/GFP or GFP mice were infected with adenovirus expressing Cre recombinase (AdCre, 
gift of J. Relvas) to excise the floxed STOP cassette in the promoters. For transduction of 
neurospheres, cell suspensions were incubated with AdCre at a multiplicity of infection (MOI 
= ratio of infectious virus particles to cells) of 500. Cells were infected with virus under 
occasional shaking for 1 h at 37°C at 5x103 cells/ml and then plated at 105 cells/ml for 
neurosphere cultures. 
 
Stable Expression of Notch2ICD in GBM Cell Lines 
 
 U373 GBM cells [34] were grown in Dulbecco’s Modified Eagle Medium (DMEM, 
Invitrogen) supplemented with 10% (v/v) fetal bovine serum (FBS, No: S1810, Labforce, 
Inauguraldissertation  Roland M. Huber 
 - 143 - 
Basel, Switzerland), 1% glutamax solution (v/v) (Invitrogen) and 1% (v/v) 
penicillin/streptomycin solution (Invitrogen). Cells were suspended by proteolysis with 1x 
trypsin-EDTA (Invitrogen) for 5 minutes at 37°C and transfected with expression plasmids 
using CaCl2 precipitation. Stably transfected clones were selected in 100µg/ml Geneticin® or 
G418 (Invitrogen Corporation, California. USA) for 20 days. Notch2ICD (nucleotides 5107 to 
7425 of the human Notch2 cDNA, AF308601) was expressed from pcDNA 3.0-IRES-EGFP, 
dominant-negative Mastermind-like I (MAML1dn) from pEGFP-N3-MAML1dn (kind gift of Dr. 
Aster). For GBM sphere culture, U373 GBM cells were cultured under the same conditions as 
described above for neurospheres. 
 
RT-PCR 
 
Total RNA was isolated from whole brain of E16.5 embryos using SV total RNA 
isolation system (Promega, Switzerland) and used as template to synthesize cDNA with 
GoScript reverse transcriptase (Promega). Relative quantitative RT-PCR was performed using 
Power SYBR Green PCR Master Mix (Applied Biosystems, Switzerland) according to 
manufacturer’s protocol. Normalization was performed with GAPDH cDNA. The following 
primers were used for Notch2 (sense 5’ CCCAAGGACTGCGAGTCAGG 3’  and antisense 5’ 
GGCAGCGGCAGGAATAGTGA 3’) , Hes1 (sense 5′ CTACCCCAGCCAGTGTCAAC 3′ and 
antisense 5′ AAGCGGGTCACCTCGTTCAT 3′), Hey1 (sense 5’CTTGAGTTCGGCGCTGTGTTCC 3’ 
and antisense 5’ GATGCCTCTCCGTCTTTTCCT 3’) and GAPDH (sense 5′ 
TTAGCCCCCCTGGCCAAGG 3′ and antisense 5′CTTACTCCTTGGAGGCCATG 3′. 
 
Apoptosis assay 
 
 Neurospheres (N2ICD/NestinCre and single N2ICD control) (2-4 passages) with day in 
vitro (div) 6 were dissociated to obtain a single cell suspension. Cells were plated at 5x104 
cell/ml in a 6-well plate (Falcon) in neurosphere medium for 4 days to allow neurosphere 
formation. On the fourth day etoposide (Sigma) was added at 20uM for 6h or 10h or not 
added as a control. Neurospheres were harvested by centrifugation at 300g 5min and 
lysated for protein extraction. At least three independent experiments were performed.  
U373-GBM cells transfected either with N2ICD or GFP were plated at 5x104 cell/ml. After 2 
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days 20uM or 40uM etoposide was added for 24h. Protein extract were obtained as 
described above for neurospheres. 
 
Correlation Analysis 
 
To calculate correlation coefficients we used absolute expression values from 
published microarray data [28]}. Briefly, total RNA from two normal brains and 12 GBM 
samples was amplified and labeled using the Affymetrix 2-cycle amplification protocol 
according to the manufacturer's instructions (Affymetrix, Santa Clara, CA). Samples were 
hybridized to Affymetrix U133v2.0 Gene Chips and scanned using an Affymetrix Gene Chip 
scanner. Expression values were estimated using the GC-RMA implementation in the 
Genedata Refiner 4.1 (Genedata, Switzerland) package. Data-mining was performed using 
the Genedata Analyst 4.1 package. All samples were quantile normalized and median scaled 
to correct for minor variation in expression distribution. 
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Supplemental Material 
 
 
 
Supplementary Figure 1.  
 
N2ICD/Nestin-Cre mice express Notch2ICD selectively in the neuronal lineage. (A) Immunostaining for the Myc 
tag allowed for detection of transgenic Notch2ICD expression in the developing brain. Coronal cranial sections 
of E18.5 N2ICD/Nestin-Cre (upper panels) and N2ICD mice (lower panels) show DAPI stained nuclei (left 
panels). The brain is highlighted by a dashed line. Transgenic Notch2ICD expression was detected specifically in 
the developing brain of N2ICD/Nestin-Cre but never in N2ICD controls, showing that the Stop cassette 
functionally shielded the Notch2ICD transgene and that Nestin-Cre mediated Stop excision efficiently directed 
Notch2ICD expression to Nestin expressing cells and their progeny. (B) Immunostaining for Neurofilament 200 
(NF200) and Bungarotoxin that marks muscle innervating synapses, shows that E18.5 N2ICD/Nestin mice have 
a properly innervated diaphragm as seen in E18.5 wt controls.  
 
 
 
 
Supplementary Figure 2.  
 
Activated Notch2 increases the NSC pool and blocks neurogenesis in the ventral forebrain. (A) Immunostaining 
for the NSC marker Nestin in the ventral forebrain of E18.5 N2ICD/Nestin-Cre and wt mice. N2ICD/Nestin-Cre 
mice show increased ventricle (V) size and a highly increased density of DAPI+ nuclei (left panels) and increased 
amounts of Nestin+ NSCs (middle panels) in the ventral forebrain when compared to wt mice. Magnified areas 
showing the Nestin+ ganglionic eminence (GE) in wt mice, which is expanded throughout most of the ventral 
forebrain in N2ICD/Nestin-Cre mice (right panels). (B) Immunostaining for NeuN, a marker staining mature 
neurons, shows that E18.5 N2ICD/Nestin-Cre mice show a dramatic decrease in neurons in the ventral 
forebrain when compared to E18.5 wt mice. This indicates that Notch2ICD expression in the developing brain 
increases the Nestin+ NSC pool at the expense of neurogenesis in the ventral forebrain. Scale bar (A,B) = 50 
µm. 
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Supplementary Figure 3.  
 
Immunostaining of U373 derived spheres overexpressing Notch2ICD for GSC markers (Nestin, Sox2, CD133) 
confirms that GSC spheres analyzed retain stem-like properties and represent proper GSCs. Box plot diagrams 
show median (red line), boxed 25% and 75% percentiles and whiskers marking minima and maxima, statistics 
were performed using Mann-Whitney test. (E) Western blot analysis in U373 and LN319 GBM cells shows 
increased levels for the antiapoptotic proteins Mcl1 and Bcl2 in GBM cells overexpressing Notch2ICD. Scale bar 
= 50µm. 
 
 
 
 
Supplementary Figure 4.  
 
Correlation coefficients of Notch2 (probe 202443_x_at) and  selected genes in human GBMs Affymetrix probes, 
gene symbols, names and values for all genes illustrated in Figure 5 are summarized in this table.  
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Future Perspectives 
 
 Consistent with the three main therapeutic lines of attack – surgery, radiotherapy 
and chemotherapy – future progress is needed and can be expected in all three of them in 
the future. The ‘magic bullet’, meaning a single treatment eradicating all HGG, will probably 
never be found. To contemplate the future perspectives of GBM research and therapy, we 
will formulate 6 hypotheses which we will critically discuss; draw conclusions out of this 
discussion and thereby identify the fields of research key to future improvements. We will 
relate our work presented here to these key fields aiming at identifying promising 
approaches for the nearer future.   
 
 
Six Hypotheses on the Future Perspectives of GBM Research and Therapy. 
 
Hypothesis 1: Improvements in surgical methods will not substantially improve GBM 
patient prognosis. Intraoperative photodynamic diagnosis with 5-ALA during HGG surgery 
[80] is one of several approaches recently implemented aiming to improve the extent of 
tumor resection. Additionally, preoperative radiation or chemotherapy are also analyzed  
[81] trying to facilitate the discrimination of tumor versus normal brain by inducing 
apoptosis or necrosis in the tumor tissue. Preoperative brachy-therapy has proven to be 
particularly efficient at inducing tumor specific necrosis resulting in an average tumor 
resection of ~96% [82]. However, major limitations of resection cannot be overcome by 
these approaches, even if they could be further improved. GBM have a pronounced 
phenotype of infiltration with individual cells spreading out radially form the tumor bulk. 
These cells can not be removed surgically without causing inacceptable damage to the 
adjacent brain structures. Therefore, improved visualization and demarcation of tumors will 
help to remove more of the malignant tissue, but the reservoir of remaining cancer cells will 
always pose major therapeutic problems.   
 
Hypothesis 2: Improvements in radio-therapeutic methods will improve patient prognosis 
but will not cure HGG. Radio-therapy faces similar limitations as surgery. Although 
molecular imaging and irradiation techniques allow highly precise application of radiation, 
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the issue of individual, migrating cancer cells is not resolved. Brachy-therapy with diffusible 
substances should at least partially overcome this limitation. Chelator-peptide constructs 
known to be specifically enriched in glioma cells are loaded with a radiation source (eg. the 
beta-emitter Yttrium-90 or most promising the alpha emitter Bi-213). After injection, these 
constructs distribute within in the main tumor mass including its margins and specifically 
bind to tumor cells via receptor-mediated internalization and then damage them by short 
range radiation inducing apoptosis and tumor necrosis [83]. However, it is unclear up to 
which distances such constructs can efficiently penetrate the brain. Furthermore, glioma 
initiating cells (GIC) have been attributed high radiation resistance. Recent data indicates 
that a considerable amount of gliomas have mutations in the DNA damage response 
mechanism (DDR) substantially reducing their sensitivity to radiation therapy [5]. In sum, 
brachytherapy in combination with advanced surgical instrumentation is an appealing 
strategy to improve GBM therapy and patient life expectancy. Given the advanced state of 
development, considerable progress can be expected from this approach in due time. 
However, the issue of residual cancer cells spreading throughout the brain as well as high 
intrinsic radio resistance remains unresolved.  
 
Hypothesis 3: GBM will only become curable after the cell of origin has been identified.  The 
cell of origin of HGG is still heavily disputed [20, 84]. This question is not purely academic, 
since the limited advances in GBM treatment are linked to the inability to precisely predict 
tumor behavior, which critically depends on the epigenetic status of the cell of origin, the 
micro-environment and the acquired mutations [20]. For example, if the cell of origin is a 
malignant NSC, then treatment needs to target this one cell to eradicate the tumor and to 
prevent recurrence. But this cell could still reside in the original location at a distance from 
the tumor mass and emit transformed progenitor cells even after tumor debulking and 
localized radio-therapy. Interestingly, the different GBM subtypes could reflect different cell-
of-origin types. For example, HGG derived from neural progenitor cells could give rise to 
‘proneural’ type gliomas [8]. This concept would stratify HGG cases into treatment subgroups 
based on their molecular and epigenetic identity, an achievement long sought after in the 
clinic. If the cell of origin and therefore the precise cause of tumor formation are not 
identified, any treatment is prone to target secondary effects rather than the true source. 
This will inevitably lead to tumor recurrence and treatment failure. However, recurrence and 
Inauguraldissertation  Roland M. Huber 
 - 153 - 
treatment resistance can also be explained by the clonal evolution of tumor cell populations 
[1]. We need a profound understanding of the GBM biology and tumor-ontogeny before this 
question can be answered.   
 
Hypothesis 4: No single treatment or regimen will be effective in all GBM cases. Surgical 
resection will not be able to remove single cells which have migrated away from the tumor 
bulk, even if the advances made in this field are further improved (see above). Radio-therapy 
faces similar limitations, particularly when it comes to far migrating cells. Furthermore, the 
pronounced mutator phenotype described in GBM [85, 86] and the ability to survive high 
radiation doses, particularly of glioma inducing cells (GIC) [87], will limit this treatment 
option. Additionally, the lack of effectiveness of single compound regimens so far [12] 
indicates that GBM will probably not show sufficient response to individual drugs. It 
therefore becomes apparent, that only an adept combination of available treatments – 
including surgery, radio- and chemo/bio-therapy – has the potential to substantially improve 
progression free survival as well as overall survival in GBM and other HGG patients.  
 
Hypothesis 5: Without improved detection and characterization methods GBM will remain 
lethal in the majority of all cases. The central nervous system is excellent at compensating 
for lost functions or structures. Exemplary therefore is the famous case of Phineas Gage who 
suffered massive brain damage in 1848. After recovery, his brain was able to compensate for 
the lost prefrontal cortex enabling a relatively normal life despite massive changes in his 
personality. However, the ability to compensate poses a major problem in brain tumor 
diagnosis: the HGG has already reached a considerable size and tumor grade until it is finally 
diagnosed [12, 86, 88, 89]. The generalized symptoms (eg. headache, vomiting, dizziness, or 
papilloedema) of brain tumors are so unspecific that they do not immediately point to a 
neoplastic lesion in the CNS, a problem discussed since decades [88]. Furthermore, specific 
symptoms critically depend on the tumor location rather then on the tumor itself, making 
early detection based on “key” symptoms almost impossible. Together, this usually leads to 
the detection of brain tumors at late disease stages. No easy and safe early detection 
method is currently available for HGG. Ionizing radiation is the only known risk factor for 
gliomas [90], questioning the rational of certain imaging methods (eg. hole body CT scans) as 
an early detection method. Reliable detection methods which do not expose the patient to 
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risk factors (eg. blood levels of free, mutated DNA; serum concentration of CSF factors, etc.) 
are urgently needed.  
 
 Modern imaging methods are still not capable of displaying a true representation of a 
glioma, making localized therapies and adequate planning of resection difficult. Mostly, the 
tumor induced edema rather then the actual tumor mass is represented. Novel molecular 
imaging methods are needed which show the actual tumor rather then secondary effects. 
This will improve not only radiological approaches, but also surgical resection and tumor 
monitoring, a key feature for the evaluation of new treatments.  
 
 Glioma, and GBM in particular, are a highly heterogenic disease. The diagnosis GBM 
does not represent a single, well described condition but rather a compilation of stage IV 
brain tumors with glial characteristics [91]. Even within a single tumor, different areas can 
show distinct properties. Recent data is indicative of how different subtypes of GBM require 
different treatment strategies and how they correlate with patient prognosis [92]. Even if a 
highly effective treatment is found, it remains doubtful if it would be effective in more than 
few particular subtypes. In sum, if no early detection method for brain tumors can be 
established, diagnosis will likely occur at late stages of disease, when prognosis and 
treatment chances are already poor. Detected lesions then need to be characterized 
individually in order to decide on the most promising regimen. If not, treatment will remain 
a blindfolded fight against a neoplastic Hydra.  
 
Hypothesis 6: Novel chemo/bio-therapeutic strategies will significantly improve patient 
prognosis. Currently, more than 37 compounds are in clinical development for HGG. More 
than 16 different targets are evaluated, ranging from EGFR, HSP-90 and HDAC to mTOR and 
PKC [12]. In the past 10 years the FDA has solely granted approval to Bevacizumab (a 
humanized anti-VEGF antibody, Roche) for the treatment of recurrent GBM (which was not 
followed by the EMEA). MRI based data suggests that treatment of HGG with anti-VEGF 
therapies could promote tumor cell infiltration along existing blood vessels [15] further 
aggravating one of the main problems in HGG treatment. The difficulty of developing 
targeted glioma therapies is further highlighted by the fact that only 10-15% (but often less) 
of the patients show at least partial response to new drugs and no prolongation of overall 
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survival has been observed so far [89]. Except for Bevacizumab, only a handful of other 
compound has made it past phase II clinical trials for HGG treatment. Several modes of 
resistance have been described explaining the lack of efficacy of targeted strategies. For 
example, the inhibition of PI3K can lead to increased RTK expression compensating the 
inhibitory effect on PI3K or bypassing it via the Ras/Raf/MEK/Erk pathway [93]. Another 
example is the relief of feedback inhibition when signaling components are blocked. PKB 
inhibition, for example, relieves the negative feedback on RTK expression through FOXO 
transcription factors and thereby induces PI3K activation compensating for the primary 
inhibitory effect. The same holds true for the inhibition of mTORC1 which is counteracted by 
increased PI3K activation [94]. Therefore, we postulate that single target strategies will not 
lead to a significant improvement in glioma treatment. However, combination strategies 
have a much bigger potential. The combinatorial use of inhibitors to different targets or of 
compounds with multiple targets has already proven to be effective in vitro [95] and we are 
currently evaluating the potential of such strategies in vivo (Chapter 2).   
 
 The inhibition of hyper-active survival and growth promoting signaling pathways in 
HGG in combination with the inhibition of resistance mechanisms could become available 
within few years. If no additional resistance mechanisms appear, this might reduce tumor 
growth significantly. However, given the heterogeneity of HGG and of the clones within a 
single tumor, it might not lead to a complete block of glioma growth for a prolonged period 
of time in clinical settings. However, this is by far the most promising approach in the near 
future.  
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Main Conclusions and Open Questions. 
 
Conclusion A: Only multi-target therapies will significantly improve patient prognosis.   
 
Surgery and radio-therapy, even in combination, will not cure GBM. Single agent therapies 
are likely to face the same fate as the ~40 compounds which have been evaluated so far. 
Therefore, a major breakthrough in GBM therapy can only be achieved by targeting several, 
non-redundant pathways thereby blocking evasion and resistance mechanisms. A successful 
strategy will also need to include surgical resection and improved radio-therapy.   
  
 
Conclusion B: We need to improve our understanding of GBM sub-types, the cell of origin 
and glioma biology in general in order to be able to develop successful treatments.   
 
a) Different GBM sub-types show different responses to treatment [92].  Therefore, we need 
to have a better understanding of the individual sub-types as well as reliable ways to define 
the specific type of a given tumor. GBM is not a single condition but only the end stage of 
different initial lesions.  
 
b) The cell of origin of HGG defines the epigenetic background of the tumor and the cellular 
context in which the tumor initially develops. The sub-types of gliomas could be a 
representation of different cells of origin. A clear identification thereof including the 
underlying mutations of particular GBM types will allow to design personalized, 
combinatorial strategies and also to evaluate novel chemo/bio-therapies within specified 
tumor sub-groups. 
 
c) Only a profound understanding of the biology of GBM will allow tailoring treatments 
according to the underlying mutations and epigenetic state of the cancer cells in complex in 
vivo setting. It will be of key importance to understand the underlying signaling networks 
operative in an individual tumor and their unique interactions which need to be targeted.  
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Our Results in Perspective.  
 
We have extensively discussed the need of systemic GBM treatments above. Only an 
approach reaching the majority of all cancer cells can have a major impact on progression 
free and overall survival in GBM patients. Our work has focused on the understanding of 
GBM biology in general and non-canonical Notch signaling in particular (Figure 1). In parallel, 
we have set up an animal model in which we can test systemic strategies aiming to bridge 
the gap between tissue culture and the clinical bedside by using an orthotopic animal model.  
 
 
 
Figure 1. Model of DTX1 signaling in GBM cells. 
 
A schematic drawing of the signaling events and interactions observed in chapter 1 of this thesis. In short, 
activated Notch signaling leads 1) to the expression of DTX1 and the activation thereof; 2) DTX1 has a negative 
feedback role on NIC and forms a protein complex with p300, presumably in the nucleus; 3) the DTX1/p300 
complex changes gene expression, eventually with additional co-factors. Examples of DTX1 down stream 
targets are indicated (a full list can be found in chapter 1 of this thesis). 
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Notch signaling plays a fundamental role during cell-fate specification in the 
developing mammalian CNS. During neocortical development, the active Notch pathway 
inhibits neuronal differentiation and maintains the NSC and progenitor cell status permitting 
continuous waves of progenitor cells to emerge followed by neurogenesis and gliogenesis 
[96]. Notch signaling is not used in all proliferating neural precursors. Canonical Notch 
signaling is only active in NSC but not in neural progenitor cells. Recent data also implies 
Notch signaling in glioma biology [20, 25, 27, 97]. Several Notch receptor isoforms are over-
expressed in brain tumors and the Notch2 status is predictive for patient survival in 
oligodendroglioma and GBM [25]. We have analyzed the role of Notch2 in GBM and it 
appears that Notch2 signaling triggers NSC differentiation into astrocytes. Moreover, it 
increases NSC proliferation, which causes a pronounced hyperplasia of the neurogenic niche 
in mice. Neurospheres derived from mice expressing N2IC show increased proliferation and 
reduced apoptosis. Likewise, high levels of Notch2 expression in GBM cells correlates with 
increased glioma stem-like cell proliferation and reduced apoptosis. In GBM-biopsies Notch2 
mRNA levels positively correlate with expression levels of genes controlling stemness and 
astrocyte fate. High Notch2 mRNA levels also correlate with high and low expression levels 
of anti-apoptotic and pro-apoptotic markers, respectively (Chapter 4). Aberrant Notch2 
signaling may therefore contribute to a malignant transformation of NSCs.  
 
It remains to be determined if the effects described above are induced by canonical 
Notch signaling via MAML1 and RBPJκ since we have also found that the non-canonical 
Notch pathway via DTX1 has an oncogenic role in gliomas, aggravating key features of 
gliomas (Chapter 1). DTX1 increased tumor aggressiveness, seen by an increased clonogenic 
potential, elevated both migration and invasion of glioma cells and activated several 
signaling pathways protecting cancer cells form apoptosis and stimulating cell survival and 
proliferation. DTX1 mRNA levels correlate with patient prognosis in grade IV gliomas. These 
effects were linked to a set of genes specifically controlled by non-canonical Notch signaling. 
Interestingly, miR-21, a well described oncomir, is also controlled by DTX1 in GBM cells, 
linking Notch signaling to the expression of specific micro-RNA species. Therefore, Notch 
canonical and non-canonical signal pathways play important, only partially overlapping roles 
in glioma biology.  
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How do these results help to answer the main questions at hand in GBM research 
depicted above? DTX mediates MEKK1 degradation [50] and activates PI3K/PKB signaling via 
p56Lck [98]. Our results confirm these results in GBM cells and also demonstrate a link 
between Notch signaling and miR-21 expression highlighting the tight interaction of multiple 
signaling pathways within individual cells. This will help to further unravel the molecular 
programs within GBMs and offers a better understanding of its general biology. These 
results can now be used for improved or novel therapies. For example, pharmacological 
blockade of Notch signaling may represent a promising strategy (or better part of a multi-
target strategy) for therapeutic interference with GBM of the ‘classical’ sub-type [12], 
particularly because it would block both the canonical and the DTX1 mediated pathway 
branches. Furthermore, γ-secretase inhibitors are already available and in clinical use for 
Alzheimer’s disease therapy. It remains to be seen if Notch is important in more than one 
type of GBM, but the data presented here for DTX1 could point to a more general 
mechanism. Furthermore, Notch has been described to play critical roles not only in 
different leukemias, but also in many solid tumors (eg. cervical, head and neck, endometrial, 
renal, lung, ovarian, pancreatic, breast and prostate cancer [99]) and DTX1 was related to 
cell invasion in osteosarcoma [100]. Additionally, our own results demonstrate a correlation 
between DTX1 expression and survival in early breast cancer patients (Chapter 1). It is 
tempting to speculate that DTX1 has an oncogenic role in several of these solid tumors or 
eventually also in Leukemia. Therefore, tumor patients of all of these diseases could profit 
from such refined chemotherapeutic regimens.  
 
Our results could also hint to a possible cell of origin of GBM, again, one of the main 
questions at hand. NSC proliferation is Notch driven [101] and NSC and glioma inducing cells 
share several key features (self-renewal and long term proliferation, ability to differentiate 
into neurons, astrocytes, and oligodendrocytes [12]). Radio-necrosis after brachy-therapy is 
found in a trail from the tumor mass towards the SVC where NSC reside (personal 
communication A. Merlo). Therefore, several lines of evidence point to the SVC and 
therefore to NSC as the source of GBM. In line with these observations is the fact that GBM 
cells show elevated levels of stem-cell marker expression (Chapert 1, 3, 4) also found in NSC 
(eg. Nestin). However, in a clonal evolution of cancer it could also be the case that stem cell 
marker expressing cells are more competitive then others and that the expression is rather a 
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reason for fast growth and resistance rather than a remnant of the cell of origin. Never the 
less, canonical and non-canonical Notch signaling are involved both in NSC control as well as 
in GBM, a link which needs to be further analyzed.  
 
 One of the main problems in GBM research is the lack of a reliable and relevant 
animal model. Only such a model will allow testing of novel therapies in a setting as close to 
the patient situation as possible. Without such a system, future approaches are prone to 
face the same fate as the ~36 compounds tested before [12]. But such a model, based on 
defined genetics, can only be established once the cell of origin has been identified. 
However, other in vivo models can be used to evaluate promising candidates until such a 
model becomes available, even if they are limited in terms of representing a true GBM case 
in vivo. 
 
In vivo evidence on the efficacy of a treatment still is a prerequisite to any clinical 
trial. We have established an orthotopic xeno-transplantation model of GBM using 
Luciferase transfected human U87MG cells which were implanted into the brains of 
immuno-compromised ‘nude’ mice of various genetic backgrounds. Using this model, we 
were able to show the anti-tumor efficacy of HDI + 2DG on gliomas in vivo (Chapter 2). The 
HDI + 2DG combination therapy prolonged overall survival of the experimental animals and 
significantly reduced tumor growth after only four days of treatment for up to additional 19 
days. Single drug treatments were significantly less effective, and only HDI had a tumor 
reducing effect when administered alone. Therefore, the epigenetic status of glioma cells is a 
key determinant to treatment susceptibility. Again, this emphasizes the importance the cell 
of origin has on our understanding of GBM biology. It will be interesting to see if these 
results can be further optimized by more specific HDIs and refined dosing regimens or 
schedules. More importantly, this model will allow us to systematically screen novel inhibitor 
compounds in vivo based on in vitro findings already available in our labs. Ongoing 
experiments in the lab are currently evaluating some of these possible drug combinations in 
vivo. However, the results are preliminary and not suited for publication in this thesis at this 
time. 
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We hope and believe that the results presented here help answering the two main 
questions defined above. Epigenetic remodeling forms part of a promising therapeutic 
approach in our GBM animal model. This underlines the importance of the epigenetic status 
a GBM cells has, which is the result of the epigenetic status of the cell of origin in 
combination with the acquired mutations and modifications. Our results on the role of both 
canonical and non-canonical Notch signaling offer a possible explanation for the previous 
observation correlating Notch status and survival as well as indicate Notch driven cells as a 
possible source of GBMs.   
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